i 
  
SUMMARY OF CHANGES ‚Äì Pr otocol 
For Protocol Version 14 to 15, A11  
NCI Protocol #: [ZIP_CODE] 
Local Protocol #: HIC [PHONE_13302] 
 
NCI Version Date: 09/04/2020 
Protocol Date: 09/04/[ADDRESS_856803] for Amendment (RA) dated August 24, 2020: 
 
# Section Comments 
1. All U pdated Version Date in Header 
2. Title 
Page Added ‚Äú CATCHUP / Creating Access to Targeted Cancer Therapy for 
Underserved Po pulations‚Äù to the list of Partici pating Organizations 
3. Title 
Page Updated Protocol Type / Version # / Version Date 
 
II. Response to CTEP Amendment Review Recommendations dated August 3, 2020: 
 
# Section Comments 
1. Schema  
& 5.1 Part 1 ‚Äì remove the sentence ‚ÄúEntinostat will be stored at the pharmacy and it will 
not be given for the patient to take home.‚Äù   
PI [INVESTIGATOR_28516]: The procedure is indeed to give the entinostat in the clinic and 
not to give to the patient to take home, so this sentence was not removed.  
2. [IP_ADDRESS]  
 At the time of the next amendment update the following: 
x PMB Online Agent Order Processing (OAOP) application:  
https:// ctepcore.nci.nih.gov/OAOP    
PI [INVESTIGATOR_28516]: The PMB Online Agent Order Processing information has been 
updated as recommended.  
 
 
 
 
 
1 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
NCI Pr otocol #: [ZIP_CODE] 
 
Local Protocol #: HIC [PHONE_13302] 
 
Study Registry ID: [REMOVED] 
 
TITLE: A Phase 1b study of the anti-PD1 antibody Pembrolizumab in combination with the 
histone deacetylase inhibitor, Entinostat for treatment of patients with myelodysplastic 
syndromes after DNA methyltransferase inhibitor therapy failure 
 
Corresponding Organization: LAO-CT018 / Yale University Cancer Center LAO 
 
Principal Investi gator: Amer M. Zeidan 
Yale University 
[ADDRESS_856804], [ZIP_CODE], [LOCATION_003] 
Telephone: [PHONE_13303] Fax (optional): [PHONE_13304] 
e-mail address: [EMAIL_12188] 
Participating Organizations 
 
LAO-[ZIP_CODE] / University Health Network Princess Margaret Cancer Center LAO 
LAO-CA043 / City of Hope Comprehensive Cancer Center LAO 
LAO-CT018 / Yale University Cancer Center LAO 
LAO-MA036 / Dana-Farber - Harvard Cancer Center LAO 
LAO-MD017 / JHU Sidney Kimmel Comprehensive Cancer Center LAO 
LAO-MN026 / Mayo Clinic Cancer Center LAO 
LAO-NC010 / Duke University - Duke Cancer Institute LAO 
LAO-NJ066 / Rutgers University - Cancer Institute of New Jersey LAO 
LAO-OH007 / Ohio State University Comprehensive Cancer Center LAO 
LAO-PA015 / University of Pi[INVESTIGATOR_182529]-TX035 / University of [LOCATION_007] MD Anderson Cancer Center LAO 
LAO-NCI / National Cancer Institute LAO 
EDDOP / Early Drug Development Opportunity Program 
CATCHUP / Creating Access to Targeted Cancer Therapy for Underserved Populations  
2 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
Statistician: 
Name: [CONTACT_640328]: [ADDRESS_856805] [ZIP_CODE] Telephone: [PHONE_820] 
Fax: ([PHONE_13305] 
e-mail address: [EMAIL_12189] 
 
Responsible Research Nurse: 
Name: [CONTACT_640329], RN 
Address [ADDRESS_856806] [ZIP_CODE] 
Telephone ([PHONE_13306] 
Fax ([PHONE_13307] 
e-mail address  [EMAIL_12190]  Study Coordinator: 
Name: [CONTACT_640330] [ADDRESS_856807] [ZIP_CODE] 
Telephone ([PHONE_13308] 
Fax ([PHONE_13309] 
e-mail address: 
[EMAIL_12191]  
 
Responsible Data Manager: 
Name: [CONTACT_640331] [ADDRESS_856808] [ZIP_CODE] 
Telephone ([PHONE_13310] 
Fax ([PHONE_13309] 
e-m ail address 
[EMAIL_12192]  
 
NCI-Supplied Agent(s): MS-275 (SNDX-275, entinostat, NSC 706995) 
MK-3475 (pembrolizumab, NSC 776864) 
Other Agent(s) : N/A 
IND #:  
IND Sponsor : DCTD, NCI 
Protocol Type / Version # / Version Date: Original/ Version#1/ September 9, 2016 
Revision/ Version#2/ November 30, 2016 
Revision/ Version#3/ February 12, 2017 
Revision/ Version#4/ February 24, 2017 
Revision/ Version#5/ April 25, 2017 
Revision/ Version#6/ February 01, 2018 Revision/ Version#7/ April 02, 2018 
Revision/ Version#8/ May 04, 2018 
Revision/ Version#9/ June 06, 2018 
Revision/ Version#10/ October 18, 2018 
Revision/ Version#11/ September 10, 2019 Revision/ Version#12/ November 25, 2019 
Revision/ Version#13/ March 02, 2020 
Revision/ Version#14/July 14, 2020 Revision/ Version#15/ September 4, 2020 
3 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 SCHEMA 
Title of Study: A Phase 1b study of the anti-PD1 antibody Pembrolizumab in combination with the 
histone deacetylase inhibitor entinostat for treatment of patients with myelodysplastic syndromes after 
DNA methyltransferase inhibitor therapy failure 
Investigators: Principal investigator: [INVESTIGATOR_640215], MD, MHS 
Study Center(s): Yale Cancer Center 
Concept and Rationale: Besides allogeneic stem cell transplantation (allo-SCT), the DNA 
methyltransferase inhibitor (DMNTi) azacitidine (AZA) is the only treatment proven to prolong 
survival in patients with higher risk myelodysplastic syndrome (HR-MDS). Nonetheless, HR-MDS patients treated with AZA have a median survival advantage of 9.5 months (24.5 vs 15 months median 
OS)
1 and the objective response rate is only 50% with most pa tients eventually relapsing within [ADDRESS_856809] of care for those patients. Therefore, improving outcomes of MDS patients after failure of 
DNMTi remains a top clinical and research priority 
3. 
Histone deacetylase inhibitors (HDACi) comprise a group of drugs that share the ability to inhibit the 
important epi[INVESTIGATOR_640216]. As single agents, several HDACi exhibited only modest 
clinical activities in MDS4,5. Therefore, the interest to develop these agents further has focused on 
combination-based strategies, usually with DNMTi. To date, no HDACi-DNMTi combination has 
improved survival of MDS p atients in ra ndomized studies when used in the frontline or the post- DNMTi 
failure setting. These observations suggest that while HDACi therapy has modest activity in MDS, 
DNMTi might not be the best choice for combination-based regimen with HDACi. Exploration of 
alternative agents to combine with HDACi in the post-DNMTi failure setting might be a more rational 
approach. Recent advances in tumor immunology have facilitated understanding the role of immune escape as important mechanism of cancer progression and treatment resistance. One important mechanism which cancers employ commonly to evade the immune system involve the exploitation of T-cell inhibitory pathways and molecules such as the programed death-1 (PD-1) and cytotoxic T-lymphocyte associated 
antigen-4 (CTLA-4) 
[ADDRESS_856810] PD-1, itsligand 
(PD-L1), and CTLA-[ADDRESS_856811] that myeloid-derived suppressor cells (MDSCs), which are 
significantly increased in bone marrows of MDS patients (~35% vs <5% in non-MDS bone marrow), 
play an important role in ineffective he matopoiesis in MDS14. MDSCs also induce resistance to immune 
checkpoint blockade (anti-CTLA4 and anti-PD1) in colon cancer bearing mice15. Importantly, in this 
mouse model MDSCs were significantly decreased by [CONTACT_640286][INVESTIGATOR_640217] 
(ENT), leading to rejection of tumors when combined with immune checkpoint blockade15. 
Primary Objective(s): To identify the maximum tolerated total dose (MTD) of entinostat given in 
combination with pembrolizumab (MK-3475)  in post-HMA failure setting for patients with MDS. 
Secondary Objective(s): To obtain a preliminary estimate of efficacy of entinostat in combination 
with pembrolizumab (MK-3475). 
4 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
Primary Endpoint(s): MTD as defined by [CONTACT_517446]-limiting toxicity (DLT) among 2 
dose schedules 
Secondary Endpoint(s): Overall response rate (ORR), with a target if at least 15% to be continued 
for a phase 2 study. 
Exploratory Endpoint(s): 
x Median response duration for responders, median time of progression to AML, median overall 
survival (OS) and 1- and 2-year OS rates. 
x Assessment of the dynamic quantitative change in proportion of MDSCs and PD-1 expression 
in BM with combined therapy and correlation with any observed clinical responses. 
Study Design: This will be a phase 1b study [see schema]. The proposed dosing of ENT has been 
5 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
previously tested in MDS as single agent and shown to be well-tolerated. While the combination of 
ENT with the anti-PD1, pembrolizumab (MK-3475) has not been studied clinically in MDS patients, 
based on mechanisms of action it is unlikely that this combination would have overlappi[INVESTIGATOR_50685]. 
PART 1: ENT has been previously evaluated as a single agent therapy in patients with MDS at these 
doses and has been well tolerated. The ENT monotherapy run-in part (cycle 1) will allow to study the 
changes in MDSCs at pre- and post- ENT treatment (the end of cycle 1) to dissect the effects of ENT 
monotherapy from those of the combined ENT/anti-PD1 therapy. 
We will perform ‚Äò3+3‚Äô classical dose escalation design to determine DLT. The first 3 patients will 
receive ENT at dose level 1 (DL1: 8mg on D1, 8 of 21-day cycles). pembrolizumab (MK-3475) 
will be added starting day 1 cycle 2 at the approved dose (200mg intravenously [IV] over 30 
minutes on D1 of 21-day cycles) for [ADDRESS_856812] 3 treated patients in 
that dose level if there are toxicity/safety concerns that did not qualify as DLT (maximum of 6 
evaluable patients to be enrolled at any dose level). The committee can also decide to enroll patients at a lower dose level after the first [ADDRESS_856813] 6 patients enrolled in any dose level 
even if no or one DLT occurred at that dose level if there are toxicity/safety concerns that did not 
qualify as DLT. The following regarding enrollment in different dose levels will be considered 
guidance for the safety committee but can be modified in accordance of above: If no patient of the 
3 patients treated with combined therapy at DL1 develops DLT, then dose level 2 (DL2) will be tested. DL2 will be with ENT at 8mg on D1, 8 and 15 and pembrolizumab (MK-3475) at 200mg 
IV on D1 of 21-day cycles. If 1 patient out of the 3 patients has DLT at DL1, we will expand 
cohort to 3 more patients and if 1 patient of the 6 patients has DLT (i.e. only 0/3 or 1/6), we will 
test next dose (DL2). If no patient of the 3 patients treated with combined therapy at DL2 develop 
DLT, then DL2 will be used for part 2 (expansion cohort). If 1 patient out of the 3 patients has DLT at DL2, we will expand cohort to 3 more patients and if 1 patient of the 6 patients has DLT 
(i.e. only 0/3 or 1/6), dose level 2 (DL2) will be used for part 2 (expansion cohort). If 2 patients or 
more of the 6 patients at DL2 experience DLT, DL1 will be used for expansion cohort. The cycle 
duration will be 21 days, the maximum number of treatment cycles of entinostat will be 18 cycles 
and for pembrolizumab (MK-3475) the maximum number of cycles will be 17. Cycle [ADDRESS_856814] concurrent administration. In all the phases of the study, entinostat will be 
administered in clinic within 2 hours before administration of pembrolizumab (MK-3475). 
Entinostat will be stored at the pharmacy and it will not be given for the patient to take home. 
 
An additional dose level (DL -1) in which day 8 of ENT will be omitted (i.e. ENT at 8mg on D1, and pembrolizumab (MK-3475) at 200mg IV on D1 of 21-day cycles) will be used if [ADDRESS_856815] 2 cycles of combined therapy at DL1. If 0 or 1 patients of the 6 patients 
treated with combined therapy at DL-1 develop DLT then DL-1 will be used in the second part of the 
study. If 2 or more 6 patients enrolled in DL -1 develop DLT, then the study will be terminated. If the 
AE drug causality is clear (e.g. immune related event) and one of the drugs is discontinued, the patient can remain on the study and receive the non-causative agent. 
Toxicities will be tabulated and graded according to the Common Terminology Criteria for Adverse 
Events Version 5 (CTCAE-5). DLT will be assessed after the first 2 cycles of combined therapy. 
Responses will be as defined by [CONTACT_55578] (IWG)-2006 criteria (CR, PR, or HI) and 
6 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856816] 2 cycles, and every 2 cycles afterwards. Patients who achieve an 
objective response or maintain a stable disease (SD) status after the first 4 combination cycles will 
continue receiving both drugs at the same schedule t ill progression or up to 1 year of combined therapy. 
 
PART 2: After the safe dose of the combination is established, 15 patients will be treated with ENT+ 
pembrolizumab (MK-3475) combination at that same dose and schedule. Participants who go off-study 
during the 1st cycle of entinostat will be replaced in the escalation phase. Participants who do not 
complete the first 2 cycles of combined therapy without experiencing a DLT (as DLT period is defined 
in the first 2 combined therapy cycles) during dose escalation will also be replaced. To be DLT- 
evaluable, the patient must complete the first two cycles of combined therapy without experiencing a 
DLT. Any patient who is dose reduced during the entinostat run-in first cycle due to entinostat-related 
toxicity will be analyzed on the dose level that corresponds to the reduced dose level delivered during the first cycle of combined therapy. 
Assessment of response will occur after 4 combination cycles and similar to part 1, those who achieve 
an objective res ponse or SD w ill continue to receive the therapy till progression. Patients who progress 
or respond and subsequently lose response will be withdrawn from study. BM biopsy/aspi[INVESTIGATOR_640218], after first cycle of ENT monotherapy, every 2 cycles of combined therapy, and at time of progression or study discontinuation. Formal safety assessment will be 
performed at end of DLT-observing period (i.e. 1 ENT monotherapy cycle and 2 cycles of combined 
therapy) for each patient) for each DL to assess for any unexpected autoimmune or other toxicity. The 
cycle duration will be 21 days, the maximum number of treatment cycles of entinostat will be 18 cycles 
and for pembrolizumab (MK-3475) the maximum number of cycles will be 17. Cycle [ADDRESS_856817] concurrent administration. 
The following early stoppi[INVESTIGATOR_640219] w ill be used: We will cease 
enrollment in the expansion phase at the dose determined from dose escalation part of the study if we 
observe two or more DLTs among the first six evaluable patients enrolled in the expansion cohort. An 
evaluable patient is any patient who received a study drug. If the true toxicity rate is 50% or greater at the MTD then this rule will stop the trial with probability at least .89. S imilarly, if the true toxicity rate 
is 33% at the MTD then this stoppi[INVESTIGATOR_640220] .65. In that event, a new 
expansion cohort w ill start at the dose level immediately below the dose level that was expanded. If the 
dose level bein
g expanded is dose level -1, then the stud y will be terminated. 
7 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
Study Schema 
 
Study design 
 
 
 
   
 

8 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
Dose Escalation Schedule 
Dose Level Dose* 
Entinostat Pembrolizumab 
  
Level -1(Backup dose 
level) 8mg po D1 200mg 
Level 1 (starting dose 
level) 8mg po D1,8 200mg 
Level 2 8mg po D1,8,15 200mg 
Number of Patients: 6-27 
 
Main Criteria for Inclusion/Exclusion: 
 
Pathologically confirmed MDS diagnosis (regardless of initial IPSS risk category) or oligoblastic 
AML with 21-30% BM blasts in whom DNMTi have failed. Patients who have developed AML after 
DNMTi therapy can be enrolled as long as they have initiated DNMTi therapy while they were in the MDS or oli goblastic AML (20-30% BM blasts) phase and the study chair agrees. Failure of DNMTis 
is defined as: Failure to achieve a CR, PR or HI after at least [ADDRESS_856818] results within these ranges: 
Calculated creatinine clearance by [CONTACT_86605] (CrCl) =>60 ml/min/1.73 squared meter 
x 7RWDOELOLUXELQ¬îPJG/XQOHVVGXHWR*LOEHUW¬∂VV\QGURPHKH PRO\VLVRULQHIIHFWLYH
KHPDWRSRLHVLVDQG$676*27DQG$/76*37¬î[ ULN Females of childbearing 
potential must have a negative serum or urine pregnancy test within [ADDRESS_856819] no serious or uncontrolled medical conditions 
‚Ä¢ Patients, who relapsed [ADDRESS_856820] 4 months of 
DNMTi therapy, are eligible to be enrolled in this clinical trial. 
 
 
 
Exclusion criteria: 
x Any patients eligible for allo-SCT and willing to undergo allo-SCT as determined at time of 
screening for trial. Patients who are ineligible or not interested in undergoing allo-SCT will be 
eligible for the trial. 
x Any serious medical condition, uncontrolled intercurrent illness (e.g., active infection, 
symptomatic congestive heart failure (CHF), unstable angina, cardiac arrhythmias, laboratory 
abnormalities, or psychiatric illness and/or biopsychosocial conditions that may limit 
9 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856821] for hepatitis B virus surface antigen (HBV sAg) or hep atitis 
C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection might be 
enrolled if the viral load by [CONTACT_622317]/without active treatment. 
x Pregnant or breast-feeding females (lactating females must agree not to breast feed while taking 
the study drugs) 
x Use of any other experimental drug or therapy within [ADDRESS_856822] not recovered from adverse events due to agents administered more than 4 weeks earlier 
x Known hypersensitivity to pembrolizumab (MK-3475) or entinostat or history of allergic 
reactions to compounds of similar chemical or biologic composition to anti-PD1 antibodies or 
entinostat. 
x Prior treatment with any anti-PD-[ADDRESS_856823] 3 months of enrollment in the study. 
x Any history of active or severe autoimmune disease including: 
‚Ä¢ Inflammatory bowel disease, including ulcerative colitis and Crohn‚Äôs Disease 
Rheumatoid arthritis, systemic progressive scleroderma, systemic lupus 
erythematosis, autoimmune vasculitis (e.g., Wegener‚Äôs Granulomatosis). 
‚Ä¢ Note: patients with hypothyroidism who are on stable doses of hormone replacement 
therapy are allowed 
x CNS or motor neuropathy considered of autoimmune origin (e.g. Guillain-Barre Syndrome, 
myasthenia gravis, multiple sclerosis) 
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitisPatients who are Human Immunodeficiency Virus (HIV) positive may participate IF theymeet the following eligibility requirements: They must be stable on their anti-ret roviral regimen, and they must be healthy 
from an HIV perspective. 
They must have a CD4 count of greater than 250 cells/mcL. They must not be receiving prophylactic therapy for an opportunistic infection. 
10 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
 
Intervention and Mode of Delivery: Entinostat, PO administration, pembrolizumab (MK-3475), IV 
infusion 
Duration of Intervention and Evaluation: 1 year or until disease is progressed 
 
Statistical Methods: 
(a) Definition of primary outcome/endpoint: The primary endpoint is the maximum tolerated dose 
(MTD), which is the highest dose level where 1 or fewer of 6 participants experience a dose 
limiting toxicity (DLT) during the first two cycles of treatment. The RP2D is the same as the 
MTD. The maximally administered dose is the dose at which two or more of 6 participants experience a DLT. 
 
Definition of DLT: DLT will be defined as the occurrence of any of the following during the 
first 2 cycles of combined therapy unless the event can clearly be determined to be unrelated to 
the study drugs. 
 
x Any grade 3 or 4 non-hematologic toxicity with the following exceptions: A) Transient 
laboratory abnormalities that can be treated or resolve to grade 2 or less within 72 hours. 
x Grade 4 hematologic toxicity, including treatment-associated aplasia lasting >[ADDRESS_856824] dose of study drug. Given that severe anemia, neutropenia and thrombocytopenia are features of advanced MDS and commonly encountered in this patient population, they will not be used to define DLT except if associated with prolonged treatment-associated aplasia as 
described above. 
x Patients with grade 3 immune related adverse events will be removed from the treatment and 
this will be considered to be a DLT as well as any other immune-related adverse event that results in pembrolizumab interruption, dose modification, or discontinuation of therapy. 
x
x Definition of secondary outcomes/endpoints: Overall response rate (ORR: The sum of rates of 
complete response [CR], partial response [PR], and hematologic improvement [HI]) as defined 
by [CONTACT_27710]-2006 criteria (Appendix A) with a goal of at least 20% to be considered 
clinically meaningful for further evaluation in larger studies. 
x Analytic plan for primary objective: Toxicities will be tabulated and graded according to the 
Common Terminology Criteria for Adverse Events Version 5 (CTCAE-5). DLT w ill be 
assessed after the first 2 cycles of combined therapy. 
x Analytic plan for secondary objectives/ Sample size justification: Currently there is no therapy 
that has been shown to prolong survival in MDS in the post-DNMTi s etting and that the 
expected best response in patients receiving supportive care only in post- DNMTi setting is 
QHJOLJLEOHRUOHVV,WLVJHQHUDOO\DFFHSWHGWKDWD¬ï2 55LQWKHSRVW -DNMTi is 
clinically meaningful and would be worth further evaluation in larger studies. We therefore 
calculated that treating a total of 21 patients in the combination arm ([ADDRESS_856825] part of the 
study and 15 in the second part of the study) to test the difference of ORR between 1% (null hypothesis-supportive care only) and 15% (alternative hypothesis, combination therapy). The 
null hypothesis response rate of 1% will be rejected if we observe [ADDRESS_856826]. The criterion has power between .84 and .93 for testing an alternative response rate of 15%. 
The total number of patients enrolled in the study will range from 6 to 27. 
x Analytic plan for exploratory objectives: The quantitative change in MDSCs (% MDSCs by 
11 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
 flow cytometry, QIF score by [CONTACT_485200]) during treatment with the ENT/anti-PD1 combined 
therapy will be estimated using mixed effects models to take into account the within-patient 
correlation. Likelihood ratio tests will be performed to confirm if random intercepts and slopes 
are necessary in the model. The fixed effect for change in MDSCs over time will be evaluated 
for significance. The variability in the rate of change in MDSCs across patients will also be examined. The association between the clinical outcome and a meaningful reduction in MDSCs, 
which will be defined after a review of the data, will be assessed with the chi- square test. The 
quantity of MDSCs at baseline and during treatment as continuous variables can also be 
compared between responding and non-responding patients using a t-test or Mann- Whitney U- 
Test, if more appropriate. 
12 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 TABLE OF CONTENTS 
SCHEMA ........................................................................................................................ .................2 
TABLE OF CONTENTS ............................................................................................................. ..10 
1. OBJECTIVES .................................................................................................................... 13 
1.1 Primary Objectives .................................................................................................13 
1.2 Secondary Objectives .............................................................................................13 
1.3 Exploratory objectives ...........................................................................................13 
2. BACKGROUND ...............................................................................................................13 
2.1 Myelodysplastic syndrome (MDS) ........................................................................13 
2.2 CTEP IND Agents..................................................................................................16 
2.3 Rationale for combining anti-PD1 antibody with entinostat in MDS after 
DNMTi failure .......................................................................................................21 
2.4 Correlative Studies Background (full correlative proposal attached in Appendix J) ............................................................................................................21 
3. PATIENT SELECTION ....................................................................................................23 
3.1 Eligibility Criteria ..................................................................................................23 
3.2 Exclusion Criteria ..................................................................................................24 
3.3 Inclusion of Women and Minorities ......................................................................25 
4. REGISTRATION PROCEDURES (Rostered Protocol Model)........................................25 
4.1 Investigator and Research Associate Registration with CTEP ..............................25 
4.2 Site Registration .....................................................................................................26 
4.3 Patient Registration ................................................................................................28 
4.4 General Guidelines.................................................................................................29 
5. TREATMENT PLAN ........................................................................................................29 
5.1 Agent Administration.............................................................................................29 
5.2 Definition of Dose-Limiting Toxicity ....................................................................34 
5.3 Dose Expansion Cohorts ........................................................................................36 
5.4 General Concomitant Medication and Supportive Care Guid elines ......................36 
5.5 Duration of Therapy ...............................................................................................38 
5.6 Duration of Follow Up ...........................................................................................40 
5.7 Criteria for Removal from Study ...........................................................................41 
5.8 Criteria to Resume Treatment ................................................................................41 
5.9 Treatment Beyond Progression ..............................................................................41 
5.10 Discontinuation of Treatment Following Complete Response ..............................42 
5.11 Treatment Up to 1 Years ........................................................................................43 
6. DOSING DELAYS/DOSE MODIFICATIONS ................................................................43 
6.1 Entinostat Dose Modifications and Supportive Care Guidelines for Drug- 
Related Adverse Events .........................................................................................43 
6.2 MK-3475 Dose Modifications and Supportive Care Guidelines for Drug- 
13 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 Related Adverse Events .........................................................................................45 
7. ADVERSE EVENTS:  LIST AND REPORTING REQUIREMENTS .............................[ADDRESS_856827](s) (CAEPRs) ...............63 
7.2 Adverse Event Characteristics ...............................................................................71 
7.3 Expedited Adverse Event Reporting ......................................................................71 
7.4 Routine Adverse Event Reporting .........................................................................74 
7.5 Secondary Malignancy ...........................................................................................74 
7.6 Second Malignancy ................................................................................................74 
7.7 Reporting of Pregnancy and Lactation to the Sponsor ...........................................75 
8. PHARMACEUTICAL INFORMATION ..........................................................................75 
8.1 CTEP IND Agent(s) ...............................................................................................75 
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES .........................................80 
9.1 Exploratory/Ancillary Correlative Studies .............................................................80 
9.2 Special Studies: N/A ..............................................................................................[ADDRESS_856828] ........................................................................................85 
11.1 Definitions..............................................................................................................85 
11.2 Response criteria ....................................................................................................85 
11.3 Other response parameters .....................................................................................86 
12. STUDY OVERSIGHT AND DATA REPORTING / REGULATORY 
REQUIREMENTS ............................................................................................................. 86 
12.1 Study Oversight ......................................................................................................86 
12.2 Data Reporting .......................................................................................................87 
12.3 Collaborative Agreements Language .....................................................................89 
13. STATISTICAL CONSIDERATIONS ...............................................................................91 
13.1 Study Design/Endpoints .........................................................................................91 
13.2 Sample Size/Accrual Rate ......................................................................................93 
13.3 Stratification Factors ..............................................................................................93 
13.4 Analysis of Secondary Endpoints ..........................................................................93 
13.5 Reporting and Exclusions ......................................................................................94 
14. Study Status Updates and Study Closure ...........................................................................95 
14.1 Definitions of Study S tatus Changes ......................................................................95 
14.2 Responsibility for Filing Protocol Status Update Forms........................................96 
REFERENCES .................................................................................................................... ..........98 
APPENDIX A1 Modified International Working G roup (IWG)-2006 response criteria for 
altering natural history of MDS ....................................................................................... 104 
APPENDIX A2 Modified International Working G roup (IWG)-2006 response criteria for 
14 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 hematologic im provement................................................................................................106 
 
APPENDIX A3 International W orking Group Acute Myeloid Leukemia Response Criteria 
107 
 
APPENDIX B ....International Prognostic Scoring System (IPSS) for Myelodysplastic Syndrome 
108 
 
APPENDIX C Pe rformance Status by [CONTACT_640287].......................................109 
 
APPENDIX D ..................................... Protocol for mononuclear cells isolation (Ficoll Hypaque): 
[ADDRESS_856829] 
111 
 
APPENDIX F TRANSPORTER MDR1/PgP TRANSPORTER MDR1/PGP ................114 
 
APPENDIX G examples of sensitive in vivo cyp substrates and cyp substrates with 
narrow therapeutic range1 ............................................................................................................................. ....................116 
APPENDIX H Gastric acid reducing drugs......................................................................118 
 
APPENDIX I BIOASSAY TEMPLATES ......................................................................119 
 
APPENDIX J Correlative study proposal .......................................................................120 
15 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 1. OBJECTIVES 
 
1.1 Primary Objectives 
 
To assess safety, tolerability, and identify the maximum tolerated dose (MTD) of 
entinostat given in combination with pembrolizumab (MK-3475). 
 
1.2 Secondary Objectives 
 
To obtain a preliminary estimate of efficacy of entinostat in combination with 
pembrolizumab (MK-3475). 
 
1.3 Exploratory objectives 
 
To assess the dynamic quantitative change in measurable immunological biomarkers (proportions of myeloid-derived suppressor cells [MDSCs], and programmed death 
protein-1 [PD-1] expression in bone marrow) with the combined epi[INVESTIGATOR_18193]- 
immunotherapy and correlation with any observed clinical responses. 
 
 
2. BACKGROUND 
 
2.1 Myelodysplastic syndrome (MDS) 
 
Novel treatment options after azacitidine failure represent a major unmet clinical need in MDS 
Myelodysplastic syndromes (MDS) are among the most common hematologic malignancies and 
constitute the most common chronic myeloid malignancy in [LOCATION_003]
16,17. The age-adjusted incidence 
in [LOCATION_003] has been estimated at 3.3-4.6 per 100,000 persons (ex ceeding that of acute myeloid 
leukemia [AML]) which translates into more 20,[ADDRESS_856830] higher- 
risk (HR)-disease, typi[INVESTIGATOR_640221] (I PSS) of 
intermediate-2 or high risk groups [Appendix B] , and have an expected median survival of less 
than one year if treated only with supportive measures20. The only curative treatment modality for 
HR-MDS is allogeneic bone marrow transplantation ( allo-SCT), but due to the typi[INVESTIGATOR_640222], less than 5% of patients undergo 
allo-SCT21. Aside of allo-SCT, the DNA methyltransferase inhibitor (DNMTi) azacitidine is the 
only treatment proven to prolong survival in HR-MDS1. Nonetheless, the survival advantage with 
azacitidine has a median duration of only 9.5 months (24.5 vs 15 months in median overall survival 
[OS])1. Additionally, only 50% of patients receiving azacitidine exhibit an objective response 
(complete response rate [CR] only 17%) with most patients eventually relapsing within [ADDRESS_856831] improved 
16 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856832] a graft source. As the mechanisms of primary and secondary resistance to DNMTi therapy are poorly 
understood, it has been difficult to rationally design targeted therapi[INVESTIGATOR_640223]. 
 
Histone deacetylase inhibitors (HDACi) demonstrated modest activity in MDS 
Histone deacetylase inhibitors (HDACi) comprise a group of drugs that share the ability to inhibit 
the important epi[INVESTIGATOR_640224] (HDAC) but vary significantly in 
terms of their structure, target specificity, and pharmacokinetic profiles. There are [ADDRESS_856833]-HMA failure setting, usually by [CONTACT_640288] (in case of primary resistance) or re-acquiring (in 
case of secondary resistance) a clinical response. 
 
One of the HDACs studied in MDS in entinostat: an orally bioavailable, isotype-selective class 1- 
specific HDACi with long half-life (100 hours). A phase I clinical trial published in abstract form at Johns Hopkins University combined entinostat with a lower dose, prolonged administration 
schedules of azacitidine
22. In this trial, patients were treated with SQ azacitidine for 10 days at 
different dose levels (30, 40, or 50mg/m2/day) and given oral entinostat (2, 4, 6, 8 mg/m2/dose) on 
days 3 and 10. Out of 31 enrolled patients, 13 had MDS, 4 had c hronic myelomonocytic leukemia 
(CMML), and 14 had acute myeloid leukemia (AML). Patients were evaluable for response if they 
received 4 or more cycles of treatment. Of the 27 evaluable patients, 12 had responses (2 CR, 4 had partial responses [PR], and 6 bilineage hematologic improvement [HI]) according to the 
International Working Group [IWG] 2000 criteria. The 50mg/m
2/day dose of azacitidine D1-10 
and the entinostat 4 mg/m2/dose on D3 and D10 were subsequently studied in the randomized 
phase 2 ECOG1905 study versus azacitidine monotherapy at the same 50mg/m2/day dose D1- 
D1023. Both arms achieved rates of trilineage hematologic normalization (32% for azacitidine 
monotherapy and 27% for combination) that were exceeded that of the historical control in which the standard regimen of azacitidine at 75mg/m2/day D1-7 was used (16% in CALBG9221 trial). While there was no survival advantage with the combination compared to azacitidine, this could be potentially related to pharmacologic anta gonism caused by [CONTACT_640289], a 
potent cell-cycle inhibitor with a long half-life of 4.5 days, in each cycle (day 3) which could have 
inhibited incorporation of azacitidine into DNA and subsequent cell cycling
23. These findings 
suggest that wh ile entinostat has a modest activity in MDS, HMAs might not be the best choice 
17 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856834]-DNMTi failure setting might be a more rational approach . 
 
Rationale for use of immune-check point inhibitors in MDS after DNMTi failure Programmed death receptor-1 (PD-1) is a molecule expressed on antigen-stimulated T-cells and induces downstream signaling that cause inhibition of T-cell proliferation, cytokine release, and 
cytotoxicity
24. Recent data showed that multiple types of tumor are capable of evading the immune 
system by [CONTACT_640290]-1 ligands (e.g. PD-L1) which engages the PD-1 receptor on the surface 
of cytotoxic T-cell leading to suppression of their activity6. Immune checkpoint blockade with 
anti-PD-1 and anti-PDL-1 antibodies (and anti-cytotoxic T-Lymphocyte-associated antigen 4 
[CTLA-4] antibodies) has emerged as a novel promising approach to reverse this phenomenon and 
has resulted in a significant and durable clinical activity in some patients with advanced solid 
malignancies especially metastatic melanoma9. Pembrolizumab (MK-3475, KEYTRUDA¬Æ) is a 
humanized monoclonal IgG4-kappa antibody that inhibits PD-1 with highly selectivity which has recently been granted an accelerated approval in 2014 by [CONTACT_640291] (Keyt ruda product information. 
http://www.merck.com/product/usa/pi_circulars/k/ keytruda/keytrudapi. pdf .). In a large open- 
label, multicenter phase 1b trial, 173 adult patients with refractory metastatic melanoma were 
randomized to IV pembrolizumab at 2 or 10 mg/kg every 3 weeks9. With a median follow-up of 8 
months, the ORR was 21-26% at both doses. Survival data has not yet been reported. Most common drug-related adverse events of any grade in the 2 and 10 mg/kg doses were fatigue (33% 
vs 37%), pruritus (26% vs 19%), and rash (18% vs 18%). Grade 3 fatigue (in 3%) was the only 
drug-related grade 3 to 4 adverse event reported in more than one patient
9, suggesting that the drug 
is well tolerated and is potentially associated with less severe side effects than the CTLA-4 inhibitor ipi[INVESTIGATOR_125]. Advanced non-small cell lung cancer showed 19.4% of ORR and 12.5 
months of median duration of response
25. Metastatic or refractory squamous cell carcinoma of the 
head and neck showed 18% of ORR to pembro lizumab in a phase Ib trial26. Pembrolizumab is now 
approved for advanced melanoma, non-s mall cell l ung cancer, and advanced head and neck cancer. 
 
Several lines of evidence suggest that the immune system dysregulation is important in the 
pathogenesis and progression of MDS and that targeting key immune effector and regulatory steps 
can be a novel therapeutic approach for disease control in MDS27. We are in fact evaluating the 
use of the CTLA-4 inhibitor ipi[INVESTIGATOR_62607] a multi-center CTEP-s ponsored phase 1 study in 
DNMTi-refractory MDS and there are other active phase 1 studies of anti-PD1 and anti-PD-L1 
antibodies in MDS. 
 
Data suggests that during disease progression in MDS the clonal blasts become more aggressive 
while the non-clonal immune cells become less efficient via unknown mechanisms12. In a Chinese 
study of 38 MDS patients, the percentages of CTLA-4, PD-1 and CD25 were significantly higher 
in patients with MDS compared to normal and the differences of CTLA-4, PD-1 and the ratio of CTLA-4/CD28 between patients with HR-MDS and lower-risk (LR)-MDS were more significant 
with progression of MDS further suggesting involvement of the PD-1 axis in MDS progression
28. 
Using MDS cell lines and patient samples, Kondo and colleagues12 showed that the expression of 
an immune-inhibitory molecule PD-L1 (B7-H1, CD274) was induced by [CONTACT_14234]- ‹µ( IFN-‹µ and 
tumor necrosis factor- ƒÆ71) -ƒÆRQ0'6EODVWVDQGWKDWWKHVHEODVWVH[KLELWHGPRUHSRWHQW
intrinsic proliferative capacity than PD-L1-negative MDS blasts. Additionally, these PD-L1- 
18 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856835] an intrinsic proliferative 
advantage and induce T-cell suppression through interactions with PD-1 r eceptors leading 
potentially to disease progression and suggesting a role for therapeutic intervention12. The MD 
Anderson group studied mRNA in CD34+ cells from 124 patients with MDS, AML and chronic myelomonocytic leukemia (CMML) and found that 34%, 15%, and 8% had aberrant up- regulation 
(·ÄÖ2-fold) in PD-L1, PD-1 and CTLA4, respectively
13. PD-L1 protein expression was observed in 
MDS CD34+ cells, whereas stromal and non-blast c ellular elements were positive for PD-1. More 
importantly, in subgroup of patients treated with DNMTi therapy, PD-L1, PD- 1 and CTLA4 
expression was increased with the patients who exhibited resistance to DNMTi therapy showing 
higher relative up-regulation in gene expression than responding patients. Furthermore, treatment of leukemia cells with decitabine resulted in a dose-dependent up- regulation of these genes and 
partial hypomethylation of PD-1 in leukemia cell lines and human samples
13. In addition to 
providing further evidence to the role of PD-1/PD-L1 axis in MDS progression, these results suggest this axis might mediate resistance to DNMTi therapy and provide rationale for combining 
epi[INVESTIGATOR_640225]-PD1 antibody as a novel 
therapeutic approach to improve outcomes of HR- MDS p atients. 
 
2.2 CTEP IND Agents 
 
 
2.2.1 Pembrolizumab (MK-3475) 
 
MK-3475 (SCH 900475, pembrolizumab) is a humanized immunoglobulin (Ig) G4 
monoclonal antibody (mAb) which binds the programmed death 1 (PD-1) receptor, thus inhibiting the interaction with its ligands, PD-L1 or PD-L2 (Investigator‚Äôs Brochure, 
2014). PD-[ADDRESS_856836] may be a critical mechanism to evade T-cell mediated tumor 
rejection30,31. High levels of PD-L1 expression are correlated with poor prognosis and 
survival in renal cell carcinoma (RCC)32, pancreatic carcinoma33, hepatocellular 
carcinoma (HCC)34, and ovarian carcinoma35. 
 
Immune-checkpoint inhibition of another inhibitory T-cell receptor, cytotoxic T- 
lymphocyte-associated antigen 4 (CTLA-4), with the mAb ipi[INVESTIGATOR_640226] (OS) in patients with melanoma in two phase 
[ADDRESS_856837] from CTLA-4 because it can 
be activated directly by [CONTACT_640292] T-cell response, 
19 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856838] demonstrated durable objective responses in phase 1 and 2 trials. Nivolumab showed an overall response rate (ORR) of approximately 28% in subjects with advanced melanoma, 27% in subjects with RCC, and 18% in subjects with non- 
small cell lung cancer (NSCLC) who had failed prior therapy
40. Pembrolizumab (MK-
3475) has shown an ORR of approximately 38% in patients with melanoma41 and ~20% 
in patients with NSCLC (Investigator‚Äôs Brochure, 2014). 
 
[IP_ADDRESS]  Clinical Development of pembrolizumab (MK-3475) 
 
Pharmacokinetics 
The half-life (t 1/2) of pembrolizumab (MK-3475) is approximately 4 weeks and there 
is no indication of dose dependency of half-life in the three dose groups (1, 3, and 10 
mg/kg) (Investigator‚Äôs Brochure, 2014). The long t 1/2 supports a dosing interval of 
every 2 or 3 weeks. 
 
There was a dose-related increase in exposure from 1 to 10 mg/kg (Investigator‚Äôs 
Brochure, 2014). Serum concentrations of MK-3475 were lower by a factor of 
approximately 5 in patients receiving 2 mg/kg Q3W than in those receiving 10 mg/kg 
Q3W 41 (Investigator‚Äôs Brochure, 2014). Steady-state trough concentrations were 
20% greater in the patients receiving 10 mg/kg Q2W than in those receiving the same dose Q3W. 
 
Anti-Drug Antibodies (ADA) Data 
The occurrence of ADA has been observed in less than 1% of the patients screened, 
indicating a low potential of pembrolizumab (MK-3475) to elicit the formation of 
ADA (Investigator‚Äôs Brochure, 2014). No impact of ADA on MK-3475 exposure has 
been observed. 
 
Efficacy 
When treated with pembrolizumab (MK-3475) monotherapy, the ORR for IPI-
treated patients with melanoma (Part B) was 25%/27% according to the Response 
Evaluation Criteria in Solid Tumors (RECIST)/investigator-assessed immune-related 
response criteria (irRC), respectively (Investigator‚Äôs Brochure, 2014). The ORR for IPI-na√Øve patients with melanoma (Parts B and D) was 39%/43% by 
[CONTACT_393]/investigator-assessed irRC, respectively. The majority of responses were 
seen in patients with melanoma by 16 weeks of therapy with pembrolizumab (MK-
3475); however, some responses have been reported after [ADDRESS_856839]-defined progression followed by a response has been observed. 
 
The preliminary objective response rate for 38 patients with NSCLC (Part C) was 
21%/24% by [CONTACT_393]/investigator-assessed irRC, respectively (Investigator‚Äôs 
Brochure, 2014). 
 
Pharmacodynamics/Biomarkers PD-L1 is being investigated as a predictive biomarker for pembrolizumab (MK-3475) 
treatment. At the 
20 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 15th World Conference on Lung Cancer, Garon et al. presented preliminary data on a 
subset of patients suggesting that higher levels of tumor PD-L1 expression are associated with increased clinical activity. 
Preliminary clinical safety and activity of MK- 
3475 monotherapy for the treatment of previously treated patients with non-small cell lung 
cancer (NSCLC). J Thor Oncol . [ADDRESS_856840] 2:S364-365 ). Objective responses by [CONTACT_393] 
1.1 occurred in 4 out of 7 patients with higher levels of PD-L1 expression (57%, 95% 
confidence interval [CI] 18-90%) vs. 2 out of 22 patients with lower levels of PD-L1 
expression (9%, 95% CI 1-29%).  These data are extremely preliminary, and PD-L1 
is not being used for patient s election. 
 
Biomarkers to evaluate immune modulation and markers in the tumor microenvironment, such as T-cell infiltration, the baseline expression of markers of T-cell suppression FoxP3 or the immunoregulatory enzyme indoleamine 2,3- 
dioxygenase (IDO) in tumor biopsies, were associated with a high response rate
42. 
 
[IP_ADDRESS]  Safety data 
 
The most frequent treatment-related adverse events (AEs) were fatigue, nausea, cough, pruritus, diarrhea, and rash (Investigator‚Äôs Brochure, 2014). Most AEs were 
not considered serious. The most commonly reported immune-related AEs were rash, 
pruritus, vitiligo, hypothyroidism, arthralgia, diarrhea, and pneumonitis. 
 
Important identified risks include: pneumonitis, thyroid disorders (hypothyroidism and hyperthyroidism), colitis, diarrhea, hepatitis, nephritis, uveitis, rash/pruritus and 
neuropathy. 
 
2.2.2 Entinostat (NSC 706995) 
 
Entinostat, SNDX-275, an orally available synthetic pyridylcarbamate licensed from 
Bayer Schering AG by [CONTACT_640293]-275, inhibits 
HDACs. SNDX -[ADDRESS_856841] set of genes. This ultimately leads to the inhibition 
of cell proliferation, induction of terminal differentiation, and/or apoptosis
43. DNA within 
the cell nucleus combines with a class of proteins called histones to form chromatin. 
Histones have amino terminal groups that are positively charged and are hypo-acetylated by [CONTACT_178904]. The positive charge tightly binds the histones to the negatively charged DNA 
phosphodiester backbone. Gene transcription and expression are inhibited by [CONTACT_88318] a 
condensed conformation of the DNA. Histone acetyltransferases acetylate the amino terminal ends and neutralize their positive charges, thus leading to a more open chromatin 
conformation, facilitating DNA transcription. Altered activity of HDACs and inactivation 
of histone acetyltransferases within transformed cells are key events that affect chromatin 
remodeling. There is evidence that HDACs are associated with a wide range of tumors 
including melanomas, neuroblastomas, lymphomas, and lung, breast, prostate, ovarian, bladder, and colon cancers. In a number of in vitro models, HDAC inhibitors triggered 
growth arrest and induced cell differentiation or apoptosis. In acute promyelocytic 
leukemia, recruitment of HDACs by [CONTACT_640294]. 
21 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 Entinostat inhibited HDAC in various tumor cell lines. In particular, entinostat induced 
accumulation of acetylated histones adjacent to the promoter of the transforming growth factor (TGF)- »ïW\SH,,UHFHSWRUJHQHZLWKUHVXOWLQJJHQHH[SUHVVLRQ0XWDWL RQV affecting 
the TGF-»ïVLJQDOLQJSDWKZD\KDYHEHHQDVVRFLDWHGZLWKGHYHORSPHQWDQGS URJUHVVLRQRI
human malignancies, including carcinomas of the lung, breast, prostate, and colon. 
Entinostat also induced histone hyperacetylation and induced expression of various tumor 
suppressor genes. Various in vitro studies in a range of human cancer cell lines have demonstrated the 
antiproliferative activity of entinostat. In vivo , entinostat inhibited the growth of a range 
of human tumor xenografts, including models of lung, prostate, breast, pancreatic, renal cell, and glioblastoma. More recently, entinostat has been shown to modify the phenotype of cancer cells from a mesenchymal to an epi[INVESTIGATOR_640227], with impact on reducing the 
metastatic potential of the cancer cells
44. In addition, there is a suggestion that entinostat 
may have longer term effects on cancer phenotypes, cancer stem cells (CSCs) or 
progenitor cell pool and potential sensitization to subsequent post-study treatments45. 
 
[IP_ADDRESS]  Entinostat in Patients with Solid Tumors, including Lung Cancer and 
Melanoma 
To date, entinostat has been investigated alone or in combination in >900 patients 
with cancer in clinical studies, including >600 patients with solid tumors, including 
NSCLC and melanoma. Entinostat has been investigated specifically in patients with NSCLC in combination with erlotinib in clinical studies sponsored by [CONTACT_640295] 5-azacitadine (AZA) in clinical studies sponsored by [CONTACT_6812]. Of 
the studies of entinostat in combination with AZA, evidence of the anti-tumor activity 
of this combination was demonstrated in an initial study
45, in which adults with 
metastatic NSCLC who experienced disease progression after at least 1 anticancer regimen received 7 mg of entinostat by [CONTACT_1966] (PO) on Days 3 and 10 and 30 or 40 mg/m2/day of AZA subcutaneously (SC) on Days 1-6 and 8-10 of a 28-day cycle. 
Of 31 evaluable patients, 1 experienced a CR, with a duration of 14 months; a second 
patient experienced a PR, with a duration of 8 months; and [ADDRESS_856842] 12 weeks. Furthermore, 4 patients had major objective 
responses to the immediate subsequent therapy. Based on these encouraging findings, 
the NCI has initiated a follow-up study utilizing this combination regimen to investigate the premise that epi[INVESTIGATOR_640228]. 
Evidence of the efficacy of entinostat also was seen in patients with Stage IV 
nonresectable melanoma, with 25% of patients experiencing disease stabilization
46. 
Based on these encouraging findings, further investigation of entinostat in combination was considered warranted in patients with melanoma. 
Overall, among all patients treated, entinostat has been well tolerated at the doses and 
schedules investigated. Regardless of indication and regimen, the most frequently 
reported AEs with entinostat included gastrointestinal (GI) disturbances, primarily 
nausea with or without vomiting and diarrhea; fatigue; and hematologic 
abnormalities, primarily anemia, thrombocytopenia, neutropenia, and leukopenia. 
Most occurrences of these events are Grade 1 or 2 in severity and non-serious. Grade 3 and 4 hematologic abnormalities are commonly seen in patients with hematologic 
22 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856843] prevalent AEs regardless of the patient population or the agent given in combination. 
 
[IP_ADDRESS]  Entinostat in Patients with MDS and AML 
One of the HDACs studied in MDS in entinostat: an orally bioavailable, isotype- 
selective class 1-specific HDACi with long half-life (100 hours). A phase I clinical 
trial published in abstract form at Johns Hopkins University combined entinostat with 
a lower dose, prolonged administration schedules of azacitidine22. In this trial, 
patients were treated with SQ azacitidine for 10 days at different dose levels (30, 40, 
or 50mg/m2/day) and given oral entinostat (2, 4, 6, 8 mg/m2/dose) on days 3 and 10. 
Out of 31 enrolled patients, 13 had MDS, 4 had chronic myelomonocytic leukemia (CMML), and 14 had acute myeloid leukemia (AML). Patients were evaluable for response if they received 4 or more cycles of treatment. Of the 27 evaluable patients, 12 had responses (2 CR, 4 had partial responses [PR], and 6 bilineage hematologic 
improvement [HI]) according to the International Working Group [IWG] 2000 
criteria. The 50mg/m
2/day dose of azacitidine D1-10 and the entinostat 4 mg/m2/dose 
on D3 and D10 were subsequently studied in the randomized phase 2 ECOG1905 
study versus azacitidine monotherapy at the same 50mg/m2/day dose D1-D1023. Both 
arms achieved rates of trilineage hematologic normalization (32% for azacitidine monotherapy and 27% for combination) that were exceeded that of the historical control in which the standard regimen of azacitidine at 75mg/m2/day D1-7 was used 
(16% in CALBG9221 trial). While there was no survival advantage with the 
combination compared to azacitidine, this could potentially have been related to pharmacologic antagonism caused by [CONTACT_640289], a potent cell- cycle inhibitor with a long half-life of 4.5 days, in each cycle (day 3) which could 
have inhibited incorporation of azacitidine into DNA and subsequent cell cycling
23. 
[IP_ADDRESS]. Clinical Development of Entinostat 
Potential Drug Interactions : Metabolism: Data from in vitro metabolism experiments 
in human tissues demonstrated that entinostat is not metabolized by [CONTACT_166113]47, 
but UGT 1A4 did metabolize entinostat to its M2 glucuronide metabolite. No metabolites could be detected after incubation of entinostat in human liver 
microsomes
47. While inhibition of CYP enzymes 2B6 and 3A4 was seen, the data 
show that the degree of the inhibition makes it unlikely that any in vivo systemic 
interactions would occur. Intestinal CYP 3A4 may be inhibited by [CONTACT_166120]. 
However, entinostat did not inhibit any UGT enzymes tested. Entinostat was found to 
induce CYP 1A2, CYP 2C6, and CYP 2B8 as well as UGT 1A4. Finally, entinostat 
was found to be a substrate for P-gp and BCRP transporters, but did not inhibit either of these transport proteins. 
23 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 Patient Care Implications: 
Entinostat may cause fatigue or malaise; advise patient to exercise caution while driving a vehicle or operating machinery. 
 
Administration of entinostat is contraindicated in patients with a history of allergy 
to entinostat or other medications that have a benzamide structure (eg, tiapride, 
remoxipride, clebropride). 
Careful monitoring of patients for signs of infection or reactivation of past 
infections is recommended, as reactivation of infection has been reported in 
patients treated with entinostat, in some cases without evidence of neutropenia. The clinical significance of this finding and the potential association with 
entinostat is unknown. 
 
Entinostat must not be used during pregnancy or while breast-feeding. Women 
and men participating in entinostat clinical studies must agree to use acceptable 
contraceptive methods, as indicated in the clinical study protocol, during 
treatment and for 4 months thereafter. 
 
2.3 Rationale for combining anti-PD1 antibody with entinostat in MDS after DNMTi 
failure 
More recently, myeloid-derived suppressor cells (MDSCs) were found to be significantly 
expanded in Bone marrows of p atients with MDS and to play an im portant role in the pathogenesis 
of the disease especially in driving ineffective hematopoiesis14. In another very provoking study 
by [CONTACT_146360], the authors demonstrated in murine models with metastatic tumors that MDSCs can mediate resistance to immune checkpoint blockade therapy. In this study, treatment with anti-PD-1 and anti-CTLA-4 inhibitor antibodies could not eliminate CT26 tumors or 
metastatic 4T1 tumors 
15. Interestingly, when the animals were co-treated with epi[INVESTIGATOR_640229], the outcomes improved significantly with cure rates in excess of 80% of the tumor-bearing mice. Specifically, the use of anti-PD1 + anti-CTLA-4 with 
azacitidine plus entinostat or the combination of the antibodies with entinostat alone eradicated the 
tumors while when the antibody combination was used with azacitidine monotherapy the primary tumors were not eradicated. Azacitidine and entinostat (alone or together) in absence of the immune-checkpoint inhibitors also failed to eradicate the tumors. These findings suggested that 
the combination of the class [ADDRESS_856844] primarily by [CONTACT_100276]-regulating MDSCs suggesting that cancers which are resistant to immune checkpoint blockade can be potentially controlled or cured 
by [CONTACT_225017]. 
 
2.4 Correlative Studies Background (full correlative proposal attached in  Appendix J ) 
 
The role of MDSCs in MDS and the preclinical data of HDACi to suppress MDSCs: 
Myelopoiesis is altered in cancer, which induces expansion of relatively immature and activated 
myeloid cells, now called MDSCs48. MDSCs have been reported to facilitate tumor metastasis 
and angiogenesis49-51. Recently, MDSCs were found to be significantly expanded in bone 
marrows of patients with MDS and to play an important role in the pathogenesis of the disease 
24 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856845] 
cancers15. Interestingly, when the animals were co-treated with epi[INVESTIGATOR_640230] (i.e. 
ENT+AZA or ENT alone) in addition to the antibodies, the outcomes improved significantly 
with cure rates in excess of 80% of the tumor-bearing mice15. Importantly, AZA and ENT (alone 
or together) in absence of the immune-checkpoint inhibitors also failed to eradicate the tumors. These findings suggested that the combination of the class [ADDRESS_856846]- ENT/anti-PD1 therapy to achieve our primary goal of this study via 
Specific Aim 1. 
 
PD-L1 expression in MDS and its correlation with the response to anti-PD1 therapy: Kondo 
and et al. demonstrated that PD-L1-positive MDS blasts have an intrinsic proliferative advantage 
and induce T-cell suppression through interactions with PD-1 receptors potentially contributing 
to disease progression
12. They also showed in BM samples, blasts from HR-MDS patients 
expressed PD-L1 molecules more often compared with those from LR-MDS p atients while the 
BM T-cells over-expressed PD-1 mo lecules12. The MD Anderson group studied mRNA in 
CD34+ cells from 124 patients with MDS, AML and chronic myelomonocytic leukemia 
(CMML) and found that 34%, 15%, and 8% had aberrant up-regulation ( ·ÄÖ2-fold) in PD-L1, PD- 
1 and CTLA4, respectively13. PD-L1 protein expression was observed in MDS CD34+ cells, 
whereas stromal and non-blast cellular elements were pos itive for PD -1. More importantly, in a 
subgroup of patients treated with DNMTi therapy, PD-L1, PD-[ADDRESS_856847] the 
PD-1/PD-L1 axis might mediate resistance to DNMTi therapy and provide rationale for using immune checkpoint blockade with an anti-PD1 antibody as a novel therapeutic approach to improve outcomes of HR-MDS patients. However, preliminary results from ongoing early phase 
clinical trials of ant-CTLA-4 and anti-PD1/PD-L1 agents in MDS patients s uggest that immune 
checkpoint therapy as a monotherapy only leads to disease stabilization in some patients but very few responses. This observation provides rationale for combining immune checkpoint therapy 
with other novel agents with distinct mechanisms of action to improve patient outcomes. 
Additionally, there is no single biomarker to predict the response to anti-PD1 therapy in cancers. 
25 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856848] the question about the expression of PD-L1 in CD34+ blasts from human MDS BM and its correlation with the response to combined anti-PD1/ENT therapy in MDS in specific aim 2. 
 
 
3. PATIENT SELECTION 
 
3.1 Eligibility Criteria 
 
3.1.1 Pathologically confirmed MDS diagnosis (regardless of initial IPSS risk category) or oligoblastic AML with 21-30% BM blasts in whom DNMTi have 
failed. Patients who have developed AML after DNMTi therapy can be enrolled 
as long as they have initiated DNMTi therapy while they were in the MDS or 
oligoblastic AML (20-30% BM blasts) phase and the study chair agrees. Failure 
of DNMTis is defined as: Failure to achieve a CR, PR or HI after at least 4 cycles 
of DNMTi or progressed after such therapy. 
 
3.1.2 $JH¬ï  years 
  Because no dosing or adverse event data are currently available on the use of 
entinostat in combination with pembrolizumab (MK-3475) in patients <18 years 
of age, children are excluded from this study, but will be eligible for future pediatric trials. 
 
3.1.3 (&2*SHUIRUPDQFHVWDWXV¬î Appendix C ). 
 
3.1.[ADDRESS_856849] results within these ranges: 
x Calculated creatinine clearance by [CONTACT_86605] (CrCl) =>60 ml/min/1.73 squared meter 
x 7RWDOELOLUXELQ¬îPJG/XQOHVVGXHWR*LOEHUW¬∂VV\QGURPH
hemolysis, or ineffective hematopoiesis and AST (SGOT) and 
$/76*37¬î[  ULN 
 
3.1.[ADDRESS_856850] cycle of therapy. 
‚Ä¢ Patients must have no clinical evidence of CNS or pulmonary leukostasis, disseminated intravascular coagulation, or CNS 
leukemia. 
‚Ä¢ Patients must have no serious or uncontrolled medical conditions 
26 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 3.1.6 The effects of entinostat and pembrolizumab (MK-3475) on the developi[INVESTIGATOR_195096]. For this reason, women of child-bearing potential and men who are sexually active with women of childbearing potential must agree to 
use adequate contraception (hormonal or barrier method of birth control; 
abstinence) prior to study entry and for the duration of study participation. 
Should a woman become pregnant or suspect she is pregnant while she or her 
partner is participating in this study, she should inform her treating physician immediately. Men who are sexually active with women of childbearing 
potential, treated or enrolled on this protocol must also agree to use adequate 
contraception prior to the study, for the duration of study participation, and 4 
months after completion of entinostat and MK3475 (pembrolizumab) 
administration. 
 
3.1.[ADDRESS_856851] 4 months of 
DNMTi therapy, are eligible to be enrolled in this clinical trial. 
 
3.1.9 Patients who are Human Immunodeficiency Virus (HIV) positive may participate IF they meet the following eligibility requirements:  
x Must be on an effective anti-retroviral therapy with undetectable viral load 
within [ADDRESS_856852] a CD4 count of greater than 250 cells/mcL. 
x They must not be receiving prophylactic therapy for an opportunistic infection. 
 
 
3.[ADDRESS_856853] will be eligible for the trial. 
3.2.2.  Any serious medical condition, uncontrolled intercurrent illness (e.g., active 
infection, symptomatic CHF, unstable angina, cardiac arrhythmias, laboratory abnormalities, or psychiatric illness and/or biopsychosocial conditions that may limit 
compliance 
3.2.3.  Patients with known active cancers who are on therapy for those cancers at time of 
screening. 
3.2.4.  Patients with a known positive test for hepatitis B virus surface antigen (HBV sAg) 
or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection 
might be enrolled if the viral load by [CONTACT_622317]/without active treatment. 
3.2.5.  Pregnant or breast feeding females (lactating females must agree not to breast feed 
while taking the study drugs) 
27 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856854] not recovered from adverse events due to agents administered more than 4 weeks earlier 
3.2.7.  Known hypersensitivity to pembrolizumab (MK-3475) or history of allergic 
reactions to compounds of similar chemical or biologic composition to anti-PD1 or PD- 
L1 antibodies or entinostat. 
3.2.8.  Prior treatment with any anti-PD-[ADDRESS_856855] 3 months of enrollment in the study. 
3.2.9.  Any history of active or severe autoimmune disease: Inflammatory bowel disease, 
including ulcerative colitis and Crohn‚Äôs Disease, rheumatoid arthritis, systemic 
progressive scleroderma, systemic lupus erythematosis, autoimmune vasculitis (e.g., 
Wegener‚Äôs Granulomatosis), CNS or motor neuropathy considered of autoimmune origin 
(e.g. Guillain-Barre Syndrome, myasthenia gravis, multiple sclerosis). Patients with hypothyroidism with stable hormone replacement therapy dosing are allowed on study. 
3.2.10.  Has a history of (non-infectious) pneumonitis that required steroids or has current 
pneumonitis 
 
3.3 Inclusion of Women and Minorities 
 
NIH policy requires that women and members of minority groups and their subpopulations be 
included in all NIH-supported biomedical and behavioral research projects involving NIH- defined clinical research unless a clear and compelling rationale and justification establishes to 
the satisfaction of the funding Institute & Center (IC) Director that inclusion is inappropriate 
with respect to the health of the subjects or the purpose of the research. Exclusion under other 
circumstances must be designated by [CONTACT_25513], NIH, upon the recommendation of an IC 
Director based on a compelling rationale and justification. Cost is not an acceptable reason for exclusion except when the study would duplicate data from other sources. Women of 
childbearing potential should not be routinely excluded from participation in clinical research. 
Please see http://grants.nih.gov/grants/funding/phs398/phs398.pdf . 
 
4. REGISTRATION PROCEDURES (ROSTERED PROTOCOL MODEL) 
 
4.1 Investigator and Research Associate Registration with CTEP 
 
Food and Drug Administration (FDA) regulations and National Cancer Institute (NCI) policy 
require all individuals contributing to NCI-sponsored trials to register and to renew their registration annually. To register, all individuals must obtain a Cancer Therapy Evaluation 
Program (CTEP) Identity and Access Management (IAM) account 
(https://ctepcore.nci.nih.gov/iam). In addition, persons with a registration type of Investigator 
(IVR), Non-Physician Investigator (NPI[INVESTIGATOR_6731]), or Associate Plus (AP) (i.e., clinical site staff 
requiring write access to OPEN or RAVE or acting as a primary site contact) must complete their annual registration using CTEP‚Äôs web-based Registration and Credential Repository (RCR) 
(https://ctepcore.nci.nih.gov/rcr). Documentation requirements per registration type are outlined 
in the table below. 
28 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
Documentation Required IVR NPI[INVESTIGATOR_278536] A 
FDA Form 1572  
D 
D  
Financial Disclosure Form  
D 
D 
D 
NCI Biosketch (education, training, employment, 
license, and certification)  
 
D 
 
D 
 
D 
HSP/GCP training  
D 
D 
D 
Agent Shipment Form (if applicable)  
D   
CV (optional)  
D 
D 
D 
An active CTEP-IAM user acc ount and appropriate RCR registration is required to access all 
CTEP and CTSU (Cancer Trials Support Unit) websites and applications. In addition, IVRs and 
NPI[INVESTIGATOR_25458] 1572 in RCR to allow the following: 
x Added to a site roster 
x Assigned the treating, credit, consenting, or drug shipment (IVR only) tasks in OPEN 
x Act as the site-protocol PI [INVESTIGATOR_6734]. 
Additional information can be found on the CTEP website at 
https://ctep.cancer.gov/investigatorResources/default.htm . For questions, please contact [CONTACT_412429] < [EMAIL_088] >. 
 
 
4.2 Site Registration 
 
This study is supported by [CONTACT_6818] (CTSU). 
 
Each investigator or group of investigators at a clinical site must obtain IRB approval for this 
protocol and submit IRB approval and supporting documentation to the CTSU Regulatory Office before they can be approved to enroll patients.  Assignment of site registration status in the 
CTSU Regulatory Support System (RSS) uses extensive data to make a determination of whether 
a site has fulfilled all regulatory criteria including but not limited to the following: 
x An active Federal Wide Assurance (FWA) number, 
x An active roster affiliation with the Lead Network or a participating organization, 
x A valid IRB approval 
x Compliance with all protocol specific requirements. 
29 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 In addition, the site-protocol Principal Investigator (PI) must meet the following criteria: 
x Active registration status 
x The IRB number of the site IRB of record listed on their Form FDA [ADDRESS_856856] submit a Study Specific Worksheet for Local 
Context (SSW) to the CIRB via IRBManager to indicate their intent to open the study locally. The CIRB‚Äôs approval of the SSW is then communicated to the CTSU Regulatory Office. In 
order for the SSW approval to be processed, the Signatory Institution must inform the CTSU 
which CIRB-approved institutions aligned with the Signatory Institution are participating in the 
study. 
 
4.2.1 Downloading Regulatory Documents 
 
Site registration forms may be downloaded from the NCI protocol # [ADDRESS_856857] be associated with the Corresponding 
or Participating protocol organization in the RSS. 
 
x Go to  https://www.ctsu.org and log in using your CTEP-IAM username [CONTACT_25558]. 
x Click on the Protocols tab in the upper left of your screen. 
x Either enter the protocol # in the search field at the top of the protocol tree, or 
x Click on the By [CONTACT_56124], and then select LAO-CT018 
and protocol #[ADDRESS_856858] the Site Registration documents link, and 
download and complete the forms provided. (Note: For sites under the CIRB initiative, IRB data will load to RSS as described above.) 
 
4.2.2 Requirements For NCI protocol # [ZIP_CODE] Site Registration: 
 
x IRB approval (For sites not participating via the NCI CIRB; local IRB 
documentation, an IRB-signed CTSU IRB Certification Form, Protocol of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption 
Form, or combination is accepted). 
 
4.2.3 Submitting Regulatory Documents 
 
Submit required forms and documents to the CTSU Regulatory Office, where they w ill 
be entered and tracked in the CTSU RSS. 
Regulatory Submission Portal: www.ctsu.org (members‚Äô area) t Regulatory  
30 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 Tab tRegulatory Submission 
When applicable, original documents should be mailed to: 
CTSU Regulatory Office [ADDRESS_856859] Philadelphia, PA [ZIP_CODE] 
Institutions with patients waiting that are unable to use the Portal should alert the CTSU 
Regulatory Office immediately at [PHONE_3811] in order to receive further instruction and support. 
 
4.2.4 Checking Site Registration Status 
 
You can verify your site registration status on the members‚Äô section of the CTSU 
website. 
x Go to https://www.ctsu.org and log in to the members‚Äô area using your CTEP-IAM 
username [CONTACT_2383] 
x Click on the Regulatory tab at the top of your screen 
x Click on the Site Registration tab 
x Enter your 5-character CTEP Institution Code and click on Go 
 
Note: The status given only reflects compliance with IRB documentation and institutional 
compliance with protocol-specific requirements as outlined by [CONTACT_6819]. It does not reflect compliance with protocol requirements for individuals participating on the 
protocol or the enrolling investigator‚Äôs status with the NCI or their affiliated networks. 
 
4.3 Patient Registration 
 
4.3.1 OPEN / IWRS 
 
Patient enrollment will be facilitated using the Oncology Patient Enrollment Network (OPEN). OPEN is a web-based registration system available to users on a 24/7 basis. It is integrated with the CTSU Enterprise System for regulatory and roster data interchange 
and with the Theradex Interactive Web Response System (IWRS) for retrieval of patient 
registration/randomization assignment. Patient enrollment data entered by [CONTACT_33979] / IWRS will automatically transfer to the NCI‚Äôs clinical data management system, 
Medidata Rave. 
 
The OPEN system will provide the site with a printable confirmation of registration and 
treatment information. Please print this confirmation for your records. 
 
For trials with slot reservation requirements, OPEN will connect to IWRS at enrollment 
initiation to check slot availability. Registration staff should ensure that a slot is 
31 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 available and secured for the patient before completing an enrollment. 
 
4.3.2 OPEN/IWRS User Requirements 
 
OPEN/IWRS users must meet the following requirements: 
x Have a valid CTEP-IAM account ( i.e., CTEP username [CONTACT_2383]). 
x To enroll patients or request slot reservations: Be on an ETCTN Corresponding 
or Participating Organization roster with the role of Registrar. Registrars must 
hold a minimum of an AP registration type. 
x To approve slot reservations or access cohort management: Be identified to 
Theradex as the ‚ÄúClient Admin‚Äù for the study. 
x Have regulatory approval for the conduct of the study at their s ite. 
 
Prior to accessing OPEN/IWRS, site staff should verify the following: 
x All eligibility criteria have been met within the protocol stated timeframes. 
x If applicable, all patients have signed an appropriate consent form and HIPAA 
authorization form. 
 
4.3.3 OPEN/IWRS Questions? 
 
Further instructional information on OPEN is provided on the OPEN tab of the CTSU 
website at https://www.ctsu.org or at https://open.ctsu.org . For any additional questions 
contact [CONTACT_25518] [PHONE_031] or [EMAIL_013] . 
 
Theradex has developed a Slot Reservations and Cohort Management User Guide, which 
is available on the Theradex website: 
http://www.theradex.com/clinicalTechnologies/?National-Cancer-Institute-NCI-[ADDRESS_856860] the Theradex Helpdesk: [PHONE_3915] or 
Theradex main number [PHONE_3916]; [EMAIL_411] . 
 
4.4 General Guidelines 
 
Following registration, patients should begin protocol treatment within 28days. Issues that 
would cause treatment delays should be discussed with the Principal Investigator. If a patient does not receive protocol therapy following registration, the patient‚Äôs registration on the study 
may be canceled. The Study Coordinator should be notified of cancellations as soon as possible. 
 
5. TREATMENT PLAN 
 
5.1 Agent Administration 
 
Treatment will be administered on an outpatient basis. Reported adverse events and potential risks are described in Section 7. Appropriate dose modifications are described in Section 6. 
No investigational or commercial agents or therapi[INVESTIGATOR_640231] 
32 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 be administered with the intent to treat the patient's malignancy. 
 
ENT has been previously evaluated as a single agent therapy in patients with MDS at these 
doses and has been well tolerated as in below table: 
 
Clinical trial 
Reference Phase Treated 
patient 
population  Doses and schedule used Safety profile 
Liquid Malignancies 
Gojo et al, 
Blood 2007 
[1] I 38 AML 
patients 18 primary 
refractory AML 20 
relapsed 
AML Entinostat 4 mg/m2 Days 1 
and 8 every 4 weeks escalated at increments of 
2 mg/m2 up to 10 mg/m
2 MTD: 8 mg/m2 weekly for 4 weeks every 
6 weeks. DLT: infections and neurologic toxicity manifesting as unsteady gait and somnolence Frequent non-DLTs: fatigue, anorexia, 
nausea, vomiting, hypoalbuminemia, and hypocalcemia. 
Ryan et al JCO 
2015 [2] I 28 patients 
with advanced solid tumors and lymphoma Part 1: Entinostat 2 
mg/m2 daily for 28 days, followed by 2 weeks off (6-week cycle) 
 
 
Part 2: Entinostat 2, 4, 6, 8, 10, or 12 mg/m2 every 2 weeks MTD: 10 mg/m2 every 2 weeks 
daily schedule was Intolerable at a dose and schedule explored. 
DLT: Nausea, vomiting, anorexia, and fatigue DLT daily schedule, dose 2 mg/m
2 (only 
2 patients): MTD was exceeded at the first dose level. abdominal/epi[INVESTIGATOR_640232], and cardiac arrhythmia (supraventricular tachycardia), elevated AST/ALT, hypotension, hypoalbuminemia, and hypophosphatemia in a second patient. 
   Part 3: Entinostat 2, 4, 6, 
8 mg/m2 weekly for [ADDRESS_856861] (fasting or fed) DLT every 14-day schedule, dose 10 
mg/m
2 (28 patients): 
DLT were nausea, vomiting, anorexia, and fatigue. The first patients with first course DLTs were observed at dose level 3 (6 mg/m
2). After five patients tolerated dose 
level 4 without DLT, dose escalation continued to level 5 (10 mg/m
2). One 
patient experienced similar DLTs at level 5 as had been seen at level 3. At dose level 6 (12 mg/ m
2), two patients experienced 
similar DLTs. 
Gore et al, Clin I 27 patients Part 1: Entinostat 2, 4, or MTD: 6 mg/m2 every other week or 4 
Cancer  with 6 mg/m2 PO every 2 mg/m2 weekly for 3 weeks followed by 1 
Research [3]  refractory weeks week of rest 
  solid Part 2: Entinostat 2 DLT: Hypophosphatemia and asthenia 
  tumors and mg/m2 twice weekly for 3 were dose limiting on the weekly and 
  lymphomas of 4 weeks twice-weekly dosing schedules no dose- 
   Part 3: Entinostat 4 or 5 limiting toxicity on every other week 
   mg/m2 weekly for 3 of 4 schedule 
   weeks  
33 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
Batlevi et al, 
Haematologica 
[4] II 49 patients 
with relapsed /refractory Hodgkin lymphoma Part 1: Entinostat 10 to 15 
mg PO every 2 weeks (Days 1 and 15) of a 4- week cycle 
Part 2: Entinostat [ADDRESS_856862] frequent grade 3 and 4 AE: 
thrombocytopenia (63%), anemia (47%), neutropenia (41%), leukopenia (10%), 
hypokalemia (8%), and hypophosphatemia (6%). 
Does reduction/delays: 51% of patients 
Solid malignancies 
Denis et al, 
JCO 2014 
(abstract) 
[5] I/ ER+ breast 
cancer or NSCLC Cycle 1: All patients: 
Entinostat [ADDRESS_856863] form without many details provided 
   Cycle2: Breast cancer: 
Entinostat [ADDRESS_856864] IROORZHGE\D¬ï -hour fast 
every 28 days + exemestane 25 mg QD PO  
   NSCLC: Entinostat [ADDRESS_856865] followed by a 
¬ïB-hour fast every 28 
days + erlotinib 150 mg 
QD PO  
Hausschild et 
al, Melanoma Research [6] II 28 patients 
with non- resectable metastatic melanoma Arm A: Entinostat 3 mg 
Days 1 and 15 of 4-week cycle 
 
Arm B: 7 mg Days 1, 8, 15 of 4-week cycle No treatment-related serious adverse 
events occurred. 
 
Toxicity was mild to moderate with nausea (39%) and hypophosphatemia (29%) as the most frequently reported events. occurrence of the most common adverse events was similar in both treatment arms 
   
As can be seen from the table, the dose we proposed (4mg/m2 weekly) has been widely used 
in other studies and has been well tolerated (see especially Hausschild et al, Gore et al and 
Batlevi et al) and there fore was chosen as the RP2D. This dose was already used in combination 
with azacitidine (a drug which has more myelosuppressive potential than pembrolizumab). This E1905 study was a randomized phase 2 study ( [STUDY_ID_REMOVED] ) of 10 days of AZA (50 
mg/m(2)/d) +/- entinostat (4 mg/m2) given on days 3 and 10 of each cycle and enrolled 149 
patients with MDS and the combination was well tolerated 23. Given that the entinostat 
manufacturer recommended the use of a flat dose of entinostat of 8 mg Po ins tead 
34 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 of 4mg/m2 based on a study that showed BSA-based dosing is not more accurate than fixed 
dosing 47. 
 
PART 1: 
 
 
The ENT monotherapy run-in part (cycle 1) will allow to study the changes in myeloid derived suppressor cells (MDSCs) at pre- and post- ENT treatment (the end of cycle 1) to 
dissect the effects of ENT monotherapy from those of the combined ENT/anti-PD1 therapy. 
 
We will perform ‚Äò3+3‚Äô classical dose escalation design to determine dose limiting toxicity 
(DLT). The first 3 patients will receive ENT at dose level 1 (DL1: 8mg on D1, 8 of 21-day cycles). pembrolizumab (MK-3475) will be added starting day 1 cycle 2 at the approved dose of 
200mg intravenously [IV] over 30 minutes on D1 of 21-day cycles) for 4 cycles (cycle 2-5). A 
safety committee that includes the study chair, the principal investigator [INVESTIGATOR_640233] a patient on the specific DL, as well as two sub-investigators from Yale will review 
safety data after enrollment of every [ADDRESS_856866] 3 treated patients in that dose level if there are toxicity/safety concerns 
that did not qualify as DLT (maximum of 6 evaluable patients to be enrolled at any dose level). 
The committee can also decide to enroll patients at a lower dose level after the first [ADDRESS_856867] 6 patients enrolled in any dose level even if no or one DLT occurred at that dose level if there are toxicity/safety concerns that did not qualify as DLT. The following regarding 
enrollment in different dose levels will be considered guidance for the safety committee but can 
be modified in accordance of above: If no patient of the 3 patients treated with combined therapy 
at DL1 develops DLT, then dose level 2 (DL2) will be tested. For instance, DL2 will be with 
ENT at 8mg on D1, 8 and 15 and pembrolizumab (MK-3475) at 200mg IV on D1 of 21-day 
cycles. If 1 patient out of the 3 patients has DLT at DL1, we will expand cohort to 3 more 
patients and if 1 patient of the 6 patients has DLT (i.e. only 0/3 or 1/6), we will test next dose 
(DL2). If no patient of the 3 patients treated with combined therapy at DL2 develop DLT, then 
DL2 will be used for part 2 (expansion cohort). If 1 patient out of the 3 patients has DLT at DL2, 
we will expand cohort to 3 more patients and if 1 patient of the 6 patients has DLT (i.e. only 0/3 or 1/6), dose level 2 (DL2) will be used for part 2 (expansion cohort). If [ADDRESS_856868] DLT, DL1 will be used for expansion cohort. The cycle duration will be 21 days, 
the maximum number of treatment cycles of entinostat will be 18 cycles and for pembrolizumab 
(MK-3475) the maximum number of cycles will be 17. Cycle [ADDRESS_856869] concurrent 
administration. In all the phases of the study, entinostat will be administered in clinic within 2 
hours before administration of pembrolizumab (MK-3475). Entinostat will be stored at the 
pharmacy and it will not be given for the patient to take home. 
 
 
An additional dose level (DL -1) in which day 8 of ENT will be omitted (i.e. ENT at 8mg on D1, and pembrolizumab (MK-3475) at 200mg IV on D1 of 21-day cycles) will be used if [ADDRESS_856870] 2 cycles of combined therapy at DL1. If 0 or 1 
patients of the 6 patients treated with combined therapy at DL-1 develop DLT then DL-1 will be used in the second part of the study. If 2 or more 6 patients enrolled in DL -1 develop 
35 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 DLT, then the study w ill be terminated. 
 
Toxicities will be tabulated and graded according to the Common Terminology Criteria for 
Adverse Events Version 5 (CTCAE-5). DLT will be assessed after the first 2 cycles of 
combined therapy. Responses will be as defined by [CONTACT_57937]-2006 criteria (CR, PR, or HI) and 
assessed at the end of the combined first 2 cycles, and every 2 cycles afterwards. Patients 
who achieve an objective response or maintain a stable disease (SD) status after the first 4 combination cycles will continue receiving both drugs at the same schedule till progression 
up to 1 year of combined therapy. 
 
PART 2: After the safe dose of the combination is established, 15 patients will be treated 
with ENT+ pembrolizumab (MK-3475) combination at that same dose and schedule. Assessment of response will occur after 4 combination cycles and similar to part 1, those 
who achieve an objective response or SD will continue to receive the therapy till progression. 
Patients who progress or respond and subsequently lose response will be withdrawn from 
study. BM biopsy/aspi[INVESTIGATOR_640234], after first cycle of ENT 
monotherapy, every [ADDRESS_856871] 5 cycles (i.e. 1 ENT monotherapy cycle and 4 cycles 
of combined therapy (DL1, DL2) for each patient) to assess for any unexpected autoimmune 
or other toxicity. In all the phases of the study, entinostat will be administered in clinic 
within 2 hours before administration of pembrolizumab (MK-3475). Entinostat w ill be stored 
at the pharmacy and it will not be given for the patient to take home. 
 
 
 

36 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
 
Dose Escalation Schedule 
Dose Level Dose* 
Entinostat MK-3475 - Pembrolizumab 
Level -1(Backup dose 
level) 8mg po D1 200mg 
Level 1 (starting dose 
level) 8mg po D1,8 200mg 
Level 2 8mg po D1,8,15 200mg 
*Doses are stated as exact dose in units ( e.g., mg/m2, mcg/kg, etc.) rather than as a percentage. 
 
5.1.1 Pembrolizumab (MK-3475) 
 
Trial treatment should be administered on Day 1 of each cycle after all 
procedures/assessments have been completed. Trial treatment may be administered up to 
1 day (calendar states +/- 1 day window, so does Entinostat dosing, and needs to be 
administered within 2 hours after entinostat dose so needs to be 1 day window) before or after the scheduled Day 1 of each cycle due to administrative reasons. 
 
Pembrolizumab (MK-3475) is added on day one of each subsequent cycle starting 
Cycle 2. Pembrolizumab (MK-3475) trea tment will be administered on an 
outpatient basis. 
 
Pembrolizumab (MK-3475) w ill be administered as a 30 minute IV infusion (treatment 
cycle intervals may be increased due to toxicity as described in Section 6.1). Infusion 
timing should be as close to 30 minutes as possible; however, a window of -5 minutes 
and +10 minutes is permitted ( i.e., infusion time is 30 minutes: -5 min/+10 min). 
 
5.1.[ADDRESS_856872] 1 hour before or 2 
hours after a meal. Entinostat is supplied as pi[INVESTIGATOR_22759] (1 mg) or yellow (5 mg) 
coated tablets. Entinostat is to be stored at controlled room temperature (15¬∫C to 25¬∫C) in 
a secure, locked storage area to which access is limited. Entinostat is to be protected from light. Entinostat is not to be exposed to extremes of temperature (greater than 30¬∫C or less 
than 5¬∫C). The medication will be dispensed in the clinic. Administration one day prior to 
or one day after the scheduled day will be allowed. 
 
5.1.3 Other Modality(ies) or Procedures: N/A 
 
5.2 Definition of Dose-Limiting Toxicity 
 
The primary endpoint is the maximum tolerated dose (MTD), which is the highest dose level 
where 1 or fewer of 6 participants experience a dose limiting toxicity (DLT) during the first two combined cycles of treatment. The recommend phase 2 dose (RP2D) is the same as the MTD. 
37 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 The maximally administered dose is the dose at which two or more of 6 participants experience a 
38 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856873] 2 cycles of combined 
therapy unless the event can clearly be determined to be unrelated to the study drugs. 
 
¬É Any grade 3 or 4 non-hematologic toxicity with the following exceptions: A) Transient 
laboratory abnormalities that can be treated or resolve to grade 2 or less within 72 hours. 
¬É Grade 4 hematologic toxicity, including treatment-associated aplasia lasting >[ADDRESS_856874] 2 cycles of combined therapy without experiencing a 
DLT (as DLT period is defined in the first 2 combined therapy cycles) during dose escalation will 
also be replaced. To be DLT-evaluable, the patient must complete the first two cycles of combined 
therapy without experiencing a DLT. Any patient who is dose reduced during the entinostat run- in first cycle due to entinostat-related toxicity will be analyzed on the dose level that corresponds 
to the reduced dose level delivered during the first cycle of combined therapy. 
 
A safety committee that includes the study chair, the principal investigator [INVESTIGATOR_640235] a patient on the specific DL, as well as two sub-investigators from Yale will review safety data after enrollment of every [ADDRESS_856875] 3 treated patients in that dose level if there are toxicity/safety 
concerns that did not qualify as DLT (maximum of 6 evaluable patients to be enrolled at any 
dose level). The committee can also decide to enroll patients at a lower dose level after the first [ADDRESS_856876] 6 patients enrolled in any dose level even if no or one DLT occurred at that dose 
level if there are toxicity/safety concerns that did not qualify as DLT. The following regarding enrollment in different dose levels will be considered guidance for the safety committee but can 
be modified in accordance of above. Dose escalation will proceed within each cohort according 
to the following scheme. 
 
Number of Patients with DLT at a 
Given Dose Level 
 
Escalation Decision Rule 
0 out of 3 Enter 3 patients at the next dose level. 
¬ï Dose escalation will be st opped. This dose level w ill be 
declared the maximally administered dose (highest dose 
administered). Three (3) additional patients will be 
entered at the next lowest dose level if onl y 3 patients 
39 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856877] 3 more patients at this dose level. 
x If 0 of these 3 patients experience DLT, proceed to 
the next dose level. 
x If 1 or more of this group suffer DLT, then dose 
escalation is stopped, and this dose is declared the maximally administered dose. Three (3) additional 
patients will be entered at the next lowest dose level 
if only 3 patients were treated previously at that dose. 
¬îRXWRIDWKLJKHVWGRVHOHYHO
below the maximally administered 
dose This is generally the recommended phase 2 dose 
(RP2D)= MTD. At least [ADDRESS_856878] be entered at 
the recommended phase 2 dose (RP2D). 
 
Management and dose modifications associated with the above adverse events are outlined in Section [ADDRESS_856879] 2 cycles of combined therapy without experiencing a DLT (as DLT period 
is defined in the first 2 combined therapy cycles) will also be replaced. To be DLT-evaluable, the 
patient must complete the first two cycles of combined therapy without experiencing a DLT. Any 
patient who is dose reduced during the entinostat run-in first cycle due to entinostat-related toxi city 
will be analyzed on the dose level that corresponds to the reduced dose level delivered during the first cycle of combined therapy. 
 
The following early stoppi[INVESTIGATOR_640236]: We will cease enrollment in the expansion phase at the dose determined from dose escalation part of 
the study if we observe two or more DLTs among the first six evaluable patients enrolled in the 
expansion cohort. An evaluable patient is any patient who received a study drug. If the true 
toxicity rate is 50% or greater at the MTD then this rule will stop the trial with probability at 
least .89. Similarly, if the true toxicity rate is 33% at the MTD then this stoppi[INVESTIGATOR_640220] .65. In that event, a new expansion cohort will start at the dose level 
immediately below the dose level that was expanded. If the dose level being expanded is dose 
level -1, then the study w ill be terminated. 
Monitoring of all safety and toxicity data is done by [CONTACT_079] [INVESTIGATOR_640237] a real-time basis as data are entered into Medidata Rave using 
the Web Reporting Module. All participating sites are expected to notify the Principal 
Investigator [CONTACT_152561] a DLT has occurred. 
 
 
5.4 General Concomitant Medication and Supportive Care Guidelines 
40 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856880] of drugs to avoid or minimize use 
of. Appendix F (Patient Drug Information Handout and Wallet Card) should be provided to 
patients if available. 
 
5.4.1 Pembrolizumab (MK-3475) 
 
[IP_ADDRESS] Pembrolizumab (MK-3475) Concomitant Medication 
 
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing trial. If there is a clinical indication for one of these or other medications or 
vaccinations specifically prohibited during the trial, discontinuation from trial therapy or vaccination may be required. The investigator should discuss any questions regarding this with 
CTEP. The final decision on any supportive therapy or vaccination rests with the investigator 
and/or the subject's primary physician; however, the decision to continue the subject on trial 
therapy or vaccination schedule requires the mutual agreement of the Investigator, CTEP, and 
the patient. 
 
Acceptable Concomitant Medications 
All treatments that the investigator considers necessary for a patient‚Äôs welfare may be 
administered at the discretion of the investigator in keepi[INVESTIGATOR_12983]. All concomitant medication will be recorded on the case report form (CRF) including all prescription, over-the-counter (OTC), herbal supplements, and IV medications and 
fluids. If changes occur during the trial period, documentation of drug dosage, frequency, route, 
and date may also be included on the CRF. 
 
All concomitant medications received within [ADDRESS_856881] dose of trial treatment should be recorded for SAEs. 
 
Prohibited Concomitant Medications 
Patients are prohibited from receiving the following therapi[INVESTIGATOR_80025] (including retreatment for post-complete response relapse) of this trial: 
 Anti-cancer systemic chemotherapy or biological therapy. 
 Immunotherapy not specified in this protocol. 
 Chemotherapy not specified in this protocol. 
 Investigational agents other than pembrolizumab (MK-3475). 
 Radiation therapy 
41 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 o Note: Radiation therapy to a symptomatic solitary lesion or to the brain may be 
allowed after consultation with Sponsor. 
 Live vaccines within [ADDRESS_856882] dose of trial treatment and while 
participating in the trial. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus 
vaccines and are allowed; however, intranasal influenza vaccines ( e.g. Flu-Mist
¬Æ) are live 
attenuated vaccines, and are not allowed. 
 Glucocorticoids for any purpose other than to modulate symptoms from an event of 
suspected immunologic etiology. The use of physiologic doses of corticosteroids may be 
approved after consultation with the Sponsor. 
 
Patients who, in the assessment by [CONTACT_093], require the use of any of the aforementioned treatments for clinical management should be removed from the trial. Patients may receive other 
medications that the investigator deems to be medically necessary. 
 
The Exclusion Criteria describes other medications which are prohibited in this trial. 
There are no prohibited therapi[INVESTIGATOR_3927]-Trea tment Follow -up Phase. 
Co-administration of drugs sensitive substrates of CYPs 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6 
with a narrow therapeutic window are permitted, as it appears that entinostat is unlikely to inhibit these enzymes in humans. 
 
 
5.5 Duration of Therapy 
 
In the absence of treatment delays due to adverse event(s), treatment may continue for one year 
(maximum 18 cycles or entinostat and maximum 17 cycles of pembrolizumab (MK-3475) or 
until one of the following criteria applies: 
 
x Disease progression as defined in modified IWG-2006 (Appendix A1 , Appendix 
A2) for MDS 
 
x If disease has shown evidence of progression based on an increase in the blast counts 
according to the modified IWG-2006, but the patient is otherwise clinically stable and 
his transfusion requirement have not changed, the investigator can give two additional 
cycles of combined treatment and bone marrow biopsy will be repeated after that 
cycle. If repeat bone marrow biopsy confirms disease progression, the patient will be taken off the trial. 
 
x Intercurrent illness that prevents further administration of treatment 
 
x Patient decides to withdraw from the study 
 
x General or specific changes in the patient's condition render the patient unacceptable 
for further treatment in the judgment of the investigator 
42 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856883] they might be pregnant (e.g., missed or late menstrual period) at any time during study participation. 
 
o The investigator must immediately notify CTEP in the event of a confirmed 
pregnancy in a patient participating in the study. 
 
x Termination of the study by [CONTACT_3211] 
 
x The drug manufacturer can no longer provide the study agent 
 
x Unacceptable adverse event(s), including: 
 
x Any Grade 2 drug-related uveitis or eye pain or blurred vision that does not 
respond to topi[INVESTIGATOR_20308] 1 severity within the re- 
treatment period OR requires systemic treatment. 
 
x Grade 3 drug-related autoimmune or inflammatory event including uveitis, 
pneumonitis, diarrhea, colitis, neurologic adverse events, hypersensitivity 
reaction, or infusion reaction of any duration requires discontinuation. 
 
x Any Grade 3 or 4 drug-related laboratory imbalance or electrolyte abnormality, 
not associated with underlying organ pathology and that do not require treatment 
except for electrolyte replacements, do not require treatment discontinuation, with 
the following exceptions with approval of the Principal Investigator: 
 
x Grade 2-4 hypophysitis or pan-hypopi[INVESTIGATOR_640238] (MK-3475) and discontinuing treatment if unable to reduce 
FRUWLFRVWHURLGGRVHWR¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUG D\ZLWKLQ  
weeks. 
 
x Grade 4 amylase or lipase abnormalities that are not associated with diabetes 
mellitus, associated liver or gall bladder inflammation clinical manifestations 
of pancreatitis and which decrease to <Grade [ADDRESS_856884] (LFT) abnormality that meets the 
following criteria requires discontinuation: Grade [ADDRESS_856885] or ALT (>[ADDRESS_856886]) 
and total bilirubin >[ADDRESS_856887]. 
 
x Grade 3 drug-related thrombocytopenia >7 days or associated with bleeding 
43 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 requires discontinuation. 
 
x Any patient requiring systemic steroid or other immunosuppressive treatment. 
 
x For patients with skin-only toxicity, when symptoms improve to ¬îGrade 1, steroid 
taper should be started and continued over no less than 4 weeks. Discontinue MK- 
LIXQDEOHWRUHGXFHFRUWLFRVWHURLGGRVHIRULU$(VWR¬îP Jpembrolizumab 
(MK-3475) treatment may be restarted and the dose modified as specified in the 
protocol. 
 
x Patients with peripheral thyroiditis and no other autoimmune/inflammatory event may 
be restarted after a short course of steroids on a stable replacement regimen. 
 
x Any dosing interruption lasting >12 weeks with the following exceptions: 
x Dosing interruptions >[ADDRESS_856888] with a dosing interruption lasting >[ADDRESS_856889] be consulted. 
x Tumor assessments should continue as per protocol even if dosing is 
interrupted. 
 
The reason(s) for protocol therapy discontinuation, the reason(s) for study removal, and the 
corresponding dates must be documented in the Case Report Form (CRF). 
 
 
5.[ADDRESS_856890] dose 
of entinostat in combination with pembrolizumab (MK-3475) or 6 months after they are removed 
for the presence of any toxicity (early or late). 
 
During maintenance: Patients whose primary oncologist is at one of the study sites will be followed and seen by a member of the study team at least monthly in person or by [CONTACT_640296]. For patients who are followed by [CONTACT_640297], a study team member will evaluate the patients at least monthly in person or by [CONTACT_648]. 
 
During [ADDRESS_856891] dose or after removal from study: all patients will be evaluated by [CONTACT_640298]. Evaluations may be done during routine clinic visits in patients 
followed longitudinally at the study Cancer Center or via phone if in person visits are not possible due to logistical reasons. The study team will note the follow-up in the medical records 
and source documents will be sought for any change in condition related to the study or study 
drug. 
 
Patients removed from study for unacceptable adverse event(s) will be followed in person or by 
[CONTACT_640299] [ADDRESS_856892] showed a median OS of 5 months for pa tients with HR-MDS who 
44 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856893] be documented in the Case Report 
Form. 
 
5.8 Criteria to Resume Treatment 
 
For non-autoimmune or inflammatory events, patients may resume treatment with study drug 
when the drug- UHODWHG$(VUHVROYHWR*UDGH¬îRUEDVHOLQHYDOXHZLWKWKHI ROORZLQJ
exceptions: 
x Patients may resume treatment in the presence of Grade [ADDRESS_856894]/ALT or total bilirubin who require dose delays for 
reasons other than a 2-grade shift in AST/ALT or total bilirubin may resume treatment in 
the presence of Grade [ADDRESS_856895]/ALT OR total bilirubin. 
x Patients with combined Grade [ADDRESS_856896]/ALT AND total bili rubin values meeting study 
parameters outlined in Section 5.[ADDRESS_856897] resolved to baseline before treatment is resumed. 
x Drug-related endocrinopathies (not including drug-related adrenal insufficiency or 
hypophysitis) adequately controlled with only physiologic hormone replacement may resume treatment after replacement correction and clinically stable regimen. 
 
If the criteria to resume treatment are met, the patient should restart treatment no sooner than the next scheduled time point per protocol. However, if the treatment is delayed past the next scheduled time point per protocol, the treatment should resume at the ear liest c onvenient point 
that is within the 12 week delay period. 
 
If treatment is delayed >[ADDRESS_856898] be permanently discontinued from study 
therapy, except as specified in Section 5.4 (Duration of Therapy). 
 
5.9 Treatment Beyond Progression 
 
Immunotherapeutic agents such as pembrolizumab (MK-3475) may produce antitumor 
effects by [CONTACT_134981]-specific immune responses. The response patterns 
seen with such an approach may extend beyond the typi[INVESTIGATOR_640239], and can manifest as a clinical res ponse after an initial increase in 
tumor burden. 
 
If bone marrow biopsy shows progressive disease (PD) but patient is clinically stable and blood 
45 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856899] evidence of disease progression determined by (bone marrow biopsy) is at the Investigator‚Äôs discretion based on the clinical status of the patient as described in the table below. 
 
 
Patients may receive study treatment while waiting for confirmation of PD if they are clinically stable as defined by [CONTACT_4868]: 
x Absence of signs and symptoms (including worsening of laboratory values) indicating 
disease progression 
x No decline in ECOG performance s tatus 
x Absence of rapid progression of disease 
 
 Clinically Stable Clinically Unstable 
 - Bone Marrow 
Biopsy Treatment Bone Marrow 
Biopsy Treatment 
1st bone marrow 
evidence of PD Repeat bone 
marrow biopsy 
at approximately 
4 weeks to 
confirm PD May continue 
study treatment 
at the 
Investigator‚Äôs 
discretion while awaiting 
confirmatory 
scan Repeat bone 
marrow biopsy 
at approximately 
4 weeks to 
confirm PD if possible Discontinue 
treatment 
Repeat bone 
marrow biopsy 
confirms PD No additional 
bone marrow 
biopsyrequired Discontinue 
treatment No additional 
bone marrow 
biopsy required N/A 
Repeat bone 
marrow biopsy 
shows SD, PR, 
or CR Continue 
regularly 
scheduled bone 
marrow biopsies 
every 6 weeks Continue study 
treatment at the 
Investigator‚Äôs 
discretion Continue 
regularly 
scheduled bone 
marrow biopsies 
every 6 weeks May restart 
study treatment 
if condition has 
improved and/or 
clinically stable 
per 
Investigator‚Äôs 
discretion 
Bone marrow biopsies will occur at the end of Cycle [ADDRESS_856900] attained a confirmed 
complete response (CR) that have been treated for at least 24 weeks with entinostat and MK- 
46 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/[ADDRESS_856901] two treatments with entinostat and pembrolizumab (MK-3475) beyond 
the date when the initial CR was declared. 
 
5.11 Treatment Up to 1 Years 
 
Treatment with entinostat and pembrolizumab (MK-3475) will continue for up to one year of 
combined therapy administered, documented disease progression, una cceptable adverse 
event(s), intercurrent illness that prevents further administration of treatment, investigator‚Äôs 
decision to withdraw the patient, patient withdraws consent, pregnancy of the patient, 
noncompliance with trial treatment or procedure requirements, or administrative reasons. 
 
 
6. DOSING DELAYS/DOSE MODIFICATIONS 
 
Although entinostat and pembrolizumab (MK-3475) have distinct toxicity profiles, they do share some AEs 
such as fatigue and nausea. There is the theoretical possibility that 1 agent may potentiate the 
other and hence drug causality will not always be clear. In the event of uncertainty, dose 
reductions and/or delays will follow the most conservative approach (i.e., delays and/or dose 
reductions for both drugs) until resolution of the event. No dose reductions will be performed for pembrolizumab (MK-3475). Guidance for delays and or dose reductions for entinostat are 
presented. 
 
 
6.1 Entinostat Dose Modifications and S upportive Care Guidelines for Drug-Related 
Adverse Events 
 
6.1.1 Dose Modifications: see tables below 
 
6.1.2 Dose Modifications: see tables below 
 
6.1.3 Table of Dose Modifications and Supportive Care Guid elines 
 
Dose Level Entinostat Dose 
-1 8 mg, po D1 
+1 8 mg, po D1, D8 
+2 8 mg, po D1, D8, D15 
Note: All treatment modifications must be expressed as a specific dose or amount rather than as 
a percentage of the starting or previous dose. 
 
Nausea Management/Next Dose for Entinostat 
¬î*UDGH  No change in dose 
Grade 2 +ROGXQWLO¬î*UDGH5HVXPHDWVDPHGRVHOHYHO  
Grade 3 Hold* until < Grade 2. Resume at one dose level lower, if indicated.** 
Grade 4 Off protocol therapy 
*Patients requiring a delay of >2 weeks s hould go off protocol therapy. 
47NCI Protocol #:[ZIP_CODE] 
Version Date: 09/04/2020
Nausea Management/Next Dose for Entinostat
**Patients requiring > two dose reductions should go off protocol therapy.
Recommended management: antiemetics.
Vomiting Management/Next Dose for entinostat
¬î*UDGH No change in dose
Grade 2 +ROGXQWLO¬î*UDGH5HVXPHDWVDPHGRVHOHYHO
Grade 3 Hold* until < Grade 2. Resume at one dose level lower, if indicated.**
Grade 4 Off protocol therapy
*Patients requiring a delay of >2 weeks should go off protocol therapy.
**Patients requiring > two dose reductions should go off protocol therapy.
Recommended management: antiemetics.
Diarrhea Management/Next Dose for entinostat
¬î*UDGH No change in dose
Grade 2 +ROGXQWLO¬î*UDGH5HVXPHDWVDPHGRVHOHYHO
Grade 3 Hold* until < Grade 2. Resume at one dose level lower, if indicated.**
Grade 4 Off protocol therapy
*Patients requiring a delay of >2 weeks should go off protocol therapy.
**Patients requiring > two dose reductions should go off protocol therapy.
Recommended management: Loperamide antidiarrheal therapy
Dosage schedule: [ADDRESS_856902] onset, followed by 2 mg with each loose motion until diarrhea- 
free for 12 hours (maximum dosage: 16 mg/24 hours) 
Adjunct anti-diarrheal therapy is permitted and should be recorded when used.
For other non-hematological toxicities that are grade 2 and do not resolve within a week, the 
investigator can reduce the entinostat dosing by [CONTACT_30560] (e.g. go from DL2 dosing to DL1 
dosing). 
Given the frequent occurrence of severe cytopenias among patients with MDS and AML which 
are disease and not drug related and that worsening of cytopenias is a common occurrence during 
the disease course, the below dose modifications of entinostat for hematologic adverse events are 
considered guidance for the treating investigator and not mandatory. The decision to modify/hold 
dose will be at the discretion of the treating investigator and should include consideration of the clinical situation including severity consideration of baseline counts. 
Dose Modifications 
Hematologic adverse
events 
48 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
¬ï*UDGHQHXWURSHQLD  
¬ï*UDGH
thrombocytopenia, Administer symptomatic remedies/ start prophylaxis. 
Hold dose1 until recovery to Grade 1 or study baseline under the 
following direction: 
1. If not recovered by [CONTACT_513720], skip the dose. If 
recovered by [CONTACT_513720], resume study drug at 
prior dose. 
2. If receiving 8 mg dose on day 1 and 8, and not recovered by 
[CONTACT_513721] 2 scheduled doses, permanently 
discontinue study treatment. Otherwise, skip each dose. If 
recovered for either of these doses, resume study drug as follows: 
x If receiving 8 mg on days 1 and 8, restart study drug at 8 
mg only on day 1. 
x If receiving 8 mg on days 1, 8, and 21, restart study drug at 
8 mg only on days 1 and 8. 
3. If not recovered within 4 weeks, permanently discontinue 
study drug. 
Recurrence of the same 
hematologic toxicity 1. If the same hematologic toxicity recurs: 
x Administer symptomatic remedies/ start prophylaxis. 
Hold1 dose until recovery to Grade 1 or baseline. 
2. If recovered within 2 weeks, resume study drug as follows: 
x If receiving 8 mg on days 1 and 8, restart study drug 
at 8 mg on day 1 only 
x If receiving 8 mg on day 1 only, permanently 
discontinue study drug 
3. ,IWKHVDPH¬ï*UDGHHYHQWUHFXUVLHWKLUGRFFXUUHQFH
despi[INVESTIGATOR_640240] 8 mg on day 1 only, as 
described above, permanently discontinue study drug. 
* Therapy emergent neutropenia or thrombocytopenia is defined as 50% or more reduction from 
the baseline. 
1 If greater than 50% of doses are missed during any 6-week period, discontinue from study drug 
treatment. 
# There will be no dose modification for anemia 
 
6.2 Pembrolizumab (MK-3475) Dose Modifications and Supportive Care Guidelines for Drug-Related Adverse Events 
 
6.2.1 Dose Modifications 
 
Immune-related adverse events (irAEs), defined as AEs of unknown etiology, associated with drug exposure and consistent with an immune phenomenon, may be predicted based on the 
49 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 nature of the pembrolizumab (MK-3475) compound, its mechanism of action, and reported 
experience with immunotherapi[INVESTIGATOR_89149] a similar mechanism of action. Special attention should be paid to AEs that may be suggestive of potential irAEs. An irAE can occur shortly 
after the first dose or several months after the last dose of treatment. All AEs of unknown 
etiology associated with drug exposure should be evaluated to determine if they are possibly 
immune-related. If an irAE is suspected, efforts should be made to rule out neoplastic, 
infectious, metabolic, toxin or other etiologic causes prior to labeling an adverse event as an irAE. 
 
6.2.[ADDRESS_856903] 1 month. Based on limited data from clinical studies in patients 
whose immune-related adverse reactions could not be controlled with corticosteroid use, 
administration of other systemic immunosuppressants can be considered. KEYTRUDA will be 
resumed when the immune-mediated adverse reaction remains at Grade 1 or less following 
corticosteroid taper. KEYTRUDA will be permanently discontinue for any Grade 3 immune- 
mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse 
reaction. The following clinically significant, immune-mediated adverse reactions occ urred in 
less than 1% (unless otherwise indicated) of 2799 patients treated with KEYTRUDA: arthritis 
(1.5%), exfoliative dermatitis, bullous pemphigoid, rash (1.4%), uveitis, myositis, Guillain-Barr√© syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures 
arising in a patient with inflammatory foci in brain parenchyma.‚Äù 
See complete Keytruda prescribing information, especially regarding permanent discontinuation for any Grade 3 immune-mediated adverse reaction that recurs. 
 
6.2.3 Table of Dose Modifications and Supportive Care Guid elines 
 
The table below includes guidelines for managing irAEs that are not listed in the AE-specific 
table 
 
General Dose Modification Guidelines for Drug-Related Immune-Related Adverse Events 
irAE Withhold/Discontinue MK- 
3475? Supportive Care 
Grade 1 No action Provide symptomatic treatment 
Grade 2 May withhold pembrolizumab 
(MK-3475) Consider systemic corticosteroids in addition to 
appropriate symptomatic treatment 
Grade 3 and Grade 4 Withhold pembrolizumab (MK-
3475) 
Discontinue if unable to reduce 
corticosteroid dose to < 10 mg 
per day prednisone equivalent 
within 12 weeks of toxicity Systemic corticosteroids are indicated in addition to 
appropriate symptomatic treatment. May utilize 1 to 2 
mg/kg prednisone or equivalent per day. 
Steroid taper should be considered once symptoms 
improve to Grade [ADDRESS_856904] 4 
weeks. 
 
Additionally, pembrolizumab (MK-3475) will be withheld for other drug-related Grade 4 
hematologic toxicities, non- KHPDWRORJLFDOWR[LFLW\¬ï*UDGHLQFOXGLQJODERUDWRU\
abnormalities, and severe or life- threatening AEs. 
50 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
  
The table below includes dose modification guidelines for other toxicities that do not appear to 
be irAEs and are not listed in the AE-specific table. 
 
Dose Modification Guidelines for Other Drug-Related Adverse Events 
 
 
Toxicity  
 
Grade Hold 
Treatment 
(Y/N) Timing for 
restarting 
treatment Dose/Schedule 
for restarting 
treatment  
Discontinue 
Subject 
Hematological Toxicity 1, 2, 3 No N/A N/A N/A 
[ADDRESS_856905] infusion 
Permanent 
discontinuation 
should be considered for any severe or 
life-threatening 
event 
Non-hematological toxicity 1 No N/A N/A N/A 
 
Note: Exception to be treated 
similar to grade 1 toxicity 
x Grade 2 alopecia 
x Grade 2 fatigue 
 
For additional information 
regarding Adverse Events with 
a potential Immune-Etiology reference Section 6.1.2. 2 Consider 
withholding 
for 
persistent symptoms Toxicity 
resolves to 
Grade 0-1 or 
baseline Clinical AE 
resolves within 4 
weeks :  Same 
dose and schedule 
Clinical AE does 
not resolve within 
4 weeks: May 
increase the 
dosing interval by 
[ADDRESS_856906] 
infusion 
 4 Yes N/A N/A Subject must be 
discontinued 
 
In case toxicity does not resolve to Grade 0-[ADDRESS_856907] infusion, trial treatment 
should be discontinued. With Principal Investigator [INVESTIGATOR_73261], subjects with a laboratory 
adverse event still at Grade 2 after 12 weeks may continue treatment in the trial only if 
asymptomatic and controlled. Patients who experience a recurrence of the same severe or life- 
threatening event at the same grade or greater with re-challenge of pembrolizumab (MK-3475) 
should be discontinued from trial treatment. 
51 NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020  
 AE-specific pembrolizumab (MK-3475) Dose Modifications and Supportive Care Guidelines: 
The table below includes recommendations on the management of specific AEs and when to hold and/or discontinue pembrolizumab (MK-3475). These guidelines are intended to be applied 
when the investigator determines the events to be treatment-related. Note: if after the evaluation 
the event is determined not to be related, the investigator does not need to follow the treatment 
guidance. Therefore, these recommendations should be seen as guidelines and the treating 
physician should exercise individual clinical judgment based on the pa tient. 
Given the frequent occurrence of severe cytopenias among patients with MDS and AML which 
are disease and not drug related and that worsening of cytopenias is a common occurrence during 
the disease course, the below dose modifications of pembrolizumab (MK-3475)  for hematologic 
adverse events are considered guidance for the treating investigator and not mandatory. The 
decision to modify/hold dose will be at the discretion of the treating investigator and should include consideration of the clinical situation including severity consideration of baseline counts. 
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
49  
  
 
AE-Specific Dose Modification Guidelines for Drug-Related Adverse Events 
Event(s) CTCAE v4.0 
Grade Management / 
Next Dose for 
pembrolizu
mab (MK-
3475)  
Action / Supportive Care Guidelines  
Colitis 
x Colitis 
x Colitis microscopic 
x Enterocolitis 
x Enterocolitis, 
hemorrhagic 
x Gastrointestinal (GI) 
perforation 
x Intestinal obstruction 
x Necrotizing colitis 
x Diarrhea Grade 2 
Diarrhea/Colitis (4- 
6 stools/day over baseline, 
dehydration 
requiring intravenous (IV) 
fluids <24 hours, 
abdominal pain, mucus or blood in stool) Hold 
pembrolizumab 
(MK-3475). x Symptomatic treatment 
x For Grade 2 diarrhea that persists for >3 days, and for diarrhea with 
blood and/or mucus: 
- Consider GI consultation and endoscopy to confirm or rule out colitis; and 
- Administer oral corticosteroids (prednisone 1-2 mg/kg once daily or 
equivalent). 
x :KHQV\PSWRPVLPSURYHWR¬î*UDGHVWHURLGWDSHUVKRXOGEH  started 
and continued over no less than 4 weeks. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRI prednisone or equivalent per day within [ADDRESS_856908] >3 days treat as Grade 3 
Grade 3 
Diarrhea/Colitis (or 
Grade 2 diarrhea 
that persists for >1 
week) Hold 
pembrolizumab 
(MK-3475). x Rule out bowel perforation. Imaging with plain films or computed 
tomography (CT) can be useful. 
x Recommend consultation with Gastroenterologist and confirmation 
biopsy with endoscopy. 
x Treat with IV steroids (methylprednisolone 125 mg) followed by [CONTACT_458531] (prednisone 1 to 2 mg/kg once per day or dexamethasone 4 mg every 4 hours). When symptoms improve to 
¬î*UDGHVWHURLGWDSHUVKRXOGEHVWDUWHGDQGFRQWLQXHGRYHUQR less than 
4 weeks. Taper over 6 to 8 weeks in patients with diffuse and severe ulceration and/or bleeding. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
x If IV steroids followed by [CONTACT_458532] 48 to 72 hours, consider treatment with additional anti-  
inflammatory measures as described in the literature
a. Discontinue 
additional anti-inflammatory measures upon symptom relief and initiate 
a prolonged steroid taper over 45 to 60 days.  If symptoms worsen during steroid reduction, initiate a retapering of steroids starting at a 
higher dose of 80 or 100 mg followed by a more prolonged taper and 
administer additional anti-inflammatory measures as needed. 
Grade 4 Permanently 
discontinue MK- 
3475 x Manage as per Grade 3. 
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
50  
  
Event(s) CTCAE v4.0 
Grade Management / 
Next Dose for 
pembrolizu
mab (MK-
3475)  
Action / Supportive Care Guidelines  
Endocrine 
 
Hyperthyroidism and 
Hypothyroidism Grade 2 
hyperthyroidism 
 
Grade 2-4 
hypothyroidism No change in dose x Monitor thyroid function or other hormonal level tests and serum 
chemistries more frequently until returned to baseline values. 
x Thyroid hormone and/or steroid replacement therapy to manage adrenal 
insufficiency. 
x Therapy with pembrolizumab (MK-3475) can be continued while 
treatment for the thyroid disorder is instituted. 
x In hyperthyroidism, non-selective beta-blockers ( e.g. propranolol) are 
suggested as initial therapy. 
x In hypothyroidism, thyroid hormone replacement therapy, with 
levothyroxine or liothyroinine, is indicated per standard of care. 
x Consultation with an endocrinologist may be considered. Thyroid disorders can 
occur at any time during 
treatment. Monitor 
patients for changes in thyroid function (at the 
start of treatment, 
periodically during treatment, and as indicated based on 
clinical evaluation) and 
for clinical signs and symptoms of thyroid 
disorders.    
Grade 3 
hyperthyroidism Hold 
pembrolizumab 
(MK-3475). x Rule out infection and sepsis with appropriate cultures and imaging. 
x Treat with an initial dose of methylprednisolone 1 - 2 mg/kg IVfollowed 
by [CONTACT_88316] 1 - 2 mg/kg per day. When symptoms improve to 
¬î*UDGHVWHURLGWDSHUVKRXOGEHVWDUWHGDQGFRQWLQXHGRYHUQR OHVVWKDQ
4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
 Grade 4 
hyperthyroidism Discontinue MK- 
3475. Manage as per Grade 3  
Endocrine Grade 2-4 Hold 
pembrolizumab (MK-3475). x Rule out infection and sepsis with appropriate cultures and imaging. 
x Monitor thyroid function or other hormonal level tests and serum 
chemistries more frequently until returned to baseline values. 
x Pi[INVESTIGATOR_308605] (magnetic resonance 
imaging [MRIs] with gadolinium and selective cuts of the pi[INVESTIGATOR_640241]). 
x Treat with prednisone 40 mg by [CONTACT_1966] (PO) or equivalent per day. 
:KHQV\PSWRPVLPSURYHWR¬î*UDGHVWHURLGWDSHUVKRXOGEH  started 
and continued over no less than 4 weeks. Replacement of appropriate hormones may be required as the steroid dose is tapered. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
x Hypophysitis with clinically significant adrenal insufficiency and 
hypotension, dehydration, and electrolyte abnormalities (such as hyponatremia and hyperkalemia) constitutes adrenal crisis. 
x Consultation with an endocrinologist may be considered.  
Hypophysitis or other 
symptomatic endocrinopathy other than hypo- or 
hyperthyroidism    
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
51  
  
Event(s) CTCAE v4.0 
Grade Management / 
Next Dose for 
pembrolizu
mab (MK-
3475)  
Action / Supportive Care Guidelines  
Endocrine 
 
Type 1 diabetes mellitus 
(T1DM), if new onset, 
including diabetic ketoacidosis (DKA) and 
¬ï*UDGH
hyperglycemia, if associated with ketosis 
(ketonuria) or metabolic 
acidosis (DKA). 
 
The patients may present 
with hyperglycemia 
(abrupt onset or abrupt decompensation) with clinical evidence of 
diabetic ketoacidosis or 
laboratory evidence of insulin deficiency, such 
as ketonuria, laboratory 
evidence of metabolic 
acidosis, or low or 
undetected c- peptide. T1DM or Grade 3-4 
hyperglycemia Hold 
pembrolizumab 
(MK-3475) for new onset T1DM 
or Grade 3-4 
hyperglycemia associated with 
evidence of beta 
cell failure, and resume pembrolizumab 
(MK-3475) when 
patients are clinically and 
metabolically 
stable. x T1DM should be immediately treated with insulin. 
x Insulin replacement therapy is recommended for T1DM and for Grade 3- 
[ADDRESS_856909] is recommended. 
x Consider local testing for islet cell antibodies and antibodies to GAD, 
IA-2, ZnT8, and insulin may be obtained. 
Hematologic 
x Autoimmune 
hemolytic anemia 
x Aplastic anemia 
x Disseminated 
Intravascular 
Coagulation (DIC) 
x Hemolytic Uremic 
Syndrome (HUS) 
x Idiopathic (or 
immune) Grade 2 Hold 
pembrolizumab 
(MK-3475) x Prednisone 1-2 mg/kg daily may be indicated. 
x Consider Hematology consultation. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
Grade 3 Hold 
pembrolizumab 
(MK-3475). 
Discontinuation 
should be considered as per 
specific protocol 
guidance. x Hematology consultation. 
x Discontinuation should be considered as per specific protocol guidance. 
x Treat with methylprednisolone 125 mg IV or prednisone 1-2 mg/kg PO 
(or equivalent) as appropriate 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
52  
  
Event(s) CTCAE v4.0 
Grade Management / 
Next Dose for 
pembrolizu
mab (MK-
3475)  
Action / Supportive Care Guidelines  
Thrombocytopenia 
Purpura (ITP) 
x Thrombotic 
Thrombocytopenic Purpura (TTP) 
x Any Grade 4 anemia 
regardless of underlying 
mechanism Grade 4  x Hematology consultation. 
x Discontinue MK-3475 for all solid tumor indications; refer to protocol 
for hematologic malignancies. 
x Treat with methylprednisolone 125 mg IV or prednisone 1-2 mg/kg PO 
(or equivalent) as appropriate. 
Hepatic 
x Autoimmune hepatitis 
x Hepatitis 
x Transaminase 
elevations Grade 2 Hold 
pembrolizumab 
(MK-3475) 
when AST or ALT 
>3.0 to 5.0 √ó ULN 
and/or total bilirubin >1.5 to 
3.0 √ó ULN. x Monitor liver function tests (LFT) more frequently until returned to 
baseline values (consider weekly). 
- Treat with 0.5-1 mg/kg/day methylprednisolone or oral equivalent 
and when LFT returns to Grade [ADDRESS_856910] 1 month, consider prophylactic antibiotics for opportunistic 
infections, and resume MK-3475 per protocol. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRU equivalent per day within [ADDRESS_856911] or 
$/7LQFUHDVHV¬ïUHODWLYHWREDVHOLQHDQGODVWV¬ï  week. 
Grade 3 Discontinue 
pembrolizumab 
(MK-3475) when AST or ALT >5.0 √ó ULN 
and/or total 
bilirubin >3.0 √ó ULN. x Consider appropriate consultation and liver biopsy to establish etiology 
of hepatic injury, if necessary. 
x Treat with high-dose IV glucocorticosteroids for 24-48 hours. When 
V\PSWRPVLPSURYHWR¬î*UDGHDVWHURLGWDSHUZLWKGH[DPHWKDVRQ H 4 
mg every 4 hours or prednisone at 1-2 mg/kg should be started and continued over no less than 4 weeks. 
x If serum transaminase levels do not decrease 48 hours after initiation of 
systemic steroids, oral mycophenolate mofetil 500 mg every 12 hours 
may be given. Infliximab is not recommended due to its potential for 
hepatotoxicity. 
x Several courses of steroid tapering may be necessary as symptoms may 
worsen when the steroid dose is decreased. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQ weeks. 
Grade 4 Permanently 
discontinue MK- 
3475 x Manage patient as per Grade 3 above. 
Nausea ¬î*UDGH  No change in dose x Nausea should be treated aggressively, and consideration should be  
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
53  
  
Event(s) CTCAE v4.0 
Grade Management / 
Next Dose for 
MK-3475  
Action / Supportive Care Guidelines  
 Grade 2 +ROGXQWLO¬î*UDGH  
1. 
 
Resume at same dose level. May 
increase dosing 
interval by [ADDRESS_856912] institutional practice. Patients 
should be strongly encouraged to maintain liberal oral fluid intake. 
 
Grade 3 Hold until <Grade 
2. May increase 
dosing interval by 1 week for each 
occurrence. 
 
Discontinue if 
toxicities do not resolve within 12 
weeks. 
Grade 4 Off protocol 
therapy 
Neurologic events 
x Autoimmune 
neuropathy 
x Demyelinating 
polyneuropathy 
x Guillain-Barre 
syndrome 
x Myasthenic syndrome Grade 2 Consider 
withholding 
pembrolizumab 
(MK-3475). x Consider treatment with prednisone 1-2 mg/kg PO daily as appropriate 
x Consider Neurology consultation. Consider biopsy for confirmation of 
diagnosis. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
x :KHQV\PSWRPVLPSURYHWR¬î*UDGHVWHURLGWDSHUVKRXOGEHVWDU WHG
and continued over no less than 4 weeks. 
Grade 3-4 Discontinue 
pembrolizumab 
(MK-3475) x Obtain neurology consultation. Consider biopsy for confirmation of 
diagnosis 
x Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg 
prednisone or equivalent once per day. If condition worsens consider 
IV immunoglobulin (IVIG) or other immunosuppressive therapi[INVESTIGATOR_591059] 
x :KHQV\PSWRPVLPSURYHWR¬î*UDGHVWHURLGWDSHUVKRXOGEH  started 
and continued over no less than 4 weeks. 
Neutropenia ¬î*UDGH  No change in dose   
  
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
54  
  
Event(s) CTCAE v4.0 
Grade Management / 
Next Dose for 
pembrolizu
mab (MK-
3475)  
Action / Supportive Care Guidelines  
 Grade 2 No change in dose   
Grade 3 No change in dose 
Grade 4 Hold until resolves 
WR ¬î*UDGH 0D\ 
increase the dosing 
interval by [ADDRESS_856913] is strongly recommended. 
x Treat with topi[INVESTIGATOR_90543] 1% prednisolone acetate suspension 
and iridocyclitics. 
Grade 3 Hold 
pembrolizumab 
(MK-3475) 
and consider 
permanent 
discontinuation per 
specific protocol guidance. x Evaluation by [CONTACT_308656]. 
x Treat with systemic corticosteroids such as prednisone at a dose of 1 to 2 
PJNJSHUGD\:KHQV\PSWRPVLPSURYHWR¬î*UDGHVWHURLGWDSHU 
should be started and continued over no less than 4 weeks. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
Grade 4 Permanently 
discontinue 
pembrolizumab 
(MK-3475). x Evaluation by [CONTACT_308656]. 
x Treat with corticosteroids as per Grade 3 above. 
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
55  
  
Event(s) CTCAE v4.0 
Grade Management / 
Next Dose for 
pembrolizu
mab (MK-
3475)  
Action / Supportive Care Guidelines  
Pneumonitis 
x Pneumonitis 
x Interstitial lung 
disease 
x Acute interstitial 
pneumonitis 
 
If symptoms indicate 
possible new or worsening 
cardiac abnormalities 
additional testing and/or a cardiology consultation should be considered. Grade 2 Hold 
pembrolizumab 
(MK-3475)  x Consider pulmonary consultation with bronchoscopy and 
biopsy/bronchoalveolar lavage (BAL). 
x Consider infectious disease consult. 
x Conduct an in person evaluation approximately twice per week 
x Consider frequent chest X-ray as part of monitoring 
x Treat with systemic corticosteroids at a dose of 1-2 mg/kg/day 
SUHGQLVRQHRUHTXLYDOHQW:KHQV\PSWRPVLPSURYHWR¬î*UDGH  steroid 
taper should be started and continued over no less than 4 weeks. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
x Second epi[INVESTIGATOR_55517] ‚Äì discontinue MK-3475 if upon re- 
challenge the patient develops a second epi[INVESTIGATOR_119988] 2 or higher 
pneumonitis. 
Grade 3-4 Discontinue 
pembrolizumab 
(MK-3475) x Hospi[INVESTIGATOR_28068] 
x Bronchoscopy with biopsy and/or BAL is recommended. 
x Immediately treat with IV steroids (methylprednisolone 125 mg IV). 
:KHQV\PSWRPVLPSURYHWR¬î*UDGHDKLJKGRVHRUDOVWHURLG
(prednisone 1 to 2 mg/kg once per day or dexamethasone 4 mg every 4 
hours) taper should be started and continued over no less than 4 weeks. 
x If IV steroids followed by [CONTACT_458532] 48 to 72 hours, treat with additional anti-inflammatory 
measures. Discontinue additional anti-inflammatory measures upon 
symptom relief and initiate a prolonged steroid taper over 45 to 60 days. If symptoms worsen during steroid reduction, initiate a retapering of 
steroids starting at a higher dose of 80 or 100 mg followed by a more 
prolonged taper and administer additional anti-inflammatory measures, as needed 
x Add prophylactic antibiotics for opportunistic infections.    
Renal events 
x Nephritis 
x Nephritis autoimmune 
x Renal failure 
x Renal failure acute Grade 2 Hold 
pembrolizumab (MK-3475). x Treatment with prednisone 1-2 mg/kg PO daily. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
x :KHQV\PSWRPVLPSURYHWR¬î*UDGHVWHURLGWDSHUVKRXOGEH  started 
and continued over no less than 4 weeks. 
Grade 3-4 Discontinue 
pembrolizumab (MK-3475). x Renal consultation with consideration of ultrasound and/or biopsy as 
appropriate. 
x Treat with systemic corticosteroids at a dose of 1-2 mg/kg prednisone IV 
or equivalent once per day. 
x :KHQV\PSWRPVLPSURYHWR¬î*UDGHVWHURLGWDSHUVKRXOGEH  started 
and continued over no less than 4 weeks. 
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
56  
  
Event(s) CTCAE v4.0 
Grade Management / 
Next Dose for 
pembrolizu
mab (MK-
3475)  
Action / Supportive Care Guidelines  
Skin events Grade 2 No change in dose x Symptomatic treatment should be given such as topi[INVESTIGATOR_591061] ( e.g., betamethasone 0.1% cream or hydrocortisone 
1%) or urea-containing creams in combination with oral anti-pruritics 
(e.g., diphenhydramine HCl or hydroxyzine HCl). 
x Treatment with oral steroids is at investigator discretion for Grade 2 
events.  
x Pruritus 
x Rash 
x Rash generalized 
x Rash maculo-papular 
x Dermatitis exfoliative 
x Erythema multiforme 
x Steven‚Äôs Johnson 
syndrome 
x Toxic epi[INVESTIGATOR_640242] 3 Hold 
pembrolizumab 
(MK-3475). x Consider Dermatology consultation and biopsy for confirmation of 
diagnosis. 
x Treatment with oral steroids is recommended, starting with 1 mg/kg 
prednisone or equivalent once per day or dexamethasone 4 mg four times orally GDLO\:KHQV\PSWRPVLPSURYHWR¬î*UDGHVWHURLG  taper 
should be started and continued over no less than 4 weeks. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  
See 6.1.3 for immediate 
evaluation for skin 
events   
Grade 4 Permanently 
discontinue 
pembrolizumab 
(MK-3475). x Dermatology consultation and consideration of biopsy and clinical 
dermatology photograph. 
x Initiate steroids at 1-2 mg/kg prednisone or equivalent. When symptoms 
LPSURYHWR¬î*UDGHVWHURLGWDSHUVKRXOGEHVWDUWHGDQGFRQWLQ XHGRYHU
no less than 4 weeks. 
Thrombocytopenia ¬î*UDGH  No change in dose   
Grade 2 No change in dose  
Grade 3 No change in dose x Grade 3 drug-related thrombocytopenia >7 days or associated with 
bleeding requires discontinuation. 
Grade 4 Hold 
pembrolizumab 
(MK-3475) 
until resolves to 
¬î*UDGH0D\
increase the dosing 
interval by 1 week. x Grade 4 drug-related thrombocytopenia >7 days or associated with 
bleeding requires discontinuation. 
Vomiting ¬î*UDGH  No change in dose x Vomiting should be treated aggressively, and consideration should be 
given in subsequent cycles to the administration of prophylactic 
antiemetic therapy according to standard institutional practice. Patients 
should be strongly encouraged to maintain liberal oral fluid intake.  
Grade 2 +ROGXQWLO¬î*UDGH  
1. Resume at same 
dose level. May 
increase dosing 
interval by 1 week if it takes more 
than 4 weeks for 
toxicities to 
resolve. 
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
57  
  
Event(s) CTCAE v4.0 
Grade Management / 
Next Dose for 
pembrolizu
mab (MK-
3475)  
Action / Supportive Care Guidelines  
 Grade 3 Hold until <Grade 
2. May increase 
dosing interval by 1 week for each 
occurrence.  
 
 Discontinue if 
toxicities do not 
resolve within 12 
weeks. 
Grade 4 Off protocol 
therapy 
Other events 
x Myocarditis 
x Pericarditis 
x Pancreatitis Grade 2 or Grade 1 
events that do not 
improve with 
symptomatic 
treatment Hold 
pembrolizumab 
(MK-3475) x Systemic corticosteroids may be indicated. 
x Consider biopsy for confirmation of diagnosis. 
x If pembrolizumab (MK-3475) is held and corticosteroid required, 
manage as per Grade 3 below. 
Grade 3 Hold 
pembrolizumab 
(MK-3475). x Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone 
or equivalent once per day. 
x :KHQV\PSWRPVLPSURYHWR¬î*UDGHVWHURLGWDSHUVKRXOGEH  started 
and continued over no less than 4 weeks. 
x Permanently discontinue for inability to reduce corticosteroid dose to 
¬îPJRISUHGQLVRQHRUHTXLYDOHQWSHUGD\ZLWKLQZHHNV  Otherwise, 
pembrolizumab (MK-3475) treatment may be restarted and dose 
modified as specified in the protocol.  
Grade 4 Discontinue 
pembrolizumab 
(MK-3475). x Treat with systemic corticosteroids at a dose of 1-2 mg/kg prednisone or 
equivalent once per day. 
 
aTopalian S.L., F.S. Hodi, J.R. Brahmer, et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J 
Med. 366:2443-2454. 
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
58  
  
Dose Modification and Toxicity Management Guidelines for Immune-related AEs 
Associated with Pembrolizumab 
 
 
General instructions: 
1. Severe and life-threatening irAEs should be treated with IV corticosteroids followed by [CONTACT_13215]. Other immunosuppressive tre
irAEs are not controlled by [CONTACT_13216]. 
2. Pembrolizumab must be permanently discontinued if the irAE does not resolve or the corticosteroid dose is not ¬î mg/day withi n
pembrolizumab treatment. 
3. 7KHFRUWLFRVWHURLGWDSHUVKRXOGEHJLQZKHQWKHLU$(LV¬î*UDGH DQGFRQWLQXHDWOHDVW  weeks. 
4. ,ISHPEUROL]XPDEKDVEHHQZLWKKHOGSHPEUROL]XPDEPD\UHVXPHDI WHUWKHLU$(GHFUHDVHGWR¬î*UDGHDIWHUFRUWLFRVWHURLG  taper .
 
irAEs Toxicity grade 
(CTCAE V5.0 ) Action with 
pembrolizumab  Corticosteroid and/or 
other thera pi[INVESTIGATOR_640243]-up 
 
 
 
 
 
Pneumonitis Grade 2 Withhold x Administer 
corticosteroids (initial 
dose of 1 - 2 mg/kg prednisone or equivalent) followed by [CONTACT_13217] 
 
x Add prophylactic 
antibiotics for opportunistic infections x Monitor participants for signs and sy m
 
x Evaluate participants with suspected pi[INVESTIGATOR_640244] 2, Grade 3 or 4 Permanently 
discontinue 
 
 
 
  
Diarrhea / Colitis Grade 2 or 3 Withhold x Administer 
corticosteroids (initial dose of 1 - 2 mg/kg prednisone or equivalent) followed by [CONTACT_13217] x Monitor participants for signs and sy m
diarrhea, abdominal pain, blood or mufever) and of bowel perforation (ie, pe
r
 
x 3DUWLFLSDQWVZLWK¬ï*UDGHGLDU[LOCATION_006]HDV X
consider GI consultation and performi n
colitis 
 
x Participants with diarrhea/colitis shou l
quantities of clear fluids. If sufficient o
feasible, fluid and electrolytes should bRecurrent Grade [ADDRESS_856914] or ALT 
elevation or 
Increased Bilirubin Grade 2 a Withhold x Administer 
corticosteroids (initial dose of 0.5 - 1 mg/kg  
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
59  
    prednisone or 
equivalent) followed by [CONTACT_13217] x Monitor with liver function tests (con s
frequently until liver enzyme value ret
Grade 3 b or 4 c Permanently 
discontinue x Administer 
corticosteroids (initial 
dose of 1 - 2 mg/kg prednisone or equivalent) followed by [CONTACT_640300] 1 diabetes 
mellitus (T1DM) or Hyperglycemia New onset T1DM 
or Grade 3 or 4 hyperglycemia associated with 
evidence of E-cell 
failure Withhold 
d x Initiate insulin 
replacement therapy for participants with T1DM 
 
x Administer anti- 
hyperglycemic in participants with hyperglycemia x Monitor participants for hyperglycemisymptoms of diabetes 
 
 
Hypophys itis Grade 2 Withhold x Administer 
corticosteroids and 
initiate hormonal replacements as clinically indicated x Monitor for signs and symptoms of h y
hypopi[INVESTIGATOR_640245] n
Grade 3 or 4 Withhold or 
permanently discontinue 
d 
 
 
Hyperthyroidism Grade 2 Continue x Treat with non- 
selective beta- blockers (eg, propranolol) or thionamides as appropriate x Monitor for signs and symptoms of th y
Grade 3 or 4 Withhold or 
permanently 
discontinue d 
 
 
Hypothyroidism Grade 2, 3, 4 Continue x Initiate thyroid 
replacement 
hormones (eg, levothyroxine or liothyronine) per standard of care x Monitor for signs and symptoms of th y
NCI Protocol #:[ZIP_CODE]  
Version Date: 09/04/2020 
60  
 Nephritis: 
grading according to increased creatinine or acute kidney injury Grade 2 Withhold 
x Administer 
corticosteroids (prednisone 1 ‚Äì 2 mg/kg or equivalent) followed by [CONTACT_13217] x Monitor changes of renal function 
Grade [ADDRESS_856915]/ALT: >3.[ADDRESS_856916] if baseline normal; >3.0 - 5.0 x baseline, if baseline abnormal; 
bilirubin:>1.[ADDRESS_856917] if baseline normal; >1.[ADDRESS_856918]/ALT: >5.[ADDRESS_856919], if baseline normal; >5.0 - 20.0 x baseline, if baseline abnormal; bilirubin:>3.[ADDRESS_856920]/ALT: >20.[ADDRESS_856921], if baseline normal; >20.0 x baseline, if baseline abnormal; 
bilirubin: >10.[ADDRESS_856922] if baseline normal; >10.0 x baseline if baseline abnormal 
d The decision to withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physicia n. If c o
pembrolizumab may be resumed. 
e Events that require discontinuation include but are not limited to: Guillain-Barre Syndrome, encephalitis, Stevens-Johnson Synd rome
necrolysis. 
61                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856923] photographs if a consent form addendum 
is required by [CONTACT_5282]/ERC. 
 
x Take digital photographs of: 
o the head (to assess mucosal or eye involvement), 
o the trunk and extremities, and 
o a close-up of the skin lesion/rash. 
x If possible, a ruler should be placed alongside the site of a skin occurrence as a fixed marker 
of distance. 
x The time/date stamp should be set in the 'ON' position for documentation purposes. 
x Photographs should be stored with the patient‚Äôs study records. 
 
Dermatology Consult 
Refer the subject to a dermatologist as soon as possible. 
x For a ‚Äúsevere rash‚Äù, the subject must be seen within 1-[ADDRESS_856924] results. 
 
 
6.2.5 Treatment Guidelines for Infusion Reactions 
 
The table below shows treatment guidelines for subjects who experience an infusion reaction 
associated with administration of pembrolizumab (MK-3475). 
62                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 Treatment Guidelines for Infusion Reactions 
NCI CTCAE Grade Treatment Premedication at subsequent 
dosing 
Grade 1 
Mild reaction; infusion interruption 
not indicated; intervention not 
indicated  
Increase monitoring of vital signs as medically 
indicated until the patient is deemed medically 
stable in the opi[INVESTIGATOR_871].  
None 
Grade 2 
Requires infusion interruption but 
responds promptly to symptomatic 
treatment ( e.g., antihistamines, 
NSAIDS, narcotics, IV fluids); prophylactic medications indicated IRU¬îKRXUV   
Stop Infusion. 
Additional appropriate medical therapy may 
include but is not limited to: 
IV fluids Antihistamines NSAIDS Acetaminophen 
Narcotics 
Increase monitoring of vital signs as medically indicated until the subject is deemed medically 
stable in the opi[INVESTIGATOR_871]. 
If symptoms resolve within one hour of stoppi[INVESTIGATOR_13056], the infusion may be restarted at 50% of the original infusion rate 
(e.g. from 100 mL/hr to 50 mL/hr). Please 
note: prior to restarting the infusion, confirm 
that the [ADDRESS_856925] may be premedicated 1.5h 
(¬± 30 minutes) prior to infusion of 
pembrolizumab (MK-3475) with: 
 
Diphenhydramine 50 mg PO (or 
equivalent dose of antihistamine). 
 
Acetaminophen 500-1000 mg PO (or equivalent dose of antipyretic). 
Grades 3 or 4 
Grade 3: 
Prolonged ( i.e., not rapi[INVESTIGATOR_38194]/or brief interruption of infusion); recurrence of symptoms following initial improvement; 
hospi[INVESTIGATOR_38195] ( e.g., renal 
impairment, pulmonary infiltrates) 
 
Grade 4: 
Life-threatening; pressor or ventilatory support indicated  
Stop Infusion. 
Additional appropriate medical therapy may include but is not limited to: 
IV fluids 
Antihistamines 
NSAIDS Acetaminophen 
Narcotics 
Oxygen Pressors Corticosteroids 
Epi[INVESTIGATOR_640246]. 
Hospi[INVESTIGATOR_13021]. 
Subject is permanently discontinued from further trial treatment administration.  
Appropriate resuscitation equipment should be available in the room and a physician readily available during the period of 
drug administration. 
For Further information, please refer to the Common Terminology Criteria for Adverse Events v4.0 (CTCAE) at http://ctep.cancer.gov 
63                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 7. ADVERSE EVENTS: LIST AND REPORTING REQUIREMENTS 
 
Adverse event (AE) monitoring and reporting is a routine part of every clinical trial. The 
following list of AEs (Section 7.1) and the characteristics of an observed AE ( Section s 7.2 and 
7.3) will determine whether the event requires expedited reporting via the CTEP Adverse Event 
Reporting System(CTEP-AERS) in addition to routine reporting 
 
7.[ADDRESS_856926](s) (CAEPRs) 
 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform 
presentation of events by [CONTACT_6764]. In addition to the comprehensive list, a subset of AEs, 
the Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column 
and is identified with bold and italicized text. The SPEER is a list of events that are protocol- 
specific exceptions to expedited reporting to NCI (except as noted below). Refer to the 'CTEP, 
NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/adverse_effects.htm for further clarification. 
 
NOTE : The highest grade currently reported is noted in parentheses next to the AE in the 
SPEER. Report ONLY AEs higher than this grade expeditiously. If this CAEPR is part of a 
combination protocol using multiple investigational agents and has an AE listed on different SPEERs, use the lower of the grades to determine if expedited reporting is required. 
 
7.1.1 CAEPRs for CTEP IND Agent(s) 
 
[IP_ADDRESS]  CAEPR for entinostat 
 
Comprehensive Adverse Events and Potential Risks list (CAEPR) for 
MS-275 (SNDX-275, entinostat, NSC 706995) 
The Comprehensive Adverse Event and Potential Risks list (CAEPR) provides a single list of 
reported and/or potential adverse events (AE) associated with an agent using a uniform presentation of events by [CONTACT_6764]. In addition to the comprehensive list, a subset, the 
Specific Protocol Exceptions to Expedited Reporting (SPEER), appears in a separate column 
and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events 
that are protocol specific exceptions to expedited reporting to NCI via AdEERS (except as 
noted below). Refer to the 'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for 
further clarification. Frequency is provided based on 221 patients. Below is the CAEPR for 
MS-275 (SNDX-275, entinostat). 
NOTE : Report AEs on the SPEER ONLY IF they exceed the grade noted in parentheses 
next to the AE in the SPEER. If this CAEPR is part of a combination protocol using 
multiple investigational agents and has an AE listed on different SPEERs, use the lower of the grades to determine if expedited reporting is required. 
64                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 Version 2.5, September 10, [ZIP_CODE] 
 
Adverse Events with Possible 
Relationship to MS -275 (SNDX-275, entinostat) 
(CTCAE 5.0 Term) 
[n= 221]   
Specific Protocol Exceptions to 
Expedited Reporting (SPEER) 
Likely (>20%) Less Likely (<=20%) Rare but Serious 
(<3%)   
BLOOD AND LYMPHATIC SYSTEM DISORDERS   
Anemia    Anemia (Gr 3) 
GASTROINTESTINAL DISORDERS   
 Abdominal pain   Abdominal pain (Gr 2) 
 Constipation   Constipation (Gr 2) 
 Diarrhea   Diarrhea (Gr 3) 
 Dyspepsia   Dyspepsia (Gr 2) 
Nausea    Nausea (Gr 3) 
Vomiting    Vomiting (Gr 3) 
GENERAL DISORDERS AND ADMINISTRATION SITE 
CONDITIONS   
 Edema limbs   Edema limbs (Gr 2) 
Fatigue    Fatigue (Gr 3) 
 Fever   Fever (Gr 2) 
INFECTIONS AND INFESTATIONS   
 Infection2   Infection2 (Gr 3) 
INVESTIGATIONS   
 Alkaline phosphatase 
increased   Alkaline phosphatase increased 
(Gr 2) 
 Lymphocyte count decreased   Lymphocyte count decreased 
(Gr 4) 
Neutrophil count 
decreased    Neutrophil count decreased (Gr 
4) 
Platelet count decreased    Platelet count decreased (Gr 4) 
 White blood cell decreased   White blood cell decreased (Gr 
3) 
METABOLISM AND NUTRITION DISORDERS   
Anorexia    Anorexia (Gr 3) 
 Dehydration   Dehydration (Gr 2) 
 Hyperglycemia   Hyperglycemia (Gr 2) 
Hypoalbuminemia    Hypoalbuminemia (Gr 2) 
 Hypocalcemia   Hypocalcemia (Gr 2) 
 Hypokalemia   Hypokalemia (Gr 2) 
 Hyponatremia   Hyponatremia (Gr 3) 
Hypophosphatemia    Hypophosphatemia (Gr 3) 
65                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
  
 
Adverse Events with Possible 
Relationship to MS -275 (SNDX-275, entinostat) 
(CTCAE 5.0 Term) 
[n= 221]  
Specific Protocol Exceptions to 
Expedited Reporting (SPEER) 
Likely (>20%) Less Likely (<=20%) Rare but Serious 
(<3%)  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  
 Myalgia  Myalgia (Gr 2) 
NERVOUS SYSTEM DISORDERS  
 Dysgeusia  Dysgeusia (Gr 2) 
Headache   Headache (Gr 2) 
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  
 Cough  Cough (Gr 2) 
 Dyspnea  Dyspnea (Gr 3) 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  
  Erythema multiforme  
 
1This table will be updated as the toxicity profile of the agent is revised. Updates will be distributed to all 
Principal Investigators at the time of revision. The current version can be obtained by [CONTACT_13172] 
[EMAIL_412] . Your name, the name [CONTACT_6823], the protocol and the agent should 
be included in the e-mail. 
 
2Infection includes all 75 sites of infection under the INFECTIONS AND INFESTATION SOC. 
 
3Gastrointestinal hemorrhage includes Anal hemorrhage, Cecal hemorrhage, Colonic hemorrhage, 
Duodenal hemorrhage, Esophageal hemorrhage, Esophageal varices hemorrhage, Gastric hemorrhage, Hemorrhoidal hemorrhage, Ileal hemorrhage, Intra-abdominal hemorrhage, Jejunal hemorrhage, Lower gastrointestinal hemorrhage, Oral hemorrhage, Pancreatic hemorrhage, Rectal hemorrhage, Retroperitoneal hemorrhage, and Upper gastrointestinal hemorrhage under the GASTROINTESTINAL 
DISORDERS SOC. 
 
 
Adverse events reported on MS-275 (SNDX-275, entinostat) trials, but for which th ere is 
insufficient evidence to suggest that there was a reasonable possibility that MS -275 (SNDX- 
275, entinostat) caused the adverse event: 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS - Febrile neutropenia; Hemolysis; 
Leukocytosis 
CARDIAC DISORDERS - Atrial fibrillation; Atrioventricular block complete; Cardiac 
disorders - Other (transient right-side heart failure with worsening tricuspid regurgitation); Chest pain - cardiac; Conduction disorder; Heart failure; Left ventricular systolic dysfunction; 
Palpi[INVESTIGATOR_814]; Pericardial effusion; Pericarditis; Sinus tachycardia; Supraventricular tachycardia; 
Ventricular fibrillation EAR AND LABY[CONTACT_33993] - Hearing impaired 
EYE DISORDERS - Blurred vision 
66                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 GASTROINTESTINAL DISORDERS - Anal mucositis; Colitis; Dysphagia; Enterocolitis; 
Esophag eal pain; Es ophagitis; F latulence; Gastrointestinal disorders - Other (hyperdefecation); 
Gastrointestinal hemorrhage3; Hemorrhoids; Mucositis oral; Pancreatitis; Periodontal disease; 
Rectal mucositis; Rectal pain; Small intestinal mucositis; Typhlitis; Visceral arterial ischemia GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Chills; Edema 
face; Generalized edema; Injection site reaction; Multi-organ failure; Non-cardiac chest pain; Pain 
IMMUNE SYSTEM DISORDERS - Allergic reaction; Anaphylaxis; Autoimmune disorder 
INJURY, POISONING AND PROCEDURAL COMPLICATIONS - Bruising 
INVESTIGATIONS - Activated partial thromboplastin time prolonged; Alanine 
aminotransferase increased; Aspartate aminotransferase increased; Blood bilirubin increased; 
CPK increased; Creatinine increased; GGT increased; INR increased; Investigations - Other 
(coagulopathy); Investigations - Other (vitamin D deficiency); Lipase increased; Serum amylase 
increased; Weight loss METABOLISM AND NUTRITION DISORDERS - Acidosis; Hypercalcemia; Hyperkalemia; 
Hypermagnesemia; Hypernatremia; Hypertriglyceridemia; Hyperuricemia; Hypoglycemia; 
Hypomagnesemia; Tumor lysis syndrome 
MUSCULOSK ELETAL AND CONNECTIVE TISSUE DISORDERS - Arthralgia; Back 
pain; Bone pain; Chest wall pain; Generalized muscle weakness; Muscle cramp; Musculoskeletal and connective tissue disorder - Other (thorax pain); Myositis; Pain in extremity 
NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND 
POLYPS) - Tumor pain 
NERVOUS SYSTEM DISORDERS - Ataxia; Depressed level of consciousness; Dizziness; 
Dysphasia; Intracranial hemorrhage; Neuralgia; Olfactory nerve disorder; Peripheral motor 
neuropathy; Peripheral sensory neuropathy; Seizure; Syncope; Tremor 
PSYCHIATRIC DISORDERS - Anxiety; Confusion; Depression; Insomnia; Libido decreased 
RENAL AND URINARY DISORDERS - Acute kidney injury; Proteinuria; Renal and urinary 
disorders - Other (bladder distension); Renal calculi; Renal hemorrhage; Urinary frequency; 
Urinary retention 
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS - Allergic rhinitis; 
Atelectasis; Epi[INVESTIGATOR_3940]; H ypoxia; Laryngeal mucositis; Pharyngeal mucos itis; Pleural effusion; 
Pleuritic pain; Pulmonary edema; Respi[INVESTIGATOR_1399]; Tracheal mucositis 
SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Alopecia; Hyperhidrosis; Nail loss; 
Photosensitivity; Pruritus; Purpura; Rash maculo-papular; Skin and subcutaneous tissue 
disorders - Other (hyperkeratotic lesions/squamous cell carcinoma); Urticaria 
SURGICAL AND MEDICAL PROCEDURES - Surgical and medical procedures - Other 
(packed RBC transfusion) 
VASCULAR DISORDERS - Flushing; Hypertension; Hypotension; Thromboembolic event 
 
Note : MS-275 (SNDX-275, entinostat) in combination with other agents could cause an 
exacerbation of any adverse event currently known to be caused by [CONTACT_6767], or the 
combination may result in events never previously associated with either agent. 
67                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 [IP_ADDRESS]  CAEPR for pembrolizumab (MK-3475) 
 
Comprehensive Adverse Events and Potential Risks list (CAEPR) 
for 
MK-3475 (pembrolizumab, NSC 776864) 
 
The Comprehensive Adverse Events and Potential Risks list (CAEPR) provides a single list of reported and/or 
potential adverse events (AE) associated with an agent using a uniform presentation of events by [CONTACT_6764]. In 
addition to the comprehensive list, a subset, the Specific Protocol Exceptions to Expedited Reporting (SPEER), 
appears in a separate column and is identified with bold and italicized text. This subset of AEs (SPEER) is a list of events that are protocol specific exceptions to expedited reporting to NCI (except as noted below). Refer to the 
'CTEP, NCI Guidelines: Adverse Event Reporting Requirements' 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines.pdf for further clarification. 
Frequency is provided based on 3793 patients. Below is the CAEPR for MK-3475 (pembrolizumab). 
NOTE : Report AEs on the SPEER ONL Y IF they exceed the grade noted in parentheses next to the AE in the 
SPEER. If this CAEPR is part of a combination protocol using multiple investigational agents and has an AE 
listed on different SPEERs, use the lower of the grades to determine if expedited reporting is required. 
 
Version 2.5, December 27, [ZIP_CODE] 
   
Adverse Events with Possible 
Relationship to MK-3475 (pembrolizumab) 
(CTCAE 5.0 Term) 
[n= 3793] 
Likely (>20%) Less Likely (<=20%) Rare but Serious (<3%) 
BLOOD AND LYMPHATIC SYSTEM DISORDERS 
 Anemia2  
 Lymph node pain2  
 Thrombotic thrombocytopenic purpura2  
CARDIAC DISORDERS 
  Myocarditis2 
  Pericarditis2 
ENDOCRINE DISORDERS 
 Adrenal insufficiency2  
 Endocrine disorders - Other 
(thyroiditis)2  
 Hyperthyroidism2  
 Hypohysitis2  
 Hypopi[INVESTIGATOR_297]2  
 Hypothyroidism2  
EYE DISORDERS 
  Uveitis2 
  Eye disorders - Other (Vogt- 
Koyanagi-Harada syndrome) 
GASTROINTESTINAL DISORDERS 
 Abdominal pain  
 Colitis2  
 Diarrhea2  
 Mucositis oral2  
 Nausea  
 Pancreatitis2  
 Small intestinal mucositis2   
 
Specific Protocol Exceptions to 
Expedited Reporting (SPEER) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diarrhea2 (Gr 2) 
 
Nausea (Gr 2) 
 
 
68                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
  
 
Adverse Events with Possible 
Relationship to MK-3475 (pembrolizumab) 
(CTCAE 5.0 Term) 
[n= 3793]   
 
Specific Protocol Exceptions to 
Expedited Reporting (SPEER) 
Likely (>20%) Less Likely (<=20%) Rare but Serious (<3%)  
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS  
 Chills2   
Fatigue   Fatigue (Gr 2) 
 Fever2   
HEPATOBILIARY DISORDERS  
 Hepatobiliary disorders - Other 
(autoimmune hepatitis)2   
IMMUNE SYSTEM DISORDERS  
  Anaphylaxis2  
  Cytokine release syndrome2  
  Immune system disorders - Other 
(acute graft-versus-host-disease)2,3  
  Immune system disorders - Other 
(hemophagocytic 
lymphohistiocytosis)2  
 Immune system disorders - Other 
(pseudoprogression/tumor 
inflammation)2   
 Immune system disorders - Other 
(sarcoidosis)2   
  Serum sickness2  
INFECTIONS AND INFESTATIONS  
 Infection4   
INJURY, POISONING AND PROCEDURAL COMPLICATIONS  
  Infusion related reaction  
INVESTIGATIONS  
 Alanine aminotransferase increased2   
 Alkaline phosphatase increased   
 Aspartate aminotransferase increased2   
 Blood bilirubin increased   
 CPK increased   
  GGT increased  
  Serum amylase increased  
METABOLISM AND NUTRITION DISORDERS  
 Anorexia   
 Hyponatremia   
  Metabolism and nutrition 
disorders - Other (diabetic 
ketoacidosis)2  
  Metabolism and nutrition 
disorders - Other (type 1 diabetes 
mellitus)2  
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS  
 Arthralgia2  Arthralgia2 (Gr 2) 
 Arthritis2   
 Avascular necrosis2   
 Back pain   
 Joint effusion2   
 Joint range of motion decreased   
 Musculoskeletal and connective tissue 
disorder - Other (tenosynovitis)2   
69                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
  
 
Adverse Events with Possible 
Relationship to MK-3475 (pembrolizumab) 
(CTCAE 5.0 Term) 
[n= 3793]   
 
Specific Protocol Exceptions to 
Expedited Reporting (SPEER) 
Likely (>20%) Less Likely (<=20%) Rare but Serious (<3%)  
 Myalgia2   
 Myositis2   
NERVOUS SYSTEM DISORDERS  
  Guillain-Barre syndrome2  
  Nervous system disorders - Other 
(myasthenic syndrome)2  
  Nervous system disorders - Other 
(neuromyopathy)2  
  Nervous system disorders - Other 
(non-infectious encephalitis)2  
  Nervous system disorders - Other 
(non-infectious meningitis)2  
  Nervous system disorders - Other 
(non-infectious myelitis)  
  Nervous system disorders - Other 
(polyneuropathy)2  
  Paresthesia  
  Peripheral motor neuropathy2  
RENAL AND URINARY DISORDERS  
  Renal and urinary disorders - 
Other (autoimmune nephritis)2  
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS  
 Cough   
 Pleuritic pain2   
 Pneumonitis2   
SKIN AND SUBCUTANEOUS TISSUE DISORDERS  
 Bullous dermatitis2   
  Erythema multiforme2  
 Erythroderma   
  Palmar-plantar erythrodysesthesia 
syndrome  
 Pruritus2  Pruritus2 (Gr 2) 
 Rash acneiform2   
 Rash maculo-papular2  Rash maculo-papular2 (Gr 2) 
 Skin and subcutaneous tissue disorders 
- Other (dermatitis)2   
 Skin hypopi[INVESTIGATOR_371]2   
  Stevens-Johnson syndrome2  
  Toxic epi[INVESTIGATOR_640247]2   
VASCULAR DISORDERS  
  Vasculitis2  
 
 
1This table will be updated as the toxicity profile of the agent is revised. Updates will be distributed to all 
Principal Investigators at the time of revision. The current version can be obtained by [CONTACT_13172] 
[EMAIL_412].  Your name, the name [CONTACT_6823], the protocol and the agent should be 
included in the e-mail. 
 
2Immune-mediated adverse reactions have been reported in patients receiving MK-3475 (pembrolizumab). 
70                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 Adverse events potentially related to MK-3475 (pembrolizumab) may be manifestations of immune-mediated 
adverse events. In clinical trials, most immune-mediated adverse reactions were reversible and managed with 
interruptions of MK-3475 (pembrolizumab), administration of corticosteroids and supportive care. 
 
3Acute graft-versus-host disease has been observed in patients treated with MK-3475 (pembrolizumab) who 
received hematopoeitic stem cell transplants. 
 
4Infection includes all 75 sites of infection under the INFECTIONS AND INFESTATIONS SOC. 
 
Adverse events reported on MK-3475 (pembrolizumab) trials, but for which there is insufficient evidence to 
suggest that there was a reasonable possibility that MK-3475 (pembrolizumab) caused the adverse event: 
 
BLOOD AND LYMPHATIC SYSTEM DISORDERS - Blood and lymphatic system disorders - Other 
(pancytopenia); Disseminated intravascular coagulation; Hemolysis CARDIAC DISORDERS - Atrial fibrillation; Cardiac arrest; Chest pain - cardiac; Heart failure; Myocardial 
infarction; Pericardial effusion; Pericardial tamponade; Ventricular arrhythmia 
EYE DISORDERS - Eye pain 
GASTROINTESTINAL DISORDERS - Abdominal distension; Ascites; Constipation; Duodenal hemorrhage; 
Dysphagia; Gastritis; Gastrointestinal disorders - Other (diverticulitis); Gastrointestinal disorders - Other (intestinal obstruction); Gastrointestinal disorders - Other (intussusception); Oral pain; Rectal hemorrhage; Small 
intestinal perforation; Upper gastrointestinal hemorrhage; Vomiting 
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Edema face; Edema limbs; 
Facial pain; Gait disturbance; General disorders and administration site conditions - Other (general physical health 
deterioration); Generalized edema; Malaise; Non-cardiac chest pain; Pain INVESTIGATIONS - Cholesterol high; Creatinine increased; Fibrinogen decreased; Lymphocyte count 
decreased; Neutrophil count decreased; Platelet count decreased; Weight loss; White blood cell decreased 
METABOLISM AND NUTRITION DISORDERS - Dehydration; Hypercalcemia; Hyperglycemia; 
Hyperkalemia; Hypertriglyceridemia; Hyperuricemia; Hypoalbuminemia; Hypokalemia; Hypophosphatemia; 
Metabolism and nutrition disorders - Other (failure to thrive); Tumor lysis syndrome MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Bone pain; Generalized muscle 
weakness; Musculoskeletal and connective tissue disorder - Other (groin pain); Pain in extremity 
NERVOUS SYSTEM DISORDERS - Aphonia; Depressed level of consciousness; Dysarthria; Edema cerebral; 
Encephalopathy; Headache; Hydrocephalus; Lethargy; Meningismus; Nervous system disorders - Other 
(brainstem herniation); Seizure; Syncope; Tremor PSYCHIATRIC DISORDERS - Agitation; Confusion 
RENAL AND URINARY DISORDERS - Acute kidney injury; Nephrotic syndrome; Proteinuria; Renal and 
urinary disorders - Other (hydronephrosis); Urinary incontinence; Urinary tract pain 
REPRODUCTIVE SYSTEM AND BREAST DISORDERS - Pelvic pain 
RESPI[INVESTIGATOR_6709], THORACIC AND MEDIASTINAL DISORDERS - Dyspnea; Hypoxia; Laryngeal 
inflammation; Pleural effusion; Pneumothorax; Respi[INVESTIGATOR_372284] - Alopecia; Dry skin; Skin and subcutaneous tissue 
disorders - Other (drug eruption) 
VASCULAR DISORDERS - Hypertension; Peripheral ischemia; Thromboembolic event 
 
Note : MK-3475 (pembrolizumab) in combination with other agents could cause an exacerbation of any adverse 
event currently known to be caused by [CONTACT_6767], or the combination may result in events never previously 
associated with either agent. 
71                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 7.2 Adverse Event Characteristics 
 
x CTCAE term (AE description) and grade: The descriptions and grading scales found 
in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 
4.[ADDRESS_856927] access to a copy of the CTCAE version 5.0. A copy of the CTCAE version 5.0 can 
be downloaded from the CTEP web site http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
x For expedited reporting purposes only: 
- AEs for the agent that are bold and italicized in the CAEPR ( i.e., those listed in the 
SPEER column, Section 7.1.1) should be reported through CTEP-AERS only if the 
grade is above the grade provided in the SPEER. 
- Other AEs for the protocol that do not require expedited reporting are outlined in 
section 7.3.4. 
 
x Attribution of the AE: 
- Definite ‚Äì The AE is clearly related to the study trea tment. 
- Probable ‚Äì The AE is likely related to the study treatment. 
- Possible ‚Äì The AE may be related to the study treatment. 
- Unlikely ‚Äì The AE is doubtfu lly related to the study treatment. 
- Unrelated ‚Äì The AE is clearly NOT related to the study treatment. 
 
7.[ADDRESS_856928] use CTEP-AERS (CTEP Adverse Event 
Reporting System), accessed via the CTEP Web site ( https://eapps- 
ctep.nci.nih.gov/ctepaers ). The reporting procedures to be followed are presented in the 
‚ÄúNCI Guidelines for Investigators: Adverse Event Reporting Requirements for DCTD 
(CTEP and CIP) and DCP INDs and IDEs‚Äù which can be downloaded from the CTEP Web site 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htm  
). These requirements are briefly outlined in the tables below (Section 7.3.3). 
 
In the rare occurrence when Internet connectivity is lost, a 24-hour notification is to be made to CTEP by [CONTACT_1381] [PHONE_101]. Once Internet connectivity is restored, the 
24-hour notification phoned in must be entered electronically into CTEP-AERS by [CONTACT_25521]. 
 
7.3.2 CTEP-AERS is programmed for automatic electronic distribution of reports to the following individuals: Principal Investigator [INVESTIGATOR_33952](s) (if 
applicable) of the Corresponding Organization, the local treating physician, and the 
Reporter and Submitter. CTEP-AERS provides a copy feature for other e-mail recipi[INVESTIGATOR_840]. 
 
The Coordinating Center of the Corresponding Organization is responsible for submitting 
72                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856929]. 
 
7.3.3 Expedited Reporting Guid elines 
 
Use the NCI protocol number and the protocol-specific patient ID assigned during trial 
registration on all reports. 
 
Note: A death on study requires both routine and expedited reporting, regardless of 
causality. Attribution to treatment or other cause must be provided. 
 
Death due to progressive disease should be reported as Grade 5 ‚ÄúDisease progression‚Äù 
in the system organ class (SOC) ‚ÄúGeneral disorders and administration site conditions.‚Äù. 
Evidence that the death was a manifestation of underlying disease ( e.g., radiological 
changes suggesting tumor growth or progression: clinical deterioration associated with a 
disease process) should be submitted. 
 
Phase 1 and Early Phase 2 Studies: Expedited Reporting Requirements for Adverse Events that Occur on Studies under an IND/IDE within [ADDRESS_856930] Administration 
of the Investigational Agent/Intervention 
1, 2 
 
FDA REPORTING REQUIREMENTS FOR SERIOUS ADVERSE EVENTS (21 CFR Part 312) 
NOTE: Investigators MUST immediately report to the sponsor (NCI) ANY Serious Adverse Events, whether or not 
they are considered related to the investigational agent(s)/intervention (21 CFR 312.64) 
An adverse event is considered serious if it results in ANY of the following outcomes: 
1) Death 
2) A life-threatening adverse event 
3) An adverse event that results in inpatient hospi[INVESTIGATOR_1328] ¬ï 24 
hours 
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions 
5) A congenital anomaly/birth defect. 
6) Important Medical Events (IME) that may not result in death, be life threatening, or require hospi[INVESTIGATOR_6721], based upon medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this 
definition. (FDA, 21 CFR 312.32; ICH E2A and ICH E6). 
ALL SERIOUS adverse events that meet the above criteria MUST be immediately reported to the NCI via electronic 
submission within the timeframes detailed in the table below. 
Hospi[INVESTIGATOR_317] 1 and Grade 2 Timeframes Grade 3-5 
Timeframes  
Resulting in 
Hospi[INVESTIGATOR_059] 
¬ïKUV   
10 Calendar Days  
 
24-Hour 5 Calendar 
Days Not resulting in 
Hospi[INVESTIGATOR_059] 
¬ïKUV   
Not required 
73                NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020 
7.3.4 Additional Protocol-Specific Expedited Adverse Event Reporting Exclusions 
For this protocol only, the AEs/grades listed below do not require expedited reporting via 
CTEP-AERS. However, they still must be reported through the routine reporting 
mechanism ( Section 7.4 ): 
CTCAE SOC Adverse Event Grade Hospi[INVESTIGATOR_059]/ 
Prolongation of 
Hospi[INVESTIGATOR_640248]/Investigati 
ons Bone marrow 
cellularity 
Hemoglobin 
Leukocytes 
Lymphopenia 
Neutrophils 
Platelets 3 and 4 With or without 
hospi[INVESTIGATOR_640249] (i.e. 
prolonged duration of 
myelosuppression)
Gastrointestinal Nausea 
Vomiting 
Diarrhea 
Anorexia 
Taste alteration3 With or without 
hospi[INVESTIGATOR_640250], 
hypotension, or renal dysfunction due to 
hypotension from these 
GI toxicities do not require expedited 
reporting
Blood and 
lymphatic 
disorder/InfectionFebrile 
neutropenia 
Infection with3 and [ADDRESS_856931] administration of investigational 
agent/intervention and have an attribution of possible, probable, or definite require reporting as follows: 
Expedited 24-hour notification followed by [CONTACT_432] 5 calendar days for: 
xAll Grade 3, 4, and Grade 5 AEs 
Expedited 10 calendar day reports for: 
xGrade [ADDRESS_856932] whole day, after the agent/intervention was last administered. Footnote ‚Äú1‚Äù above 
applies after this reporting period.
Effective Date: May 5, 2011 
NOTE: Protocol specific exceptions to expedited reporting of serious adverse events are found in the Specific 
Protocol Exceptions to Expedited Reporting (SPEER) portion of the CAEPR. 
Expedited AE reporting timelines are defined as: 
‚Äú24-Hour; 5 Calendar Days‚Äù - The AE must initially be submitted electronically within 24 hours of learning 
of the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hourreport.
‚Äú10 Calendar Days‚Äù - A complete expedited report on the AE must be submitted electronically within 10 calendar days of learning of the AE. 
74                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
  
 grade 3 and 4 
neutrophils     
Blood and 
Lymphatic System/Investigati 
ons Bone marrow 
cellularity 
Hemoglobin 
Leukocytes 
Lymphopenia 
Neutrophils 
Platelets 3 and 4 With or without 
hospi[INVESTIGATOR_640249] (i.e. 
prolonged duration of 
myelosuppression) 
 
 
 
7.[ADDRESS_856933]. 
 
7.5 Secondary Malignancy 
 
A secondary malignancy is a cancer caused by [CONTACT_437] a previous malignancy ( e.g., 
treatment with investigational agent/intervention, radiation or chemotherapy). A secondary 
malignancy is not considered a metastasis of the initial neoplasm. 
 
CTEP requires all secondary malignancies that occur following treatment with an agent under an 
NCI IND/IDE be reported expeditiously via CTEP-AERS. Three options are available to 
describe the event: 
 
x Leukemia secondary to oncology chemotherapy ( e.g., acute myelocytic leukemia 
[AML]) 
x Myelodysplastic syndrome ( MDS) 
x Treatment-related secondary malignancy 
 
Any malignancy possibly related to cancer treatment (including AML/MDS) should also be reported via the routine reporting mechanisms outlined in each protocol. 
 
7.6 Second Malignancy 
 
A second malignancy is one unrelated to the treatment of a prior malignancy (and is NOT a 
metastasis from the initial malignancy). Second malignancies require ONLY routine AE 
75                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856934] (spontaneously 
reported to them) that occurs during the trial or within [ADDRESS_856935] be followed to the completion/termination of the pregnancy. Pregnancy outcomes of spontaneous abortion, missed abortion, benign 
hydatidiform mole, blighted ovum, pregnancy loss, intrauterine death, miscarriage and stillbirth 
must be reported as serious events (Important Medical Events). If the pregnancy continues to 
term, the outcome (health of infant) must also be reported. 
 
 
8. PHARMACEUTICAL INFORMATION 
 
A list of the adverse events and potential risks associated with the investigational agents 
administered in this study can be found in Section 7.1 . 
 
 
8.1 CTEP IND Agent(s) 
 
 
8.1.1 Entinostat ( NSC 706995) 
 
Chemical name: 3-Pyridylmethyl N-55carbamate 
 
Other names: MS-27-275, MS-275, SNDX-275 
 
Classification: Histone deacetylase inhibitor (HDACi) 
 
Molecular formula: C21H20N4O3 
 
M.W.: 376.41 
 
Mode of Action: Histone deacetylases ( HDACs) are a family of enzymes that regulate 
chromatin remodeling and gene transcription via the dynamic  
process of acetylation and deacetylation of core histones. Entinostat 
inhibits histone deacetylases, changes chromatin configuration, and 
induces differentiation and apoptosis of cancer cells through an 
epi[INVESTIGATOR_166099]. 
 
How Supplied: Entinostat is supplied by [CONTACT_640301], Inc. and 
distributed by [CONTACT_52375], NCI as 1 mg (pi[INVESTIGATOR_22759], in bottles of 
40), or 5 mg (yellow, in bottles of 40) film-coated tablets (round- 
76                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 biconvex). Each tablet also contains mannitol, sodium starch 
glycolate, hydroxypropyl cellulose, potassium bicarbonate, and 
magnesium stearate. The film coating consists of hypromellose, 
talc, titanium dioxide, and ferric oxide pi[INVESTIGATOR_165639] (red and yellow) as colorants. 
 
Matching placebo for entinostat has the same appearance as the 
corresponding active tablets and contains the same inactive 
ingredients and film coating. 
 
Storage: Store the bottles at controlled room temperature (15-25oC), and 
protect from light. Entinostat is not to be exposed to extremes of 
temperature (greater than 30¬∫C or less than 5¬∫C). 
 
Stability: Shelf life stability studies of the intact bottles are on-going. 
 
Route of Administration: Oral, on an empty stomach, at least 1 hour before or 2 
hours after a meal. Entinostat tablets should not be split, 
crushed, or chewed. 
 
Potential Drug Interactions: Metabolism: Data from in vitro metabolism experiments 
in human tissues demonstrated that entinostat is not metabolized by [CONTACT_166113] 
(Acharya 2006), but UGT 1A4 did metabolize entinostat to its M2 glucuronide 
metabolite. No metabolites could be detected after incubation of entinostat in human liver microsomes (Acharya 2006). While inhibition of CYP enzymes 2B6 and 3A4 was seen, 
the data show that the degree of the inhibition makes it unlikely that any in vivo systemic 
interactions would occur. Intestinal CYP 3A4 may be inhibited by [CONTACT_166120]. However, 
entinostat did not inhibit any UGT enzymes tested. Entinostat was found to induce CYP 
1A2, CYP 2C6, and CYP 2B8 as well as UGT 1A4. Finally, entinostat was found to be a substrate for P-gp and BCRP transporters, but did not inhibit either of these transport 
proteins. 
 
 
Patient Care Implications: 
 
Entinostat may cause fatigue or malaise; advise patient to exercise caution while driving 
a vehicle or operating machinery. 
 
Administration of entinostat is contraindicated in patients with a history of allergy to 
entinostat or other medications that have a benzamide structure (eg, tiapride, remoxipride, 
clebropride). 
Careful monitoring of patients for signs of infection or reactivation of past infections is 
recommended, as reactivation of infection has been reported in patients treated with 
entinostat, in some cases without evidence of neutropenia. The clinical significance of 
this finding and the potential association with entinostat is unknown. 
77                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856936] agree to use acceptable contraceptive 
methods, as indicated in the clinical study protocol, during treatment and for 4 months 
thereafter. 
 
Availability 
 
Entinostat is an investigational agent supplied to investigators by [CONTACT_131797] (DCTD), NCI. 
 
Entinostat is provided to the NCI under a Collaborative Agreement between the 
Pharmaceutical Collaborator, Syndax and the DCTD, NCI (see Section 12.3 ). 
 
 
8.1.2 MK-3475 (SCH 900475, pembrolizumab) (NSC 776864) 
 
Other Names: SCH 900475, pembrolizumab 
 
Classification : Anti-PD-1 MAb 
Molecular Weight: 148.9-149.5 KDa 
CAS Number: 1374853-91-4 
Mode of Action : The programmed cell death 1 (PD-1) receptor is an inhibitory receptor expressed 
by T cells. When bound to either of its ligands, PD-L1 or PD-L2, activated PD-[ADDRESS_856937] may be engaged by [CONTACT_640302]. pembrolizumab (MK-3475) blocks the negative immune regulatory 
signaling by [CONTACT_313852]-1 receptor, inhibiting the interaction between PD-1 and its ligands. 
 
Description: Pembrolizumab (MK-3475) is a humanized MAb of the IgG4/kappa isotype. 
 
How Supplied: Pembrolizumab (MK-3475) is supplied by [CONTACT_44873] & Co., Inc. and distributed by [CONTACT_124438], CTEP/DCTD/NCI. Pembrolizumab (MK-3475) injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution for 
intravenous use. Each vial contains 100 mg of pembrolizumab (MK-3475) in 4 mL of solution. Each 
1 mL of solution contains 25 mg of pembrolizumab (MK-3475) and is formulated in: L-histidine (1.55 
mg), polysorbate 80 (0.2 mg), sucrose (70 mg), and Water for Injection, USP.  
 
Preparation: MK-[ADDRESS_856938] be diluted prior to administration. Do not shake 
the vials. Do not use if opaque or extraneous particulate matter other than translucent to white 
proteinaceous particles is observed. Do not use if discolored. To prepare the infusion solution add the 
dose volume of MK- 3475 to an infusion bag containing 0.9% Sodium Chloride Injection, USP or 
5% Dextrose Injection, USP. Gently invert the bag 10-[ADDRESS_856939] be between 1 mg/mL to 10 mg/mL . 
78                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
  
Compatible IV bag materials: PVC plasticized with DEHP, non-PVC (polyolefin), EVA, 
or PE lined polyolefin 
 
Storage: Store intact vials between 2¬∞C - 8¬∞C (36¬∞F - 46¬∞F). Do not freeze. Protect from light by 
[CONTACT_280557]. 
 
If a storage temperature excursion is identified, promptly return MK-3475 to between 2-8¬∞C and 
quarantine the supplies. Provide a detailed report of the excursion (including documentation of 
temperature monitoring and duration of the excursion) to [EMAIL_087] for 
determination of suitability. 
 
Stability: Refer to the package label for expi[INVESTIGATOR_1516]. .  
 
Administer prepared solutions immediately after preparation. If not administered immediately, 
prepared solutions may be stored refrigerated for up to 24 hours. Pembrolizumab (MK-3475)  
solutions may be stored at room temperature for a cumulative time of up to [ADDRESS_856940] solution in vials, room temperature storage of infusion 
solution in the Infusion Solution IV bag, and the duration of infusion. 
 
Route of Administration: IV infusion only. Do not administer as an IV push or bolus injection. 
 
Method of Administration : Infuse over approximately 30 minutes (range: 25 - 40 minutes) using an 
infusion set containing a low-protein binding 0.2 to 5 Œºm in-line filter made of polyethersulfone or 
polysulfone. Infusion rate should not exceed 6.7 mL /min. A central line is not required; however, if 
a subject has a central venous catheter in place, it is recommended that it be used for the infusion. Do 
not co-administer other drugs through the same infusion line. Following the infusion, flush the IV line 
with normal saline. 
 
Compatible infusion set materials: PVC plasticized with DEHP or DEHT, PVC and tri-(2- 
ethylhexyl) trimellitate, polyethylene lined PVC, polyurethane, or polybutadiene 
 
Patient Care Implications: Refer to the protocol for information on evaluation and management 
of potential immune-related adverse events. 
 
 
Availability 
 
Pembrolizumab (MK-3475) is supplied to investigators by [CONTACT_329208] (DCTD), NCI. 
 
Pembrolizumab (MK-3475) is provided to the NCI under a Collaborative 
Agreement between the Pharmaceutical Collaborator and the DCTD, NCI (see 
Section 12.3 ). 
 
8.1.3 Agent Ordering and Agent Accountability 
79                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 [IP_ADDRESS]  NCI-supplied agents may be requested by [CONTACT_6768] (or their 
authorized designee) at each participating institution. The CTEP-assigned protocol 
number must be used for ordering all CTEP-supplied investigational agents. The 
eligible participating investigators at each participating institution must be registered with CTEP, DCTD through an annual submission of FDA Form 1572 (Statement of 
Investigator), NCI Biosketch, Agent Shipment Form, and Financial Disclosure Form 
(FDF). If there are several participating investigators at one institution, CTEP- 
supplied investigational agents for the study should be ordered under the name [CONTACT_439297]. 
 
Active CTEP-registered investigators and investigat or-designated shippi[INVESTIGATOR_485173] (OAOP) application. Access to OAOP requires the -establishment 
of a CTEP Identity and Access Management (IAM) account and the maintenance of an ‚Äúactive‚Äù account status and a ‚Äúcurrent‚Äù password. For questions about drug orders, 
transfers, returns, or accountability, call or email PMB any time. Refer to the PMB‚Äôs 
website for specific policies and guidelines related to agent management. 
In general, sites may order initial agent supplies when a subject is being screened for 
enrollment onto the study 
 
[IP_ADDRESS]  Agent Inventory Records ‚Äì The investigator, or a responsible party designated by [CONTACT_093], must maintain a careful record of the receipt, dispensing and final 
disposition of all agents received from the PMB using the appropriate NCI 
Investigational Agent (Drug) Accountability Record (DARF) available on the CTEP forms page. Store and maintain separate NCI Investigational Agent Accountability 
Records for each agent, strength, formulation and ordering investigator on this 
protocol 
 
[IP_ADDRESS]  Investigator Brochure Access for CTEP IND agents 
The current version of the Investigator Brochure (IB) will be accessible to site 
investigators and research staff through the PMB Online Agent Order Processing 
(OAOP) application. Access to OAOP requires the establishment of a CTEP Identity 
and Access Management (IAM) account and the maintenance of an ‚Äúactive‚Äù account 
status and a ‚Äúcurrent‚Äù password and active person registration status. Questions about IB access may be directed via email to [EMAIL_090] or by [CONTACT_648] 
([PHONE_032] Monday through Friday between 8:30 am and 4:30 pm (ET). 
 
[IP_ADDRESS]  Useful links and contacts ‚Äì CTEP Forms, Templates, Documents: http://ctep.cancer.gov/forms/ 
NCI CTEP Investigator Registration: [EMAIL_088] 
PMB policies and guidelines: 
http://ctep.cancer.gov/branches/pmb/agent_management.htm  
PMB Online Agent Order Processing (OAOP) application: 
https ://ctepcore.nci.nih.gov/OAOP
80                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 CTEP Identity and Access Management (IAM) account: 
https://ctepcore.nci.nih.gov/iam/  
CTEP IAM account help: [EMAIL_089]  
PMB email: [EMAIL_087]  
PMB phone and hours of service: ([PHONE_032] Monday through Friday between 
8:30 am and 4:30 pm (ET) 
 
 
9. BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES 
 
9.1 Exploratory/Ancillary Correlative Studies 
 
Site(s) Performing Correlative Study. 
The samples will be analyzed at the Yale Cancer Center 
 
Collection and Handling of Specimens 
All operating procedures for specimen collection, handling and storage will be 
standardized. Common standardized operating procedures (SOPs) will be to collect 15 cc of 
bone marrow (BM) (3 EDTA tubes) and 15 cc of blood (3 EDTA tubes) from the patient at baseline (before cycle 1), after cycles 1 (entinostat alone) and then every 2 cycles of 
entinostat and Pembrolizumab (MK-3475) dose. If a patient disease progresses, an additional 
[ADDRESS_856941] be thoroughly mixed to prevent clotting. The specimen should be delivered to the Hematology Tissue Bank (PI: [INVESTIGATOR_640251]) at Yale University within 24 hours after collection. Typi[INVESTIGATOR_897], fresh specimens 
(before cryopreservation) will be used for experiments. Specimens should be labeled with the 
patient‚Äôs initials, study number, sample collection date and time, and sample source 
(peripheral blood or bone marrow). All data should be kept in laboratory log. 
The clot sections will be obtained from each patient at the time of core biopsy and aspi[INVESTIGATOR_1516]. 
The clot section will be fixed immediately after harvesting into 10% formalin solution and 
embedded into paraffin to be delivered to Hematology Tissue Bank (PI: [INVESTIGATOR_640252]) at 
Yale University within 24 hours after collection if the sample is from outside Yale, or if the 
sample is from a Yale patient, it will be stored in the Yale Pathol ogy repository until ready 
for further processing. Paraffin blocks will be cut at maximum 3 mm thickness at the 
Research Histology laboratory at Yale University. Hematology Tissue Bank will separate 
mononuclear cells from BM aspi[INVESTIGATOR_640253] D. 
Samples will be stored in liquid nitrogen and should be clearly marked with the patient‚Äôs 
identification number (given at the time of registration), study number, sample collection date, and sample source (blood or BM). Cryopreserved samples will be batch delivered from 
Yale to [CONTACT_640334]‚Äôs laboratory at Vanderbilt University at this address: Preston 
Research Building, suite 532, Nashville TN, [ZIP_CODE] for the correlative studies that will be 
performed at Vanderbilt University Medical Center (Kim laboratory) 
81                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
  
  
9.1.1 Determine numeric and functional alteration of MDSCs in relation to ENT/anti- 
PD1 therapy and its correlation with the clinical response 
 
[IP_ADDRESS] Collection and Handling of Specimens BM aspi[INVESTIGATOR_640254] 10% formaldehyde 
will be as described above. We will separate mononuclear cells from BM aspi[INVESTIGATOR_640255] D . Samples will be used for experiments and 
samples leftover will be stored in liquid nitrogen and should be clearly marked with the 
patient‚Äôs identification number (given at the time of registration), study number, sample collection date, and sample source (blood or BM). 
Formalin-fixed paraffin-embed clot section will be cut at maximum 3 mm thickness at 
Research Histology lab of Yale University. Shippi[INVESTIGATOR_25476](s) 
Fresh BM aspi[INVESTIGATOR_640256] (according to Appendix D ) at the 
Hematology Tissue Bank at Yale University. Upon request of the Study Chair they will 
be batch shipped to Yale Cancer Center. Samples will be shipped or delivered to the Hematology Tissue Bank: 300 George, Rm 786. Tel: [PHONE_13311]. 
Formalin-fixed paraffin-embed block of clot section from external sites should be also 
delivered to Hematology Tissue Bank at Yale University, or if the sample is from a Yale 
patient, it will be stored in the Yale Pathology repository until ready for further 
processing.. Sections will be cut at maximum 3 mm thickness at Research Histology lab 
at Yale University. 
[IP_ADDRESS] Site(s) Performing Correlative Study The correlative studies will be performed at Yale Cancer Center ([CONTACT_640335]‚Äôs 
lab) and [CONTACT_640334]‚Äôs lab at Vanderbilt University as described above in 9.1 and in 
Appendix J . 
 
9.1.2 Evaluate whether PD-L1 expression in CD34+ blasts from human MDS BM 
correlates with the response to anti-PD1 therapy 
 
[IP_ADDRESS]  Collection and Handling of Specimens 
BM aspi[INVESTIGATOR_640254] 10% formaldehyde 
will be as described above. We will separate mononuclear cells from BM aspi[INVESTIGATOR_640255] D. Samples will be used for experiments and 
samples leftover will be stored in liquid nitrogen and should be clearly marked with the 
patient‚Äôs identification number (given at the time of registration), study number, sample collection date, and sample source (blood or BM). 
Formalin-fixed paraffin-embed clot section will be cut at maximum 3 mm thickness 
[IP_ADDRESS]  Shippi[INVESTIGATOR_25476](s) 
Fresh BM aspi[INVESTIGATOR_640256] (according to Appendix D ) at the 
Hematology Tissue Bank at Yale University. Upon request of the Study Chair they will 
be batch shipped to Yale Cancer Center. Samples will be shipped or delivered to the Hematology Tissue Bank: 300 George, Rm 786. Tel: [PHONE_13311] 
82                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 Formalin-fixed paraffin-embed block of clot section from external sites should be 
delivered to Hematology Tissue Bank at Yale University, or if the sample is from a Yale 
patient, it will be stored in the Yale Pathology repository until ready for further 
processing.. Sections will be cut at maximum 3 mm thickness at Research Histology lab at Yale University. 
[IP_ADDRESS]  Site(s) Performing Correlative Study 
All correlative studies will be performed at Yale Cancer Center Stephanie Halene‚Äôs lab) 
and [CONTACT_640334]‚Äôs lab at Vanderbilt University as described above and in Appendix  
J. 
 
9.1.[ADDRESS_856942]- anti-PD1 therapy 
 
[IP_ADDRESS]  Collection and Handling of Specimens 
BM aspi[INVESTIGATOR_640257]. We will 
separate mononuclear cells from BM aspi[INVESTIGATOR_640258] D . 
Samples will be used for experiments and samples leftover will be stored in liquid 
nitrogen and should be clearly marked with the patient‚Äôs identification number (given at 
the time of registration), study number, sample collection date, and sample source (or bone marrow). 
[IP_ADDRESS]  Shippi[INVESTIGATOR_25476](s) 
Fresh BM aspi[INVESTIGATOR_640256] (according to Appendix D ) at the 
Hematology Tissue Bank at Yale University. Upon request of the Study Chair they will 
be batch shipped to Yale Cancer Center. Samples will be shipped or delivered to the 
Hematology Tissue Bank: 300 George, Rm 786. Tel: [PHONE_13311]. 
[IP_ADDRESS]  Site(s) Performing Correlative Study 
All correlative studies will be performed at Yale Cancer Center Stephanie Halene‚Äôs lab) and [CONTACT_640334]‚Äôs lab at Vanderbilt University as described above and in Appendix  
J. 
 
 
9.2 Special Studies: N/A 
83                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 10. STUDY CALENDAR 
 
Baseline evaluations are to be conducted within 2 weeks prior to start of protocol therapy. In the 
event that the patient‚Äôs condition is deteriorating, laboratory evaluations should be repeated 
within [ADDRESS_856943] (Complete blood counts (CBC)) throughout the study at the clinic. CBC with 
differentials, serum chemistry and Liver function tests (LFTs) will be performed at least every 2 
weeks. 
 
 
 
Procedure Screening# 
dd 14 days 
from 
Baseline 
(First day 
study drug 
administrati 
on) Each Cycle (21 days) Discontinuation 
of Study Drug or 
progression Monthly after 
removal from 
study for any 
reason for 6 
months D1 
+/- 1 D8 
+/- 1 D15 
+/- 1 D17-D20 
Entinostat 
(depending on dose level)  X X X    
Pembrolizumab 
(MK-3475)  X 
(Starting 
in C2)      
Age, gender, 
height, baseline 
medications, record prior 
therapy, 
informed 
consent , EKG X       
Record prior anti-cancer therapi[INVESTIGATOR_014] X       
Physical 
examination, 
performance status, vital 
signs, weight X X    X  
ECOG 
performance 
status X X    X  
Hematology1 X X X X  X  
Serum 
chemistry [ADDRESS_856944] adverse 
events4  X  X  X  
84                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856945] 
concomitant 
medications/ procedures  X    X  
Bone marrow 
aspi[INVESTIGATOR_640259]
5 X    X (of first 
cycle, and 
then every 2 
cycles [C3, 5, 
etc]) X  
TSH X   X    
Survival 
Follow-up6       X 
Cycle1: Entinostat 8mg po on D1, 8 and 15, no Pembrolizumab (MK-3475) 
DL1: Entinostat 8mg on D1, 8 of 21-day cycles, Pembrolizumab (MK-3475) 200mg IV over 30 
mins on D1 of 21-day cycles 
DL2: Entinostat 8mg on D1, 8, 15 of 21-day cycles, Pembrolizumab (MK-3475) 200mg IV over 
30 mins on D1 of 21-day cycles 
DL-1: 8mg on D1 of 21-day cycles, Pembrolizumab (MK-3475) 200mg IV over [ADDRESS_856946] also be maintained. In 
cases of aplasia, CBCs will be performed weekly and Bone marrow aspi[INVESTIGATOR_640260] 3 months until recovery. 
1: Hematology assessment includes complete blood count and differential blood count. 
2: Chemistry assessment includes serum sodium, potassium, chloride, carbon dioxide, serum 
urea nitrogen, creatinine, calcium, glucose, alkaline phosphatase, AST, ALT, total bilirubin, total 
protein, albumin. Blood samples for LFTs must be collected and analyzed at local or central labs within [ADDRESS_856947] be reviewed by [CONTACT_458] (or 
designee) to meet dosing criteria specifications: d3 x ULN for AST, ALT and d2 x ULN for 
Total bilirubin unless liver metastases are present in which case LFT d5 x ULN for AST, ALT 
and Total bilirubin d3.[ADDRESS_856948]) prior to dosing. If, during the course of treatment abnormal LFT 
values are detected, entinostat and Pembrolizumab (MK-3475) w ill not be administered. The 
subject should be evaluated and managed referring to the protocol, as clinically appropriate. In addition, evaluation for pi[INVESTIGATOR_640261], TSH or both. 
3: Pregnancy tests for females of childbearing potential. A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 
2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses 
at any time in the preceding 24 consecutive months). 
4: An additional safety assessment will be done before each maintenance dose. 
5: Bone marrow assessment will be performed in patients at baseline (before cycle 1), after 
cycles 1 (entinostat alone) and then every 2 cycles of entinostat and Pembrolizumab (MK-3475) 
dose. At baseline, bone marrows will be sent for analysis of aspi[INVESTIGATOR_337], biopsy, flow cytometry, iron stain, correlative studies, cytogenetics and FISH. FISH panel will include probes to identify 
5q-, 7q-, trisomy 8, 20q-. Follow-up bone marrows will be analyzed for aspi[INVESTIGATOR_337], biopsy, and 
flow cytometry. Cytogenetics will be sent after cycle 2, 4 and subsequent bone marrow studies. 
85                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 Iron stains and FISH will be repeated at discretion of investigator. 
6: Survival follow-up should be obtained monthly from time of study drug discontinuation or 
disease progression, whichever occurs first, for [ADDRESS_856949] criteria of modified IWG-2006 guidelines (Appendix A1 and 
Appendix A2 ). Responses in AML patients will be assessed using IWG 2003 criteria 
(Appendix A3 ). In addition to a baseline bone marrow biopsy and scan, bone marrow biopsy 
will be performed at baseline, after cycles [ADDRESS_856950] 
treatment with Entinostat in combination with Pembrolizumab (MK -3475) 
 
Evaluable for objective response. Only those patients who have measurable disease present 
at baseline, have received at least one cycle of therapy, and have had their disease re- 
evaluated will be considered evaluable for response. These patients will have their response classified according to the definitions stated below. (Note: Patients who exhibit objective 
disease progression prior to the end of cycle 1 will also be considered evaluable.) 
 
11.2 Response criteria 
 
Myelodysplastic syndrome (MDS) 
Responses for MDS patients will be defined as in the modified IWG-2006 criteria 
(Appendix A1 and Appendix A1 ). These response criteria do not apply to AML as these 
patients are required to be in full remission by [CONTACT_224839]. Only relapse and survival 
as measured by [CONTACT_640303]. The OS and PFS will be measured for both AML and MDS as described in 
Appendix A1 and Appendix A2 . 
Duration of response: The duration of overall response is measured from the time 
measurement criteria are met for CR or PR (whichever is first recorded) until the first date 
that recurrent or progressive disease is objectively documented (taking as reference for 
progressive disease the smallest measurements recorded since the treatment started). 
 
Duration of stable disease: Stable disease is measured from the start of the treatment until 
the criteria for progression are met. 
 
Chronic Myelomonocytic Leukemia (CMML) 
The definitions below are consistent with those detailed by [CONTACT_27856], et al for MDS61 except 
that, as discussed earlier, for disease progression based on BM blast percentage, the patient 
must exceed 10% absolute BM blast percentage in addition to increasing above 50% of BM 
blast percentage at baseline to count as disease progression. 
86                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
  
Complete response is defined by [CONTACT_640304] <5% myeloblasts with normal 
trilineage maturation without dysplasia. When erythroid precursors constitute <50% of 
marrow cells, the blast percentage is based on total nucleated cells; otherwise, the blast percentage is based on non-erythroid compartment. Peripheral blood criteria consist of 
Hemoglobin >11 gm/dl, ANC > 1 x 109/L, Platelets > 100 x 109/L, absence of peripheral 
blood blasts, all in the absence of transfusions and growth factors. 
Partial response is defined by [CONTACT_640305] >50% from pretreatment levels and/or achievement of a less advanced 
MDS FAB classification. 
Stable Disease i s defined by [CONTACT_640306] [ADDRESS_856951] percentages: 
For patients with <5% blasts: >50% increase in blasts to >10% 
For patients with 5-10% blasts: >50% increase in blasts to >10% 
For patients with >10-20% blasts: >50% increase in blasts to >20% 
For patients with >20-30% blasts: >50% increase in blasts to >30% 
In addition, there must be >1 of the following criteria: >50% decrease from maximum 
response levels in granulocytes or platelets, a decrease in hemoglobin concentration by [CONTACT_12697] 2 gm/dl, or becoming transfusion dependent. 
 
11.3 Other response parameters 
 
Progression-free survival (PFS) and overall survival (OS) will be recorded from start of study 
to progression or death (PFS), or time from start of study to death (OS). 
 
 
12. STUDY OVERSIGHT AND DATA REPORTING / REGULATORY 
REQUIREMENTS 
 
Adverse event lists, guidelines, and instructions for AE reporting can be found in Section 7.0 
(Adverse Events: List and Reporting Requirements). 
 
12.[ADDRESS_856952] and progress of the clinical trial, including the ongoing review of accrual, patient-specific clinical and laboratory data, and routine and 
serious adverse events; reporting of expedited adverse events; and accumulation of reported 
adverse events from other trials testing the same drug(s). The Protocol Principal Investigator [INVESTIGATOR_640262]-based reporting portal. 
 
For the Phase 1 portion of this study, all decisions regarding dose escalation/expansion/de- 
escalation require sign-off by [CONTACT_124456] [INVESTIGATOR_25487]/IWRS. In addition, for the Phase [ADDRESS_856953] monthly, 
87                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 or more frequently, conference calls with the Study Investigators and the CTEP Medical 
Officer(s) to review accrual, progress, and adverse events and unanticipated problems. 
 
All Study Investigators at participating sites who register/enroll patients on a given protocol are 
responsible for timely submission of data via Medidata Rave and timely reporting of adverse 
events for that particular study. This includes timely review of data collected on the electronic CRFs submitted via Medidata Rave. 
All studies are also reviewed in accordance with the enrolling institution‚Äôs data safety monitoring 
plan. 
There are two safety/stoppi[INVESTIGATOR_640263]: 
Stoppi[INVESTIGATOR_1877] 1: Delayed immune related toxicity from dose escalation phase. If 4 or more 
patients in any dose level develop delayed protocol defined immune related grade 3/4 events, we 
will halt further therapy on that dose level 
Stoppi[INVESTIGATOR_1877] 2: Excess toxicity in the expansion cohort. We will cease enrollment in the 
expansion phase at the dose determined from the dose escalation part of the study if we observe 
two or more DLTs among the first six evaluable patients enrolled in the expansion cohort. An 
evaluable patient is any patient who received a st udy drug. If the true toxicity rate is 50% or 
greater at the MTD then this rule will stop the trial with probability at least .89. S imilarly, if the 
true toxicity rate is 33% at the MTD then this stoppi[INVESTIGATOR_640264] .65. 
In that event, a new expansion cohort will start at the dose level immediately below the dose 
level that was expanded. If the dose level being expanded is dose level -1, then the study will be 
terminated. 
 
12.[ADDRESS_856954] is granted through the iMedidata application to all persons with the appropriate roles assigned in the Regulatory Support System (RSS). To a ccess Rave via iMedidata, the site 
user must have an active CTEP IAM account (check at < https://ctepcore.nci.nih.gov/iam >) and 
the appropriate Rave role (Rave CRA, Read-Only, CRA (Lab Admin, SLA or Site Investigator) 
on either the LPO or participating organization roster at the enrolling site. To the hold Rave CRA 
role or CRA Lab Admin role, the user must hold a minimum of an AP registration type. To hold the Rave Site Investigator role, the individual must be registered as an NPI[INVESTIGATOR_6735]. 
Associates can hold read-only roles in Rave. 
 
Upon initial site registration approval for the study in RSS, all persons with Rave roles assigned 
on the appropriate roster will be sent a study invitation e-mail from iMedid ata. To accept the 
invitation, site users must log into the Select Login ( https://login.imedidata.com/selectlogin ) 
using their CTEP-IAM user name [CONTACT_2383], and click on the ‚Äúaccept‚Äù link in the upper 
right-corner of the iMedidata page. Please note, site users will not be able to access the study in 
Rave until all required Medidata and study specific trainings are completed. Trainings w ill be in 
the form of electronic learnings (eLearnings), and can be accessed by [CONTACT_124457]. 
88                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856955] not previously activated their iMedidata/Rave account at the time of initial site 
registration approval for the study in RSS will also receive a separate invitation from iMedidata 
to activate their account. Account activation instructions are located on the CTSU website, Rave 
tab under the Rave resource materials (Medidata Account Activation and Study Invitation 
Acceptance). Additional information on iMedidata/Rave is available on the CTSU members‚Äô website under the Rave tab or by [CONTACT_6821] [PHONE_031] or by e- 
mail at [EMAIL_013] . 
 
12.2.1  Method 
 
CTMS Routine Monitoring: 
This study will be monitored by [CONTACT_25540] (CTMS). Data 
will be submitted to CTMS at least once every two weeks via Medidata Rave (or other modality if approved by [CONTACT_472]). Information on CTMS reporting is available at 
http://www.theradex.com/clinicalTechnologies/?National-Cancer-Institute-NCI-[ADDRESS_856956] the Theradex Help Desk at ([PHONE_3920] 
or by [CONTACT_25541] [EMAIL_411] for additional support with Rave and 
completion of CRFs. 
 
 
12.2.2  Responsibility for Data Submission 
 
For ETCTN trials, it is the responsibility of the PI(s) at the site to ensure that all 
investigators at the ETCTN Sites understand the procedures for data submission for each 
ETCTN protocol and that protocol specified data are submitted accurately and in a timely 
manner to the CTMS via the electronic data capture system, Medidata Rave. 
 
Data are to be submitted via Medidata Rave to CTMS on a real-time basis, but no less 
than once every [ADDRESS_856957] for the CRA at the ETCTN to 
resolve. Monthly web-based reports are posted for review by [CONTACT_34001], CTEP. Onsite audits will be conducted by [CONTACT_182663], GCP, and NCI policies and procedures with the overarching 
goal of ensuring the integrity of data generated from NCI-sponsored clinical trials, as 
described in the ETCTN Program Guidelines, which may be found on the CTEP 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htm  
89                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 ) and CTSU websites. 
 
An End of Study CRF is to be completed by [CONTACT_978], and is to include a summary of study 
endpoints not otherwise captured in the database, such as (for phase 1 tr ials) the 
recommended phase 2 dose (RP2D), and a description of any dose-limiting toxicities 
(DLTs). CTMS will utilize a core set of eCRFs that are Cancer Data Standards Registry 
and Repository (caDSR) compliant ( http://cbiit.nci.nih.gov/ncip/biomedical-informatics-  
resources/interoperability-and-semantics/metadata-and-models ). Customized eCRFs will 
be included when appropriate to meet unique study requirements. The PI [INVESTIGATOR_33956], working closely with CTMS to ensure prospectively that all 
required items are appropriately captured in the eCRFs prior to study activation. CTMS 
will prepare the eCRFs with built-in edit checks to the extent possible to promote data 
integrity. 
 
CDUS data submissions for ETCTN trials activated after March 1, 2014, will be carried 
out by [CONTACT_34003], Theradex. CDUS submissions are performed by [CONTACT_34004] a monthly basis. The trial‚Äôs lead institution is responsible for timely submission to 
CTMS via Rave, as above. 
 
Further information on data submission procedures can be found in the ETCTN Program 
Guidelines (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/adverse_events.htm  
). 
 
 
12.3 Collaborative Agreements Language 
 
The agent(s) supplied by [CONTACT_472], DCTD, NCI used in this protocol is/are provided to the NCI under a Collaborative Agreement (CRADA, CTA, CSA) between the Pharmaceutical 
Company(ies) (hereinafter referred to as ‚ÄúCollaborator(s)‚Äù) and the NCI Division of Cancer 
Treatment and Diagnosis. Therefore, the following obligations/guidelines, in addition to the 
provisions in the ‚ÄúIntellectual Property Option to Collaborator‚Äù 
(http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ) contained within the 
terms of award, apply to the use of the Agent(s) in this study: 
 
1. Agent(s) may not be used for any purpose outside the scope of this protocol, nor can Agent(s) be transferred or licensed to any party not participating in the clinical study. 
Collaborator(s) data for Agent(s) are confidential and proprietary to Collaborator(s) and shall be maintained as such by [CONTACT_473]. The protocol documents for studies utilizing 
Agents contain confidential information and should not be shared or distributed without the 
permission of the NCI. If a copy of this protocol is requested by a patient or patient‚Äôs family 
member participating on the study, the individual should sign a confidentiality agreement. A 
suitable model agreement can be downloaded from:  http://ctep.cancer.gov . 
 
2. For a clinical protocol where there is an investigational Agent used in combination with 
90                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 (an)other Agent(s), each the subject of different Collaborative Agreements, the access to and 
use of data by [CONTACT_474] (data pertaining to such combination use 
shall hereinafter be referred to as "Multi-Party Data‚Äù): 
 
a. NCI will provide all Collaborators with prior written notice regarding the existence and 
nature of any agreements governing their collaboration with NCI, the design of the 
proposed combination protocol, and the existence of any obligations that would tend to 
restrict NCI's participation in the proposed combination protocol. 
 
b. Each Collaborator shall agree to permit use of the Multi-Party Data from the clinical trial 
by [CONTACT_124459], obtain regulatory approval or commercialize its own Agent. 
 
c. Any Collaborator having the right to use the Multi-Party Data from these trials must 
agree in writing prior to the commencement of the trials that it will use the Multi-Party 
Data solely for development, regulatory approval, and commercialization of its own 
Agent. 
 
3. Clinical Trial Data and Results and Raw Data developed under a Collaborative Agreement 
will be made available to Collaborator(s), the NCI, and the FDA, as appropriate and unless 
additional disclosure is required by [CONTACT_379556] ( http://ctep.cancer.gov/industryCollaborations2/intellectual_property.htm ). 
Additionally, all Clinical Data and Results and Raw Data will be collected, used and 
disclosed consistent with all applicable federal statutes and regulations for the protection of 
human subjects, including, if applicable, the Standards for Privacy of Individually 
Identifiable Health Information set forth in [ADDRESS_856958] be sent to the 
NCI, who will then notify the appropriate investigators (Group Chair for Cooperative Group studies, or PI [INVESTIGATOR_349]) of Collaborator's wish to contact [CONTACT_476]. 
 
5. Any data provided to Collaborator(s) for Phase [ADDRESS_856959] be in accordance with the 
guidelines and policies of the responsible Data Monitoring Committee (DMC), if there is a 
DMC for this clinical trial. 
 
6. Any manuscripts reporting the results of this clinical trial must be provided to CTEP by [CONTACT_477] [INVESTIGATOR_350]- 
Cooperative Group studies for immediate delivery to Collaborator(s) for advisory review and 
comment prior to submission for publication. Collaborator(s) will have [ADDRESS_856960] that publication be 
delayed for up to an additional 30 days in order to ensure that Collaborator‚Äôs confidential and 
proprietary data, in addition to Collaborator(s)‚Äôs intellectual property rights, are protected. 
Copi[INVESTIGATOR_351](s) for courtesy 
review as soon as possible and preferably at least three (3) days prior to submission, but in any case, prior to presentation at the meeting or publication in the proceedings. Press 
releases and other media presentations must also be forwarded to CTEP prior to release. 
91                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856961] and/or press release/ media presentation should be sent to: 
Email: [EMAIL_001]  
The Regulatory Affairs Branch will then distribute them to Collaborator(s). No publication, 
manuscript or other form of public disclosure shall contain any of Collaborator‚Äôs confidential/ 
proprietary information. 
 
 
13. STATISTICAL CONSIDERATIONS 
 
13.1 Study Design/Endpoints 
This will be a phase 1b study [schema]. The proposed dosing of ENT has been previously 
tested in MDS and showed to be well-tolerated. While the combination of ENT with the anti- PD1, Pembrolizumab (MK-3475) has not been studied clinically in MDS patients, it is 
unlikely that this combination would have overlappi[INVESTIGATOR_50685]. 
 
PART 1: ENT has been previously evaluated as a single agent therapy in patients with MDS 
at these doses and has been well tolerated. The ENT monotherapy run-in part (cycle 1) will allow to study the changes in myeloid derived suppressor cells (MDSCs) at pre- and post- 
ENT treatment (the end of cycle 1) to dissect the effects of ENT monotherapy from those of 
the combined ENT/anti-PD1 therapy. 
 
We will perform ‚Äò3+3‚Äô classical dose escalation design to determine dose limiting toxicity (DLT). The first 3 patients will receive ENT at dose level 1 (DL1: 8mg on D1, 8 of 21-day 
cycles). Pembrolizumab (MK-3475) will be added starting day 1 cycle 2 at the approved dose 
of 200mg intravenously [IV] over 30 minutes on D1 of 21-day cycles) for [ADDRESS_856962] 3 treated patients in that dose level if there are 
toxicity/safety concerns that did not qualify as DLT (maximum of 6 evaluable patients to be 
enrolled at any dose level). The committee can also decide to enroll patients at a lower dose level after the first [ADDRESS_856963] 6 patients enrolled in any dose level even if no or one 
DLT occurred at that dose level if there are toxicity/safety concerns that did not qualify as 
DLT. The following regarding enrollment in different dose levels will be considered 
guidance for the safety committee but can be modified in accordance of above: If no patient 
of the 3 patients treated with combined therapy at DL1 develops DLT, then dose level 2 (DL2) will be tested. For instance, DL2 will be with ENT at 8mg on D1, 8 and 15 and MK- 
3475 (pembrolizumab) at 200mg IV on D1 of 21-day cycles. If 1 patient out of the 3 patients 
has DLT at DL1, we will expand cohort to 3 more patients and if 1 patient of the 6 patients 
has DLT (i.e. only 0/3 or 1/6), we will test next dose (DL2). If no patient of the 3 patients 
treated with combined therapy at DL2 develop DLT, then DL2 will be used for part 2 (expansion cohort). If 1 patient out of the 3 patients has DLT at DL2, we will expand cohort 
to 3 more patients and if 1 patient of the 6 patients has DLT (i.e only 0/3 or 1/6), dose level 2 
92                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 (DL2) will be used for part 2 (expansion cohort). If [ADDRESS_856964] 
DLT, DL1 will be used for expansion cohort. 
An additional dose level (DL -1) in which day 8 of ENT will be omitted (i.e. ENT at 8mg on 
D1, and Pembrolizumab (MK-3475) at 200mg IV on D1 of 21-day cycles) will be used if [ADDRESS_856965] 2 cycles of combined therapy at DL1. If 0 or 1 
patients of the 6 patients treated with combined therapy at DL-1 develop DLT then DL-1 will 
be used in the second part of the study. If 2 or more 6 patients enrolled in DL -1 develop 
DLT, then the study will be termin ated. 
Toxicities will be tabulated and graded according to the Common Terminology Criteria for Adverse Events Version 5 (CTCAE-5). DLT will be assessed after the first 2 cycles of 
combined therapy. Responses will be as defined by [CONTACT_57937]-2006 criteria (CR, PR, or HI) and 
assessed at the end of cycle 1, the combined first 2 cycles, and every 2 cycles afterwards. 
Patients who achieve an objective response or maintain a stable disease (SD) status after the 
first [ADDRESS_856966] 2 
cycles of combined therapy without experiencing a DLT during dose escalation (as DLT period 
is defined in the first 2 combined therapy cycles) will also be replaced. To be DLT-evaluable, 
the patient must complete the first two cycles of combined therapy without experiencing a 
DLT. Any patient who is dose reduced during the entinostat run-in first cycle due to entinostat- 
related toxicity will be analyzed on the dose level that corresponds to the reduced dose level 
delivered during the first cycle of combined therapy. 
 
PART 2: After the safe dose of the combination is established, 15 patients will be treated 
with ENT+ Pembrolizumab (MK-3475) combination at that same dose and schedule. 
Assessment of response will occur after 4 combination cycles and similar to part 1, those 
who achieve an objective response or SD will continue to receive the therapy till progression. 
Patients who progress or respond and subsequently lose response will be withdrawn from study. BM biopsy/aspi[INVESTIGATOR_640234], after first cycle of ENT 
monotherapy, every [ADDRESS_856967] 5 cycles (i.e. 1 ENT monotherapy cycle and 4 cycles 
of combined therapy (DL1, DL2) for each patient) to assess for any unexpected autoimmune or other toxicity. 
 
Primary Endpoint(s): MTD will be defined by [CONTACT_640307] 2 dose 
schedules (see section 5.2) 
Definitions of DLT: see section 5.2 
 
 
The following early stoppi[INVESTIGATOR_640236]: 
We will cease enrollment in the expansion phase at the dose determined from dose escalation 
part of the study if we observe two or more DLTs among the first six evaluable patients 
enrolled in the expansion cohort. An evaluable patient is any patient who received a study 
drug. If the true toxicity rate is 50% or greater at the MTD then this rule will stop the trial with probability at least .89. Similarly, if the true toxicity rate is 33% at the MTD then this 
stoppi[INVESTIGATOR_640220] .65. In that event, a new expansion cohort will 
93                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 start at the dose level immediately below the dose level that was expanded. If the dose level 
being expanded is dose level -1, then the study will be terminated. 
 
Secondary Endpoint(s): Overall response rate (CR, PR, and HI) as defined by [CONTACT_640308] 2006 (IWG-2006) criteria for CR, PR, HI (Appendix A1 and 
Appendix A2 ) with at least 15% to be continued 
 
Exploratory Endpoint(s): 
x Median response duration for responders, median time of progression to AML, median 
overall survival (OS) and 1- and 2-year OS rate 
x Assessment of the dynamic quantitative change in proportion of MDSCs in BM with 
combined therapy (target of reducing to <10%) and correlation with any observed clinical responses 
 
13.2 Sample Size/Accrual Rate 
 
We expect to accrue 1-[ADDRESS_856968]-DNMTi setting is negligible (1% or less). It is generally accepte GWKDWD¬ï255LQWKH
post-DNMTi is clinically meaningful and would be worth further evaluation in larger studies. 
The total number of patients enrolled in the study will range from 21 to 27. The null 
hypothesis response rate of 1% (only supportive care) will be rejected if we observe [ADDRESS_856969]. This criterion has power between .84 and .93 for testing an alternative response 
rate of 15% with the combination therapy. Therefore, we will treat a total of 21 patients in the 
combination arm ([ADDRESS_856970] part of the study and 15 in the second part of the study). 
 
DOMESTIC PLANNED ENROLLMENT REPORT 
 
Racial Categories Ethnic Categories  
Total  Not Hispanic or Latino Hispanic or Latino 
Female Male Female Male 
American Indian/ Alaska Native 1 1 1 1 
4 
Asian 1 1 0 0 2 
Native Hawaiian or 
Other Pacific Islander 1 0 0 0 
1 
Black or African 
American 1 1 1 1 4 
White 4 4 1 1 10 
More Than One 
Race 0 0 0 0  
Total  8 7 3 3 21 
 
13.3 Stratification Factors 
 
There are no planned stratifications for this protocol. 
 
13.4 Analysis of Secondary Endpoints 
Overall response rate: defined by [CONTACT_640309] 2006 (IWG-2006) criteria 
for CR, PR, HI (Appendix A1 and Appendix A2 ). We will also record PFS and OS for the 
94                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 MDS. These endpoints will be assessed after cycle 2 and 4 of induction therapy, and every 3 
months during follow-up. Bone marrow biopsies will be done at baseline, after 1 cycle and 
then every 2 cycles, at end of study, and as clinically indicated (e.g. suspi[INVESTIGATOR_55519], 
decreasing blood counts). We aim to obtain preliminary efficacy data of entinostat in combination with Pembrolizumab (MK-3475) in terms of CR, PR, HI as defined by [CONTACT_57937]- 
[ADDRESS_856971] 95% confidence interval. Median PFS and OS will also be reported 
with a 95% confidence interval. 
The quantitative change in MDSCs (% MDSCs by [CONTACT_4133], QIF score by [CONTACT_485200]) 
during treatment with the ENT/anti-PD1 combined therapy will be estimated using mixed 
effects models to take into account the within-patient c orrelation. Likelihood ratio tests w ill 
be performed to confirm if random intercepts and slopes are necessary in the model. The 
fixed effect for change in MDSCs over time will be evaluated for significance. The 
variability in the rate of change in MDSCs across patients will also be examined. The association between the clinical outcome and a meaningful reduction in MDSCs, which will 
be defined after a review of the data, will be assessed with the chi-square test. The quantity of 
MDSCs at baseline and during treatment as continuous variables can also be compared 
between responding and non-responding patients using a t-test or Mann-Whitney U-Test, if 
more appropriate. 
 
13.5 Reporting and Exclusions 
 
13.5.1   Evaluation of toxicity: All patients will be evaluable for toxicity from the time of their 
first treatment with entinostat/  Pembrolizumab (MK-3475). 
 
13.5.2  Evaluation of response: All patients included in the study will be assessed for response 
to treatment, even if there are major protocol treatment deviations or if they are ineligible. Each patient will be assigned one of the following categories: 1) complete 
response, 2) partial response, 3) stable disease, 4) progressive disease, 5) early death 
from malignant disease, 6) early death from toxicity, 7) early death because of other 
cause, or 9) unknown (not assessable, insufficient data). [Note: By [CONTACT_640310], category 9 usually designates the ‚Äúunknown‚Äù status of any type of data in a clinical database.] 
 
All of the patients who met the eligibility criteria (with the possible exception of those 
who received no study medication) should be included in the main analysis of the 
response rate. Patients in response categories 4-[ADDRESS_856972] a treatment failure (disease progression). Thus, an incorrect treatment schedule or drug 
administration does not result in exclusion from the analysis of the response rate. Precise 
definitions for categories 4-[ADDRESS_856973] been identified ( e.g., early death due to other reasons, early 
discontinuation of treatment, major protocol violations, etc.). However, these sub- 
analyses may not serve as the basis for drawing conclusions concerning treatment 
95                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 efficacy, and the reasons for excluding patients from the analysis should be clearly 
reported. The 95% confidence intervals should also be provided. 
 
 
14. STUDY STATUS UPDATES AND STUDY CLOSURE 
 
14.1 Definitions of Study Status Changes 
 
14.1.1  Temporarily Closed to Accrual 
 
The study status is Temporarily Closed to Accrual when no patient slots are currently 
available, but there is the possibility that the trial will re-open for accrual (patient slots 
become available). Sites are not permitted to accrue additional patients until CTEP is 
notified of Re-Activation. 
 
Study status will need to be changed to Temporarily Closed to Accrual when any of the 
following criteria are met: 
 
 
x Sites are notified by [CONTACT_472] (via Request for Rapid Amendment [RRA]) of 
changes in the risk/benefit ratio that necessitate changes to the patient Informed 
Consent document. Requested changes will be specified in the RRA and must be 
reviewed by [CONTACT_1758]‚Äôs IRB. 
x CTEP and the lead investigator agree that unacceptable toxicities necessitate a 
discussion to change the dosing/regimen. 
x A protocol-defined benchmark has been achieved (such as an interim analysis 
before proceeding to the next stage). 
x Investigators encounter any of the stoppi[INVESTIGATOR_131956] 5.3. 
 
14.1.2  Closed to Accrual 
 
The study status is (permanently) Closed to Accrual when no more patient enrollment 
slots are available, and at least one patient is still actively receiving the study treatment. 
Sites are no longer permitted to enroll additional patients. 
 
Patient slots are no longer available when the following criteria are met: 
 
x The pre-specified number of evaluable patients has been successfully enrolled, 
treated, and evaluated. 
x The study treatment has failed to meet the pre-specified efficacy goal at the stage 
1 interim analysis. 
x CTEP and the investigators agree that unacceptable toxicities preclude further 
enrollment. 
x Investigators encounter any of the stoppi[INVESTIGATOR_131956] 5.3. 
96                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 14.1.3  Closed to Accrual and Treatment 
 
The study status is Closed to Accrual and Treatment when no more patient enrollment 
slots are available and no patients are c urrently receiving the study treatment. Patients 
may still be enrolled on the protocol only for the purposes of follow-up. 
 
Patient accrual and treatment will be permanently halted when any of the following 
criteria are met: 
 
x Enrollment was previously closed (study status of ‚ÄúClosed to Accrual‚Äù), and no 
patients are receiving the study trea tment. 
x CTEP and the investigators agree that unacceptable toxicities preclude further 
enrollment. In this case, CTEP and the investigators must collaborate to alter the 
regimen or to halt the study treatment altogether as soon as it can be safely done 
for patients currently receiving trea tment. 
 
CTEP and Theradex must be notified when patients are no longer receiving treatment 
[i.e., when the last patient(s) to be receiving treatment is/are no longer receiving the study 
regimen for any reason]. 
 
14.1.[ADDRESS_856974] not been removed from the study for other reasons. That is, there are no outstanding follow-up procedures to be 
performed as mandated by [CONTACT_760]. 
 
CTEP does not need to be notified of a status change to ‚ÄúClosed to Follow Up.‚Äù 
 
14.1.[ADDRESS_856975] thirty (30) days since the last patient 
follow-up evaluation. 
 
A citation to a final study report (manuscript, meeting abstract, etc.) is required with the 
submission of the Protocol Status Update Form to CTEP PIO. 
 
 
14.[ADDRESS_856976] be notified of all study status changes in Section 14.1 (except for Closed to Follow- 
Up) by [CONTACT_640311], available from the 
CTEP website at http://ctep.cancer.gov/protocolDevelopment/default.htm#amendments . 
97                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856977] be notified as soon as all patients are off treatment ( i.e., when study status 
changes to Closed to Accrual and Treatment). Theradex will produce a report within 90 days of 
this notification. 
98                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 REFERENCES 
1. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al: Effi cacy of azacitidine 
compared with that of conventional care regimens in the treatment of higher-risk 
myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223-32, 2009 
2. Prebet T, Gore SD, Esterni B, et al: Outcome of high-risk myelodysplastic 
syndrome after azacitidine treatment failure. J Clin Oncol 29:3322-7, 2011 
3. Zeidan AM, Kharfan-Dabaja MA, Komrokji RS: Beyond hypomethylating 
agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol 21:123-30, 2014 
4. Klimek VM, Fircanis S, Maslak P, et al: Tolerability, pharmac odynamics, 
and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous 
leukemia or advanced myelodysplastic syndromes. Clin Cancer Res 14:826-32, 2008 
5. Odenike OM, Alkan S, Sher D, et al: Histone deacetylase inhibitor 
romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res 14:7095-101, 2008 
6. Pardoll DM: The blockade of immune checkpoints in cancer 
immunotherapy. Nat Rev Cancer 12:252-64, 2012 
7. Egen JG, Kuhns MS, Allison JP: CTLA-4: new insights into its biological 
function and use in tumor immunotherapy. Nat Immunol 3:611-8, [ADDRESS_856978] RS, Soria JC, Kowanetz M, et al: Predictive correlates of response 
to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563-7, 2014 
9. Robert C, Ribas A, Wolchok JD, et al: Anti-programmed-death-receptor-[ADDRESS_856979] ory advanced melanoma: a randomised 
dose-comparison cohort of a phase 1 trial. Lancet 384:1109-17, 2014 
10. Powles T, Eder JP, Fine GD, et al: MPDL3280A (anti-PD-L1) tre atment 
leads to clinical activity in metastatic bladder cancer. Nature 515:558-62, 2014 
11. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with 
nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-9, 2015 
12. Kondo A, Yamashita T, Tamura H, et al: Interferon-gamma and tumor 
necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB 
activation in blasts in myelodysplastic syndromes. Blood 116:1124-31, 2010 
13. Yang H, Bueso-Ramos C, DiNardo C, et al: Expression of PD-L1, PD-L2, 
PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by [CONTACT_640312]. Leukemia 28:1280-8, 2014 
14. Chen X, Eksioglu EA, Zhou J, et al: Induction of myelodysplasia by 
[CONTACT_308091]-derived suppressor cells. J Clin Invest 123:4595-611, 2013 
15. Kim K, Skora AD, Li Z, et al: Eradication of metastatic mouse cancers 
resistant to immune checkpoint blockade by [CONTACT_108694]-derived cells. Proc Natl 
Acad Sci U S A 111:[ZIP_CODE]-9, 2014 
16. Ma X: Epi[INVESTIGATOR_301470]. Am J Med 125:S2-5, 
2012 
17. Sekeres MA: Epi[INVESTIGATOR_623], natural history, and practice patterns of 
patients with myelodysplastic syndromes in 2010. J Natl Compr Canc Netw 9:57-63, 2011 
18. Goldberg SL, Chen E, Corral M, et al: Incidence and clinical 
complications of myelodysplastic syndromes among [LOCATION_002] Medicare beneficiaries. J Clin 
Oncol 28:2847-52, 2010 
99                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 19. Zeidan AM, Komrokji RS: There's risk, and then there's risk: The latest 
clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig 
Rep 8:351-60, 2013 
20. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for 
evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-88, [ADDRESS_856980] AF, et al: Perceptions of disease state, 
treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from 
an internet-based survey. Oncologist 16:904-11, 2011 
22. Gore SD, Jiemjit A, Silverman LB, et al: Combined 
Methyltransferase/Histone deacetylase inhibition with 5Azacitidine and MS-275 in patients with 
MDS, CMMoL and AML: Clinical response, Histone Acetylation and DNA damage. Blood 
108:156a-157a, 2006 
23. Prebet T, Sun Z, Figueroa ME, et al: Prolonged administration of 
azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin 
Oncol 32:1242-8, 2014 
24. Okazaki T, Chikuma S, Iwai Y, et al: A rheostat for immune responses: 
the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 
14:1212-8, 2013 
25. Garon EB, Rizvi NA, Hui R, et al: Pembrolizumab for the treatment of 
non-s mall-cell l ung cancer. N Engl J Med 372:2018-28, 2015 
26. Seiwert TY, Burtness B, Mehra R, et al: Safety and clinical activity of 
pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and 
neck (KEYNOTE -012): an open-label, multicentre, phase 1b trial. Lancet Oncol 17:956-65, 
2016 
27. Zeidan AM, Linhares Y, Gore SD: Current therapy of myelodysplastic 
syndromes. Blood Rev 27:243-59, 2013 
28. Zeng H, Wu DP, Ouyang J, et al: [Expressions of costimulatory molecules 
on CD3(+)CD4(+) T cells in myelodysplastic syndrome]. Zhongguo Shi Yan Xue Ye Xue Za 
Zhi 16:1082-5, 2008 
29. Zou W, Chen L: Inhibitory B7-fa mily molecules in the tumour 
microenvironment. Nat Rev Immunol 8:467-77, [ADDRESS_856981], et al: Tumor-associated B7-H1 
promotes T-c ell apoptosis: a potent ial mechanism of immune evasi on. Nat Med 8:793-800, 2002 
31. Pardoll DM: Immunology beats cancer: a blueprint for successful 
translation. Nat Immunol 13:1129-32, 2012 
32. Thompson RH, Dong H, Kwon ED: Implications of B7-H1 expression in 
clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 13:709s- 
715s, 2007 
33. Nomi T, Sho M, Akahori T, et al: Clinical significance and therapeutic 
potential of the programmed death-1 ligand/programmed death-[ADDRESS_856982] in human pancreatic 
cancer. Clin Cancer Res 13:2151-7, 2007 
34. Gao Q, Wang XY, Qiu SJ, et al: Overexpression of PD-L1 significantly 
associates with tumor aggressiveness and postoperative recurrence in human hepatocellular 
carcinoma. Clin Cancer Res 15:971-9, 2009 
35. Hamanishi J, Mandai M, Iwasaki M, et al: Programmed cell death 1 ligand 
100                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. 
Proc Natl Acad Sci U S A 104:3360-5, 2007 
36. Hodi FS, Dranoff G: The biologic importance of tumor-inf iltrating 
lymphocytes. J Cutan Pathol [ADDRESS_856983] 1:48-53, 2010 
37. Robert C, Thomas L, Bondarenko I, et al: Ipi[INVESTIGATOR_640265]. N Engl J Med 364:2517-26, 2011 
38. Ribas A, Tumeh PC: Cancer therapy: Tumours switch to resist. Nature 
490:347-8, 2012 
39. Ribas A, Chesney JA, Gordon MS, et al: Safety profile and 
pharmacokinetic analyses of the anti-CTLA4 antibody treme limumab administered as a one hour 
infusion. J Transl Med 10:236, 2012 
40. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune 
correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-54, 2012 
41. Hamid O, Robert C, Daud A, et al: Safety and tumor responses with 
lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134-44, 2013 
42. Hamid O, Schmidt H, Nissan A, et al: A prospective phase II trial 
exploring the association between tumor microenvironment biomarkers and clinical activity of 
ipi[INVESTIGATOR_15172]. J Transl Med 9:204, 2011 
43. Hess-Stumpp H, Bracker TU, Henderson D, et al: MS-275, a potent orally 
available inhibitor of histone deacetylases--the development of an anticancer agent. Int J 
Biochem Cell Biol 39:1388-405, 2007 
44. Shah P, Gau Y, Sabnis G: Histone deacetylase inhibitor entinostat reverses 
epi[INVESTIGATOR_640266] E- 
cadherin. Breast Cancer Res Treat 143:99-111, 2014 
45. Juergens RA, Wrangle J, Vendetti FP, et al: Combination epi[INVESTIGATOR_640267]-small cell lung cancer. Cancer 
Discov 1:598-607, 2011 
46. Hauschild A, Trefzer U, Garbe C, et al: Multicenter phase II trial of the 
histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}- 
carbamate in pretreated metastatic melanoma. Melanoma Res 18:274-8, 2008 
47. Acharya MR, Karp JE, Sausville EA, et al: Factors affecting the 
pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer. Invest New Drugs 24:367-75, 2006 
48. Gabrilovich DI, Bronte V, Chen SH, et al: The terminology issue for 
myeloid-derived suppressor cells. Cancer Res 67:425; author reply 426, 2007 
49. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators 
of the immune system. Nat Rev Immunol 9:162-74, 2009 
50. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V: Coordinated regulation 
of myeloid cells by [CONTACT_397344]. Nat Rev Immunol 12:253-68, 2012 
51. Ostrand-Rosenberg S, Sinha P: Myeloid-derived suppressor cells: linking 
inflammation and cancer. J Immunol 182:4499-506, 2009 
52. Rodriguez PC, Zea AH, Culotta KS, et al: Regulation of T cell receptor 
CD3zeta chain expression by L-arginine. J Biol Chem 277:[ZIP_CODE]-9, 2002 
53. Gojo I, Jiemjit A, Trepel JB, et al: Phase 1 and pharmacologic study of 
MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. 
Blood 109:2781-90, 2007 
101                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 54. Ryan QC, Headlee D, Acharya M, et al: Phase I and pharmacokinetic 
study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid 
tumors or lymphoma. J Clin Oncol 23:3912-22, 2005 
55. Gore L, Rothenberg ML, O'Bryant CL, et al: A phase I and 
pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with 
refractory solid tumors and lymphomas. Clin Cancer Res 14:4517-25, 2008 
56. Batlevi CL, Kasamon Y, Bociek RG, et al: ENGAGE- 501: phase II study 
of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica 
101:968-75, [ADDRESS_856984] A. Burris: A phase [ADDRESS_856985] on the pharmacokinetics (PK) of entinostat. J Clin Oncol 32:5s, 2014 (suppl; abstr 591), 
2014 
58. Wood ML, Slater DN: Cutaneous manifestations of the hypereosinophilic 
syndrome treated with sodium cromoglycate. Clin Exp Dermatol 9:139-42, 1984 
59. Schooley RT, Flaum MA, Gralnick HR, et al: A clinicopathologic 
correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 
58:1021-6, 1981 
60. Flaum MA, Schooley RT, Fauci AS, et al: A clinicopathologic correlation 
of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood 58:1012-20, 
[ADDRESS_856986], Bennett JM, et al: Clinical application and 
proposal for modification of the International Working Group (IWG) response criteria in 
myelodysplasia. Blood 108:419-25, 2006 
62. Gajewski TF, Meng Y, Blank C, et al: Immune resistance orchestrated by 
[CONTACT_217944]. Immunol Rev 213:131-45, 2006 
63. Nagaraj S, Gabrilovich DI: Myeloid-derived suppressor cells in human 
cancer. Cancer J 16:348-53, 2010 
64. Johansson CC, Mougiakakos D, Trocme E, et al: Expression and 
prognostic significance of iNOS in uveal melanoma. Int J Cancer 126:2682-9, 2010 
65. Diaz-Montero CM, Salem ML, Nishimura MI, et al: Increased circulating 
myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49-59, 
2009 
66. Kusmartsev S, Gabrilovich DI: Role of immature myeloid cells in 
mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55:237-45, 2006 
67. Youn JI, Kumar V, Collazo M, et al: Epi[INVESTIGATOR_640268]. Nat Immunol 
14:211-20, 2013 
68. Zeidan AM, Zeidner JF, Duffield A, et al: Stabilization of 
Myelodysplastic Syndromes (MDS) Following Hypomethylating Agent (HMAs) Failure Using 
the Immune Checkpoint Inhibitor Ipi[INVESTIGATOR_125]: A Phase I Trial. Blood 126, 2015 
69. Sallusto F, Lenig D, Forster R, et al: Two subsets of memory T 
lymphocytes with distinct homing potentials and effector functions. Nature 401:708-12, 1999 
70. Twyman-Saint Victor C, Rech AJ, Maity A, et al: Radiation and dual 
checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373-7, 
102                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 2015 
71. Almand B, Clark JI, Nikitina E, et al: Increased production of immature 
myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 
166:678-89, 2001 
72. Mirza N, Fishman M, Fricke I, et al: All-trans-retinoic acid improves 
differentiation of myeloid cells and immune response in cancer patients. Cancer Res 66:9299- 
307, 2006 
73. Daud AI, Mirza N, Lenox B, et al: Phenotypic and functional analysis of 
dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 26:3235-41, 2008 
74. Kusmartsev S, Su Z, Heiser A, et al: Reversal of myeloid cell-mediated 
immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14:8270-8, 
2008 
75. Liu CY, Wang YM, Wang CL, et al: Population alterations of L-arginase- 
and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived 
suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung 
cancer. J Cancer Res Clin Oncol 136:35-45, [ADDRESS_856987] B, Ormandy LA, Ballmaier M, et al: A new population of 
myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 135:234-43, 2008 
77. Filipazzi P, Valenti R, Huber V, et al: Identification of a new subset of 
myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a 
granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 
25:2546-53, 2007 
78. Poschke I, Mougiakakos D, Hansson J, et al: Immature 
immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and 
overexpress CD80, CD83, and DC-sign. Cancer Res 70:4335-45, 2010 
79. Vuk-Pavlovic S, Bulur PA, Lin Y, et al: Immunosuppressive CD14+HLA- 
DRlow/- monocytes in prostate cancer. Prostate 70:443-55, 2010 
80. van Cruijsen H, van der Veldt AA, Vroling L, et al: Sunitinib-induced 
myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency 
predicts progression-free survival. Clin Cancer Res 14:5884-92, 2008 
81. Kotsakis A, Harasymczuk M, Schilling B, et al: Myeloid-derived 
suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 
381:14-22, 2012 
82. Camp RL, Chung GG, Rimm DL: Automated subcellular localization and 
quantification of protein expression in tissue microarrays. Nat Med 8:1323-7, 2002 
83. Schalper KA, Velcheti V, Carvajal D, et al: In situ tumor PD-L1 mRNA 
expression is associated with increased TILs and better outcome in breast carcinomas. Clin 
Cancer Res 20:2773-82, [ADDRESS_856988], et al: Multiplexed quantitative 
analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast 
cancer. Clin Cancer Res 20:5995-6005, 2014 
85. Bordeaux J, Welsh A, Agarwal S, et al: Antibody validation. 
Biotechniques 48:197-209, 2010 
86. Rodriguez PC, Quiceno DG, Ochoa AC: L-arginine ava ilability regulates 
103                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 T-lymphocyte cell-cycle progression. Blood 109:1568-73, 2007 
87. Ostrand-Rosenberg S: Myeloid-derived suppressor cells: more 
mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59:1593-600, 
2010 
88. Youn JI, Nagaraj S, Collazo M, et al: Subsets of myeloid-derived 
suppressor cells in tumor-bearing mice. J Immunol 181:5791-802, 2008 
89. Corzo CA, Cotter MJ, Cheng P, et al: Mechanism regulating reactive 
oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol 182:5693-701, 
2009 
90. Kitano S, Postow MA, Ziegler CG, et al: Computational algorithm-driven 
evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical 
outcomes. Cancer Immunol Res 2:812-21, 2014 
91. Bendall SC, Simonds EF, Qiu P, et al: Single-cell mass cytometry of 
differential immune and drug responses across a human hematopoietic continuum. Science 332:687-96, 2011 
104                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 APPENDIX A1 MODIFIED INTERNATIONAL WORKING GROUP (IWG )-2006 
RESPONSE CRITERIA FOR ALTERING NATURAL HISTORY OF MDS 
 
Category Response criteria (responses must last at least 4 week) 
 
Complete remission %RQHPDUURZ¬îP\HOREODVWVZLWKQRUPDOPDWXUDWLRQRIDOOFHO OOLQHV
* 
 
Persistent dysplasia will be noted*‚Ä† 
Peripheral blood‚Ä° 
+JE¬ïJG/
3ODWHOHWV¬ï[9/L 
1HXWURSKLOV¬ï[9/L‚Ä† 
Blasts 0% 
 
Partial remission All CR criteria if abnormal before treatment except: 
 
%RQHPDUURZEODVWVGHFUHDVHGE\¬ïRYHUSUHWUHDWPHQWEXWVWL OO!
Cellularity and morphology not relevant 
 
Marrow CR‚Ä† %RQHPDUURZ¬îP\HOREODVWVDQGGHFUHDVHE\¬ïRYHUSUHWUH DWPHQW‚Ä† 
Peripheral blood: if HI responses, they will be noted in addition to marrow CR‚Ä† 
Stable disease Failure to achieve at least PR, but no evidence of progression for > [ADDRESS_856989] 1 of the following: 
 
Return to pretreatment bone marrow blast percentage 
DeFUHPHQWRI¬ïIURPPD[LPXPUHPL ssion/re sponse  leve ls inIgranulocyte s 
or platelets 
Reduction in Hgb FRQFHQWUDWLRQE\¬ïJG/RUWUDQVIXVLRQGHSHQGHQFH  
 
Cytogenetic 
response 
 
  
Disease 
progression Complete 
 
Disappearance of the chromosomal abnormality without appearance of new ones 
Partial 
At least 50% reduction of the chromosomal abnormality 
For patients with: 
105                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 /HVVWKDQEODVWV¬ïLQFUHDVHLQEODVWVWR!EODVWV
5%-EODVWV¬ïLQFUHDVHWR!EODVWV  
10%-EODVWV¬ïLQFUHDVHWR!  blasts 
20%-30% EODVWV¬ïLQFUHDVHWR!  blasts 
 
Any of the following: 
At least 50% decrement from maximum remission/response in granulocytes or 
platelets 
5HGXFWLRQLQ+JEE\¬ïJG/
Transfusion dependency 
 
Survival Endpoints: 
Overall: death from any cause 
Event free: failure or death from any cause 
PFS: disease progression or death from MDS 
DFS: time to relapse Cause-specific death: death related to MDS 
 
To convert hemoglobin from grams per deciliter to grams per liter, multiply grams per deciliter 
by 10.  
MDS indicates myelodysplastic syndromes; Hgb, hemoglobin; CR, complete remission; HI, 
hematologic improvement; PR, partial remission; FAB, French-American-British; AML, acute 
myeloid leukemia; PFS, progression-free survival; DFS, disease-free survival.  
* Dysplastic changes should consider the normal range of dysplastic changes (modification).  
‚Ä† Modification to IWG response criteria.  
‚Ä° In some circumstances, protocol therapy may require the initiation of further treatment (eg, 
consolidation, maintenance) before the 4-week period. Such patients can be included in the 
response category into which they fit at the time the therapy is started. Transient cytopenias 
during repeated chemotherapy courses should not be considered as interrupting durability of response, as long as they recover to the improved counts of the previous course.  
106                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 APPENDIX A2 MODIFIED INTERNATIONAL WORKING GROUP (IWG )-2006 
RESPONSE CRITERIA FOR HEMATOLOGIC IMPROVEMENT 
 
 
Hematologic improvement
* 
Erythroid response 
(pretreatment, < 11 g/dL) 
 
 
 
  
Platelet response 
(pretreatment, 
< 100 x 109/L) 
 
 
Neutrophil response 
(pretreatment, < 1.0 x 10
9/L) Response criteria (responses must last at least 8 wk)‚Ä† 
 
+JELQFUHDVHE\¬ïJG/  
 
 
Relevant reduction of units of RBC transfusions by [CONTACT_640313] 4 RBC transfusions/8 wk compared with the pretreatment 
transfusion number in the previous 8 wk. Only RBC transfusions given for D+JERI¬îJG/SUHWUHDWPHQWZLOOFRXQWLQ  the RBC transfusion 
response evaluation
‚Ä† 
 
$EVROXWHLQFUHDVHRI¬ï[9/L for patients starting with > 20x 109/L 
platelets 
 
Increase from < 20 x 109/L to > 20 x 109/L and by [CONTACT_2669] 100%‚Ä† 
At least 100% increase and an absolute increase > 0.5 x 109/L‚Ä† 
 
Progression or 
relapse after HI‚Ä° At least 1 of the following: 
 
At least 50% decrement from maximum response levels in granulocytes or platelets 
5HGXFWLRQLQ+JEE\¬ïJG/
Transfusion dependence 
 
Deletions to the IWG response criteria are not shown.  
To convert hemoglobin levels from grams per deciliter to grams per liter, multiply grams per deciliter by 10.  
Hgb indicates hemoglobin; RBC: red blood cell; HI: hematologic improvement.  
* 3UHWUHDWPHQWFRXQWVDYHUDJHVRIDWOHDVWPHDVXUHPHQWVQRWLQ IOXHQFHGE\WUDQVIXVLRQV¬ï
week apart (modification).  
‚Ä† Modification to IWG response criteria.  
‚Ä° In the absence of another explanation, such as acute infection, repeated courses of 
chemotherapy (modification), gastrointestinal bleeding, hemolysis, and so forth. It is recommended that the 2 kinds of erythroid and platelet responses be reported overall as well as by [CONTACT_27753].  
107                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 APPENDIX A3 INTERNATIONAL WORKING GROUP ACUTE 
MYELOID LE[LOCATION_006]EMIA RESPONSE CRITERIA 
 
 
 
Response 
Criterion  
Time of 
Assessment   
Neutrophils 
(ŒºL)  
Platelets 
(ŒºL) Bone 
Marrow 
Blasts 
(%)  
Other 
Early treatment assessment 7-10 days after 
therapy  
NA  
NA  
< 5  
Morphologic 
leukemia-free 
State  
Varies by [CONTACT_640314]  
< 5  
Flow cytometry EMD 
Morphologic CR Varies by [CONTACT_990] > 1,000 > 100,000 < 5 Transfusion EMD 
 
Cytogenetic CR  
Varies by [CONTACT_990]  
> 1,000  
> 100,000  
< 5 Cytogenetics‚Äînormal, 
EMD 
 
Molecular CR  
Varies by [CONTACT_990]  
> 1,000  
> 100,000  
< 5 Molecular‚Äînegative, 
EMD 
 
Partial Remission  
Varies by [CONTACT_990]  
> 1,000  
> 100,000 > 50 or 
decrease to 5-25  
Blasts < 5% if Auer rod 
positive 
Table 11: Hematologic Response According to IWG Criteria for AML 
 
AML = acute myelogenous leukemia; CR = complete remission; EMD = extramedullary disease; 
onal Working Group; NA = not applicable ( Cheson, 2003 ). 
108                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 APPENDIX B INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) 
FOR MYELODYSPLASTIC SYNDROME 
 
SCORE VALUES 
PROGNOSTIC VARIABLE 0 0.5 1.0 1.5 2.0 
Marrow Blasts (%)‚Ä† <5 5-10 ‚Äì 11-20 21-30 
Karyotype* Good Intermediate Poor   
Cytopenias** 0/1 2/3    
‚Ä†Patients with 21 -30% blasts are considered as MDS or AML (WHO) 
*Cytogenetics: Good = normal, - <DORQHGHOTDORQHGHOTDORQH3RRU FRPSOH[¬ï
abnormalities) or chromosome 7 anomalies; Intermediate = other abnormalities 
**Cytopenias: neutrophil count<1800/ Œºl, platelets <100,000, Hb <10 g/dL. 
 
 
Risk category 
(% IPSS pop.) Overall score Median survival 
(yr) 25% AML 
progression (yr) 
LOW (33) 0 5.7 9.4 
INT-1 (38) 0.5-1.0 3.5 3.3 
INT-2 (22) 1.5-2.0 1.1 1.1 
HIGH (7) >2.5 0.4 0.2 
109                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 APPENDIX C PERFORMANCE STATUS BY [CONTACT_640315] 
0 Normal activity. Fully active, able to carry on all pre-disease performance 
without restriction. 
 
 
1  
Symptoms, but ambulatory. Restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature ( e.g., light 
housework, office work). 
 
2 In bed <50% of the time. Ambulatory and capable of all self-care, but unable 
to carry out any work activities. Up and about more than 50% of waking 
hours. 
3 In bed >50% of the time. Capable of only limited self-care, confined to bed or 
chair more than 50% of waking hours. 
4 100% bedridden. Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair. 
5 Dead. 
110                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 APPENDIX D PROTOCOL FOR MONONUCLEAR CELLS ISOLATION 
(FICOLL HYPAQUE): 
 
1. Resuspend bone marrow aspi[INVESTIGATOR_640269] (1:1) 
 
2. Gently layer the diluted suspension over 5 ml of F/H in a 15 ml conical tube. You can load up 
to 10 mL however limiting this to 9 ml or less reduced the chances of contact[CONTACT_640316]. 
 
3. Spin at 400g (1200rpm) for 30 minutes at Room Temp (22-24C). Do not set the brake on the 
centrifuge. 
 
4. Carefully remove the tube from the centrifuge. Using a glass pi[INVESTIGATOR_640270] (white) containing the MNC. This should take less than 2 ml per 15 ml conical (1 ml if 
you are careful not to disturb the layer). 
 
5. Transfer the cells to a fresh 15 ml conical tube and add PBS up to 10 ml (at least a 1:4 
dilution). Mix well then spin at 400g (1200rpm) for 10 minutes at Room Temp (22-24C). 
 
6. Carefully aspi[INVESTIGATOR_640271] 10 ml of PBS. Mix well then spin 
at 400g (1200rpm) for 10 minutes at Room Temp (22-24C). 
 
7. Carefully aspi[INVESTIGATOR_640271] 10 ml of PBS. Mix well then spin 
at 400g (1200rpm) for 10 minutes at Room Temp (22-24C). 
 
8. Resuspend the cell in a small volume of PBS or culture medium and count after mixing well. 
 
9. To cryopreserve the cells (minimum of 4 vials not to exceed 2x107/vial). 
 
a. The final concentration will usually be 40% Human Serum, 10% DMSO: 
1. The easiest method is to dilute the cells to a twice the final concentration in PBS and to 
add an equivalent volume of cells (500 ul) to a 2X freezing medium (80% Serum, 20% DMSO) 
prechilled to 4C. 
2. Transfer right away to a labeled cryovial and use a controlled rate device to drop the 
temperature to -80C prior to transfer to Liquid Nitrogen. The rate is usually ideal at -1C per minute for PBMC. 
 
Important considerations: 
 
1. All work should be done using standard BSL2 procedures (blood and body fluid precautions). 
2. Maintain a clean worksp ace and use a containment laminar airflow hood when possible. 
3. Minimize the chance of contamination. 
4. Work quickly but methodically. 
5. Keep tubes closed as much as possible and work quickly. 
6. Change gloves frequently and maintain situational awareness of contact [CONTACT_27922]. 
111                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856990] 
 
Information for Patients, Their Caregivers, and Non-Study Healthcare Team on Possible Interactions with Other Drugs and Herbal Supplements 
 
The patient  is enrolled on a clinical trial using the 
experimental study drug, entinostat and Pembrolizumab (MK-3475) . This clinical trial is 
sponsored by [CONTACT_29630]. This form is addressed to the patient, but includes 
important information for others who care for this pa tient. 
 
These are the things that you as a healthcare provider need to know: 
 
x Entinostat was found to induce CYP 1A2, CYP 2C6, and CYP 2B8 as well as UGT 1A4. 
x Entinostat was found to be a substrate for P-gp and BCRP transporters, but did not inhibit 
either of these transport proteins. 
 
To the patient: Take this paper with you to your medical appointments and keep the attached information card in your wallet . 
 
Entinostat may interact with other drugs which can cause side effects. For this reason, it is very 
important to tell your study doctors of any medicines you are taking before you enroll onto this 
clinical trial. It is also very important to tell your doctors if you stop taking any regular 
medicines, or if you start taking a new medicine while you take part in this study. When you talk about your current medications with your doctors, include medicine you buy without a 
prescription (over-the-counter remedy), or any herbal supplements such as St. John‚Äôs Wort. It is 
helpful to bring your medication bottles or an updated medication list with you. 
 
Many health care providers can write prescriptions. You must tell all of your health care providers (doctors, physician assistants, nurse practitioners, pharmacists) you are taking part in a 
clinical trial. 
 
These are the things that you and they need to know: 
 
Entinostat must be used very carefully with other medicines that use CYP 1A2, CYP 2C6, and 
CYP 2B8, UGT 1A4 and P-gp as well as BCRP transporters. Before you enroll onto the clinical 
trial, your study doctor will work with your regular health care providers to review any 
medicines and herbal supplements that are considered strong inducers/inhibitors or substrates of 
CYP 1A2, CYP 2C6, and CYP 2B8 as well as UGT 1A4, and P-gp and BCRP transporters 
 
x Please be very careful! Over-the-counter drugs (including herbal supplements) may 
contain ingredients that could interact with your study drug. Speak to your doctors or 
pharmacist to determine if there could be any side effects. 
 
x Your regular health care provider should check a frequently updated medical reference or 
call your study doctor before prescribing any new medicine or discontinuing any 
112                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 medicine. Your study doctor‚Äôs name [CONTACT_640332][CONTACT_6811] 
 
  . 
113                NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856991] with CYP 2B6, 3A4, 1A2, CYP 2C6, 2B8 as well 
as UGT 1A4, gp and BCRP transport protein . 
¬æBefore you enroll onto the clinical trial, your study doctor will 
work with your regular health care providers to review any medicines and herbal supplements that are considered ‚Äústrong inducers/inhibitors or substrates of CYP 2B6, 3A4, 1A2, CYP 2C6, 
2B8 as well as UGT 1A4, gp and BCRP transportprotein .‚Äù 
¬æBefore prescribing new medicines, your regular health care 
providers should go to a f requently-updated medical referencefor 
a list of drugs to avoid, or contact [CONTACT_640317].
¬æYour study doctor‚Äôs name [CONTACT_640333][CONTACT_6811] . 
STUDY DRUG INFORMATION WALLET CARD
You are enrolled on a clinical trial using the experimental study 
drug Entinostat and Pembrolizumab (MK-3475) . This clinical trial is 
sponsored by [CONTACT_6812]. Entinostat may interact with drugs that are 
processed by [CONTACT_6813], or use certain transport proteins in your 
body . Because of this, it is very important to:
¬æTell your doctors if you stop taking any medicines or if youstart 
taking any new medicines.
¬æTell all of your health care providers (doctors, physician assistants, 
nurse practitioners, or pharmacists) that you are taking part in a 
clinical trial.¬æCheck with your doctor or pharmacist whenever you need touse 
an over-the-counter medicine or herbalsupplement.
114                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
  
APPENDIX F TRANSPORTER MDR1/PGP TRANSPORTER MDR1 /PGP 
 
Amiodarone S/Inhib Methadone Inhib 
Amitriptyline Inhib Mibefradil Inhib 
Amprenavir Induc Midazolam Inhib 
Astemizole Inhib Mifepristone Inhib 
Atorvastatin S/Inhib Nelfinavir S/Induc 
Boceprevir S/Inhib Nicardipi[INVESTIGATOR_050] S/Inhib 
Bromocriptine Inhib Nifedipi[INVESTIGATOR_640272] S/Inhib Progesterone Inhib/Induc 
Desipramine Inhib Propafenone Inhib 
Dexamethasone S/Induc Propranolol S/Inhib 
Dexverapamil Inhib Quercetin Induc 
Diltiazem S/Inhib Quinidine S/Inhib 
Dipyridamole Inhib Quinine Inhib 
Disulfiram Inhib Retinoic acid Induc 
Doxepin Inhib Reserpi[INVESTIGATOR_640273] S/Inhib Rifampin S/Induc 
Fluphenazine Inhib Ritonavir S/inhib 
Glibenclamide Inhib Saquinavir S/Inhib 
Haloperidol Inhib Simvastatin S/Inhib 
Hydrocortisone S/Inhib St. John‚Äôs Wort Induc 
Imipramine Inhib Tacrolimus S/Inhib 
115                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
  
Indinavir S/Induc Tamoxifen Inhib 
Itraconazole S/Inhib Telaprevir S/Inhib 
Ketoconazole Inhib Temsirolimus S/Inhib 
Lidocaine S/Inhib Testosterone Inhib 
Lovastatin S/Inhib Trimipramine Inhib 
Maprotiline Inhib Valspodar Inhib 
Mefloquine Inhib Verapamil S/Inhib 
Meperidine Inhib   
Inhib = Inhibition; Induc = Induction; S=substrate 
116                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856992], see the following link : Drug Development and Drug 
Interactions.  
[ADDRESS_856993] been shown to increase 5-fold or higher 
when co-administered with a known CYP inhibitor.  
3 CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship indicates that small 
increases in their exposure levels by [CONTACT_178959] (e.g., Torsades de Pointes).  
[ADDRESS_856994] sensitive substrates studied with available inhibitors evaluated to date. 5 Repaglinide is also a substrate for OATP1B1, and it is only suitable as a CYP2C8 substrate if the inhibition of 
OATP1B1 by [CONTACT_135719]. 
6 Because a number of CYP3A substrates (e.g., darunavir, maraviroc) are also substrates of P-gp, the observed 
increase in exposure could be due to inhibition of both CYP3A and P-gp. 
7 Withdrawn from the [LOCATION_002] market because of safety reasons. 
117                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 Also refer to the following link for the classification of substrates: 
Classification of Substrates: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugIntera 
ctionsLabeling/ucm093664.htm#4 ) 
118                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 APPENDIX H GASTRIC ACID REDUCING DRUGS 
 
 
Proton Pump Inhibitors 
‚Ä¢ Omeprazole (Prilosec, Zegerid) 
‚Ä¢ Lansoprazole (Prevacid) 
‚Ä¢ Rabeprazole (AcipHex) 
‚Ä¢ Pantoprazole (Protonix) 
‚Ä¢ Esomeprazole (Nexium) 
H2 Inhibitors 
‚Ä¢ Cimetidine (Tagamet) 
‚Ä¢ Ranitidine (Zantac) 
‚Ä¢ Famotidine (Pepcid) 
‚Ä¢ Nizatidine (Axid) 
Antacids 
‚Ä¢ Alka-Seltzer 
‚Ä¢ Alka-2, Surpass Gum, Titralac, Tums 
‚Ä¢ Milk of Magnesia 
‚Ä¢ ALternaGEL, Amphojel 
‚Ä¢ Gaviscon, Gelusil, Maalox, Mylanta, Rolaids 
‚Ä¢ Pepto-Bismol 
 
Also refer to the following link for examples of gastric acid reducing drugs: 
Gastric acid reducing drugs: http://www.everydayhealth.com/ulcer/ulcer-treatment.aspx 
119                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 APPENDIX I BIOASSAY TEMPLATES 
 
If the protocol includes any integral biomarker studies using in situ hybridization (ISH), 
immunohistochemistry (IHC), and/or DNA-based mutation assays, you may fill out the 
appropriate template (found at 
http://www.cancerdiagnosis.nci.nih.gov/diagnostics/templates.htm ) and attach to this protocol 
submission as separate Appendices. 
 
If the laboratory or laboratories performing the studies has an alternatively-formatted document that supplies the same level of information regarding validation, materials and methods, etc., it 
may be used instead of the templates. 
 
 
N/A since the correlative biomarker of MDSCs measurements are exploratory 
120                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 APPENDIX J CORRELATIVE STUDY PR OPOSAL 
 
BACKGROUND and RATIONALE: Besides allogeneic stem cell transplantation, the DNA 
methyltransferase inhibitor (DMNTi), azacitidine (AZA) is the only treatment proven to prolong survival in higher risk myelodysplastic syndrome (HR- MDS). Nonetheless, HR-MDS patients 
treated with AZA have a median survival advantage of 9.5 months (24.5 vs 15 months median 
OS)
1 and the objective response rate is only 50% with most patients eventually relapsing within [ADDRESS_856995] that 
myeloid-derived suppressor cells (MDSCs) contribute to immune escape in some cancers63-65. 
MDSCs have been shown to exert a suppressive role against T cells in tumor microenvironment 
and lead to cancer progression in tumor-bearing mice models and cancer patients66. Murine 
MDSCs have been well defined by a combination of surface markers and its correlation with in 
vitro and in vivo suppressive functions49. However, much less has been reported on their human 
counterparts. An important recent study published in the Journal of Clinical Investigation also demonstrated the importance of MDSCs which were significantly increased in bone marrows (BM) 
of MDS patients (~35% vs <5% in non-MDS BM controls) and played an important role in 
ineffective hematopoiesis in MDS
14. Thus, reprograming MDSCs to normal myeloid lineage cells 
may be important to prevent ineffective hematopoiesis and avoid immune escape. 
Epi[INVESTIGATOR_640274] c ells 
to MDSCs in cancers and histone deacetylase inhibitors (HDACi) prevent this pathologic differentiation
67. Another recent study demonstrated that MDSCs induce resistance to immune 
checkpoint blockade (anti-CTLA4 and anti-PD1) in colon cancer bearing mice15. Importantly,the 
MDSCs were decreased by [CONTACT_640286][INVESTIGATOR_640275], entinostat (ENT), leading to 
rejection of tumors when combined with immune chec kpoint blockade15. Thus, it will be important 
to investigate whether HDAC inhibitors can decrease the quantity of MDSCs and impact the c ourse 
of disease. 
As single agents, several HDACi were safe and well-tolerated but exhibited only modest clinical 
activities in patients with MDS4,5. Therefore, the interest to develop these agents further has 
focused on combination-based strategies, usually with DNMTi. To date, no HDACi- DNMTi 
combination has improved survival of MDS patients in randomized studies when used in the 
frontline or the post- DNMTi failure setti ng. These observations suggest that while HDACi therapy 
has activity in MDS, DNMTi might not be the best choice for combination-based regimen with HDACi. Exploration of alternative agents to combine with HDACi in the post-DNMTi failure 
setting might be a more rational approach. 
Another important mechanism which cancers employ commonly to evade the immune system involve the exploitation of T-cell inhibitory pathways involving inhibitory molecules such as the 
programed death-1 (PD-1) and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4)
6,7. Immune 
checkpoint blockade with antibodies directed against PD-1, its ligand (PD-L1), and CTLA-4 has emerged as a novel promising approach to reverse immune evasion, and has resu lted in a 
significant and durable clinical activity in some patients with advanced solid malignancies 
121                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_856996] that interaction between PD-1 and 
PD-L1 may induce immune evasion in MDS
12 and moreover the upregulation of these molecules 
could be associated with resistance to DNMTi therapy in MDS13. 
 
HYPOTHESIS: We hypothesize that the HDACi ENT can reduce the quantity and suppressive 
function of MDSCs in BM of MDS patients who fail to get responses from DNMTi. We also 
hypothesize that ENT with have a synergistic effect with the anti-PD-1 antibody pembrolizumab 
leading to meaningful clinical res ponses when used in combination. The objective of this proposal 
is to assess the in vivo effects of the combined therapy with PD1 blockade and HDACi on three 
exploratory immunologic endpoints through correlative and mechanistic studies of samples collected from BM of treated patients. 
 
SPECIFIC AIMS : 
 
Aim 1. Assess the dynamic changes in MDSCs (quantitative and qualitative) in relation to 
ENT/anti-PD1 combined therapy and its correlation with the clinical res ponse. 
 
Aim 2. Evaluate PD-L1 expression in CD34+ blasts from human MDS BM and its c orrelation with 
the response to anti-PD1 therapy. 
 
Aim 3. Characterize functional dynamics of immune cell subsets in MDS BM following ENT and 
anti-PD1 treatment. 
 
Successful completion of these studies will describe the pembrolizumab-induced reprogramming 
in T-cell populations, assess whether these changes correlate with clinical events, provide critical 
insights into the future wider use of PD-1 blockade-based immunotherapy in patients with MDS 
and other myeloid malignancies, and demonstrate the significance of targeting MDSCs via 
HDACi. 
 
PRELIMINARY DATA/PRIOR STUDIES: The role of MDSCs in MDS and the preclinical data of HDACi to suppress MDSCs: Myelopoiesis is altered in cancer including the expansion of a subset of relatively immature and 
activated myeloid cells, now called MDSCs
48. MDSCs have been reported to facilitate tumor 
metastasis and angiogenesis49-51. Recently, MDSCs were found to be significantly expanded in 
BM of patients with MDS and to play an important role in the pathogenesis of the disease 
especially in driving ineffective hemat opoiesis14. The role of MDSCs in pat hogenesis of MDS and 
the optimal strategy to target MDSCs remain under investigation. Kim and colleagues recently demonstrated that MDSCs can mediate resistance to immune checkpoint blockade therapy in a 
murine tumor model
15. In this study, treatment with anti-PD-[ADDRESS_856997] 
cancers15. Interestingly, when the animals were co-treated with epi[INVESTIGATOR_640230] (i.e. 
ENT+AZA or ENT alone) in addition to the anti bodies, the outcomes improved significantly with 
cure rates in excess of 80% of the tumor-bearing mice15. Importantly, AZA and ENT (alone or 
122                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 together) in absence of the immune-checkpoint inhibitors also failed to eradicate the tumors. These 
findings suggested that the combination of the class [ADDRESS_856998]- ENT/anti-PD1 therapy to achieve our primary goal of this study in specific aim 1 . 
PD-L1 expression in MDS and its correlation with the response to anti-PD1 therapy: Kondo 
et al. demonstrated that PD-L1-positive MDS blasts have an intrinsic proliferative advantage and 
induce T-cell suppression through interactions with PD-1 receptors potentially contributing to 
disease progression
12. They also showed in BM samples, blasts from HR-MDS patients expressed 
PD-L1 molecules more often compared with those from LR- MDS patients while the BM T-cells 
over-expressed PD-1 molecules12. The MD Anderson group studied mRNA in CD34+ cells from 
124 patients with MDS, acute myeloid leukemia (AML) and chronic myelomonocytic leukemia 
(CMML) and found that 34%, 15%, and 8% had aberrant up-regulation ( ·ÄÖ2-fold) in PD-L1, PD- 
1 and CTLA4, respectively13. PD-L1 protein expression was observed in MDS CD34+ cells, 
whereas stromal and non-blast cellular elements were positive for PD-1. More importantly, in a subgroup of patients treated with DNMTi therapy, PD-L1, PD-[ADDRESS_856999] the 
PD-1/PD-L1 axis might mediate resistance to DNMTi therapy and provide rationale for using 
immune checkpoint blockade with an anti-PD1 antibody as a novel therapeutic approach to improve outcomes of HR-MDS patients. However, preliminary results from ongoing early phase clinical trials of ant-CTLA-4 and anti-PD1/PD-L1 agents in MDS patients s uggest that immune 
checkpoint therapy as a monotherapy only leads to disease stabilization in some patients but very 
few responses
68. This observation provides rationale for combining immune checkpoint therapy 
with other novel agents with distinct mechanisms of action to improve patient outcomes. Additionally, there is no single biomarker to predict the response to anti-PD1 therapy in cancers. Previous data indicate that the response rate of anti-PD-[ADDRESS_857000] the question about the expression of PD-L1 in CD34+ blasts from human 
MDS BM and its correlation with the response to combined anti-PD1/ENT therapy in MDS in 
specific aim [ADDRESS_857001] the response to anti-PD1 therapy in MDS: Compared to a 
murine model for linear T-cell differentiation, we have had to rely on cross-sectional assessment 
to define memory T-cell subsets. More than two markers (CD45RA, CCR7) enabled us to delineate 
memory T-cell compar tments69. For instance, we simply divide T-cells into four subsets: na√Øve 
123                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 (CD45RA+CCR7+), central memory (CD45RA-CCR7+), effector memory (CD45RA-CCR7-), 
late effector (CD45RA+CCR7-)69. The ratio of T CM (CD45RA-CCR7+) to T EMRA 
(CD45RA+CCR7-) and of T EM (CD45RA-CCR7-) to T EMRA (CD45RA+CCR7-) will be assessed  
in BM and peripheral blood using flow cytometry. More recent preclinical data suggest that the 
frequency of CD8+, and CD8+/regulatory T cells (Tregs) are two important predictive markers for 
anti-PD1 therapy70. Additionally, this st udy also demonstrated exhausted CD8+ T cells defined by 
[CONTACT_640318]-[ADDRESS_857002] the response to anti-PD1 therapy in MDS. 
 
METHODOLOGY OF CORRELATIVE STUDIES (EXPLORATORY BIOMARKERS): 
Specific Aim 1. Determine the numeric and functional alterations of MDSCs in relation to 
ENT/anti-PD1 therapy and their correlations with the clinical response 
Human MDSCs are defined by a cross-sectional assessment of well-known surface markers with 
functional phenotype. Initially, the expression of a common myeloid marker, CD33 without the 
expression of the lymphoid cell markers (CD3, CD19, CD56) defined human MDSCs63. 
Subsequent studies classified human MDSCs by [CONTACT_44688]-DR-/Lineage-71, HLA-DR-/Lineage- 
/CD33[PHONE_13312], HLA-DR-/Lineage-/CD33+/CD11b+65, CD14-/CD15+/CD33+/CD11b+75, or HLA- 
DR-/CD1476-80. These heterogeneous definitions of human MDSCs cause a fundamental caveat 
especially in human correlative studies, s uggesting that the most clinically relevant markers s hould 
be determined. Moreover, sample processing such as cryopreservation has been reported to affect 
some expression of surface markers and the suppressive function of human MDSCs81. Thus fresh 
BM aspi[INVESTIGATOR_640276]. Historically, human BM core biopsy has been decalcified for immunohistochemistry (IHC). This 
additional manipulation may also affect the expression of surface markers of MDSCs. Thus, we 
will use surface markers that are relatively resistant to cryopreservation
81 in formalin-fixed 
paraffin-embedded clot sections to avoid decalcification step to perform multiplex quantitative 
immunofluorescence (multiplex-QIF) while maintaining the immune architecture. We will also 
compare IHC/IF findings and its quantitative analyses by [CONTACT_640319] 
(AQUA) (described below) with flow cytometric data in BM aspi[INVESTIGATOR_337]. T hese procedures will be 
performed with a strong collaboration with Mina Xu at the Hematology tissue bank/[CONTACT_640336]‚Äôs lab (Yale and at [CONTACT_640334] laboratory at Vanderbilt University (Kim Lab).. 
We acknowledge the lack of understanding the baseline AQUA value of MDSCs in treatment na√Øve 
MDS patients, inter-patient or intra-patient variability of MDSCs at this time. While our study will 
provide important data, are collecting BM cells from treatment-na√Øve MDS patients (regardless of 
participation in the study) to show interpatient consistency of our biomarker the baseline value of 
MDSCs using QIF and flow cytometry. We will also use BM cells from one particular healthy donor as an inter-assay variability control. Intra-patient variability will be evaluated by [CONTACT_640320]√Øve- MDS patients (before 
starting any treatment except transfusion) 
SA 1.1. Assess the quan titative change of MDSCs in BM of MDS p atients in res ponse to EN T/anti- 
PD1 treatment. 
Human MDSCs, defined as CD 11b+/Lineage-ve (CD3, CD14, CD16, CD19, CD20, CD56)/HLA- 
DR-/CD33+ cells as in the prior landmark publication,14 will be enumerated in fresh BM aspi[INVESTIGATOR_640277]. All flow cytometric acquisition will be carried out using an 
124                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 LSR II (BD) or FACS Calibur (BD) and acquired data will be analyzed using FlowJo software 
(TreeStar). 
In addition, formalin-fixed paraffin-embed clot sections of BM clot sections will be investigated 
by [CONTACT_640321] (AQUA) as previously described 82. Briefly, 
AQUA¬Æ is a method to objectively and accurately measure biomarker expression within defined 
areas of interest and subcellular compartments based on co-localization with other biomarkers 
and DAPI ( 4',6-diamidino -2-phenylindole) . Pi[INVESTIGATOR_640278] a continuous scoring system directly proportional to the concentration of the biomarker of interest. Multiplexing different markers of immune cells and immune checkpoints allows identification 
and characterization of various cell types involved in immune response and in development of 
resistance to specific therapeutic approaches. Assays for multiplexing up to [ADDRESS_857003] been described previously
83,84. 
The following multiplexing panel will be applied to characterize MDSCs and their macro/micro 
environment: 
Antibody CD33 CD11b HLA-DR 
Company Abcam Novus Abcam 
Clone SP266 CL1719 MEM-267 
Species/Isotype Rabbit Monoclonal Mouse IgG1 Mouse Monoclonal 
IgG2b 
Catalogue 
Number Ab199432 NBP2-[ADDRESS_857004] cycle of ENT 
monotherapy, after every 2 cycles of combined therapy, and at progression or discontinuation from 
study. 
SA 1.2. Assess the spatial relationship between MDSCs and cell subsets in MDS BM 
Following the efforts of identification and quantification of MDSCs serial clot sections will be 
stained for CD11b, for CD34 and E-Cadherin in order to investigate the spatial relationships of 
MDSCs with myeloblasts and pro-erythroblasts. Further subclassification of MDSCs can be 
performed using the biomarkers CD14 and CD15 for differentiation of monocytic and granulocytic MDSCs, respectively. 
Further characterization of T cell subsets will be performed if sufficient tissue is available. The 
immune cell panel of CD3/CD4/CD8 will be analyzed as well as PD-1 and FOXP3 levels will be 
measured. 
In addition to protein quantification using the AQUA method of QIF, the slides will also be scanned on the Vectra platform, which is an automated quantitative pathology imaging system to be used with immunofluorescent or immunohistochemical stains. The Inform Software facilitates 
cell counting and characterization as opposed to the QIF AQUA system where scoring is based on 
measurement of protein concentration. 
125                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 SA 1.3. Assess the change of functional characteristics of MDSCs in BM of MDS patients in 
response to ENT/anti-PD1 trea tment 
The depletion of L-arginine inhibits T-cell proliferation through decreasing the expression of &'»ó
chain52 and down-regulating the expression of cyclin D3 and cyclin-dependent kinase [ADDRESS_857005] of T cells in G0-G1 of the cell cycle. The increased activity of arginase in MDSCs leads to enhanced L-arginine catabolism, which depletes L-arginine in tumor microenvironment. Now the assay to measure arginase activity is one of the classic methods to assess the function of MDSCs. Therefore, intracellular expression of arginase I in MDSCs of MDS patients will be assessed by [CONTACT_7163]-color flow cytometry using s urface markers to define MDSCs following fixation 
and permeabilization compared
87,88. 
We will also measure arginase activity of MDSCs in MDS patients. Briefly, sorted MDSCs from BM of MDS patients (sorted by [CONTACT_7811]) will be lysed and the enzyme will be activated by [CONTACT_333600] 10 mins at 56‚ÄôC. Arginine hydrolysis w ill be c onducted by [CONTACT_640322] 100 Œºl of 
0.5M L-arginine at 37‚ÄôC for 2 hrs. Urea concentration w ill be measured at 540nm after addition of 
¬óORIƒÆ -isonitrosopropi[INVESTIGATOR_640279], followed by [CONTACT_223431] 95‚ÄôC for 30mins. 
The ability to generate reactive oxygen species (ROS) has been reported to be one of the major mechanisms of MDSC-i nduced immune suppression in cancer patients
89. Thus, we will use the 
ROS production following stimulation as a surrogate functional marker for MDSCs81. Briefly, 
MDS BM cells will be incubated at 37 qC in medium in the presence of 10 PM oxidation-sensitive 
dye, dichlororodihydrofluorescein diacetate (DCFDA) (Molecular Probes, CA) for 15 min. Cells 
will be stimulated by 50ng/ml phorbol 12-myristate-13-acetate (PMA) and [ADDRESS_857006] the arginase I expression, the arginase activity and ROS generation of MDSCs to diminish following ENT treatment. 
SA 1.4. Evaluate the alteration of the suppressive function of MDSCs from BM of MDS patients 
following ENT/anti-PD1 treatment 
Functional properties of MDSC include suppression of antigen-s timulated T cell proliferation and 
IFN-»ñ production51. To determine the functional alteration of MDSCs after EN T/anti-PD1 therapy, 
we will perform T-cell proliferation assay using thymidine incorporation and ELISA for IFN- »ñ
detection. For T-cell suppression assay, MDSCs will be sorted from BM of MDS patients by 
[CONTACT_117159]-activated cell sorting (FACS). T-cells w ill be isolated by [CONTACT_150969]-activated cell 
sorting (MACS) using CD3 microbeads (Miltenyi Biotec) from autologous peripheral blood. T- 
cells (2x104) will be plated in 96-well flat bottom plates in triplicate in RPMI medium 
supplemented with 10% Fetal Bovine Serum. T-cells will be stimulated with IL-2 and anti- CD3/anti-CD28 coated beads (Invitrogen) at a 1:2 ratio of T cells to beads. MDSCs will beadded 
with T-cell cultures at ratios of 1:4. After 3 days of co-culture, supernatants will be harvested to 
measure IFN- »ñFRQFHQWUDWLRQE\(/,6$7K\PLGLQHLQFRUSRUDWLRQDVVD\ZLOOEH SHUIRUPHGWR
analyze T-cell proliferation and its suppression by [CONTACT_640323]. These studies will be performed at baseline, after the first cycle of ENT monotherapy, after every [ADDRESS_857007] the suppressive activity of MDSCs on T- 
cell function to diminish following ENT treatment. 
Potential pi[INVESTIGATOR_292723] (SA1): The quantity of MDSCs in BM samples is hard to predict. In addition to 
QIF, we will also pe rform flow cyto metric analyses using the same markers (CD 11b, CD33, HLA- 
126                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/[ADDRESS_857008]) as well as CD14, and CD15 to define granulocytic MDSCs (CD11b+/CD33+/HLA-DR- 
/CD15+) and monocytic MDSCs (CD11b+/CD33+/HLA-DR-/CD14+) in fresh aspi[INVESTIGATOR_640280]. 
 
We will prioritize patient BM aspi[INVESTIGATOR_640281] e nough to perform all of the assays described 
in SA1. Our first priority will be to measure the quantitative alteration of MDSCs pre- and post- 
anti-PD1 therapy/ENT by [CONTACT_4133]. We will measure the expression of arginase I, the generation of ROS (SA 1.3). We w ill then assess the arginase activity (SA 1.3) and the suppression 
assay (SA 1.4), and lastly measure arginase activity. Cryopreservation, decalcific ation and the type 
of collection tubes (heparin vs EDTA vs calcium phosphate) may affect the quantity or quality of 
MDSCs
81,90. We will stain fresh cells for flow cytometry and functional assay and clot section of 
BM for QIF assay81. We will also use EDTA tubes as described before if we see any significant 
difference of the quantity or quality of MDSCs depending on the types of tube90. 
 
Specific Aim 2. Evaluate whether PD-L1 expression in CD34+ blasts from MDS BM correlates with the response to anti-PD1 therapy: Clot sections of BM will be fixed. PD-L1 
expression w ill be evaluated on MDS CD34+ blasts by [CONTACT_640324]. Specimens w ill be classified 
as negative or positive if <5%, ¬ï of CD34+ cells are PD-L1 positive, respectively as previously 
described
8,10,13. Flow cytometry will be carried out on the BM aspi[INVESTIGATOR_640282]-L1 expressing CD34+ blasts in BM of MDS patients using rabbit anti-PD-L1 monoclonal antibody (E1L3N, Cell Signaling). Specimens w ill be classified as FACS negative or positive if 
¬ïRI&'DUH3' -L1 positive, respectively. These studies will be performed at the 
beginning of trial and after the first cycle of ENT monotherapy, after every [ADDRESS_857009]- anti-PD1 therapy: Using multi-color flow cytomet ry, we will examine CD4+, 
CD8
+ T-cell subpopulations (expressing CD45RA, CCR7, and CD27), Foxp3+ regulatory T cells 
(T-regs), and also natural killer (NK), NKT cells and de ndritic cells (DC) with the following panel 
of mAbs: CD16 and CD56 (markers of NK cells and NKT cells), CD11c (a marker of myeloid 
DCs) and CD123 (a marker of plasmacytoid DCs) in BM aspi[INVESTIGATOR_640283] (pre- and post- anti-PD1). We will also analyze PD-1 expression and 
intracellular molecules such as F oxp3, Ki67, Eomes and Granzyme B (GzmB). All flow cyto metric 
acquisition will be carried out using an LSR II (BD) or FACS Cali bur (BD) and acquired data will 
be analyzed using FlowJo software (TreeStar). The changes in these subsets w ill be correlated with 
clinical responses. 
 
Potential pi[INVESTIGATOR_640284] (for SA2 & SA3): We will possibly have limited 
number of cells in BM aspi[INVESTIGATOR_337], so we will prioritize patient samples if not enough to perform all the assays described in SA2, SA3. Our priority will be to ca rry out SA3 since SA2 w ill be assessed 
by [CONTACT_4658]. Alternatively, we will analyze the immune profile combining a high-throughput technique 
that will allow us to study more than 20 markers in a single cell analysis using mass cytometry 
(CyTOF). These techniques will provide information about the architecture of the tumor microenvironment (TME) (i.e. BM) and the distribution of markers of interest detected with 
CyTOF. CyTOF-based single cell analysis is a new technology that combines flow cytometry with 
metal-conjugated anti bodies detected by [CONTACT_640325] 
(up to 100 molecules) on a single cell analysis
91. For this assay, the staining will be pe rformed 
127                 NCI Protocol #:[ZIP_CODE]  
                Version Date: 09/04/2020  
 using MaxPar Human T Cell Phenotypi[INVESTIGATOR_640285] (CD11a, CD4, CD8a, CD16, CD25, CD45, 
CCR7, CD69, CD45RO, CD44, CD27, CD45RA, CD3, CD57, HLA-DR, and CD127) along with 
CD28, CD117, and CD95), modified MaxPar human AML phenotypi[INVESTIGATOR_4395] (added 
CD10,CD13, CD16 on top of CD19, CD117, CD11b, CD64, CD7, CD123, CD45, CD33, CD15, CD34, CD3, CD44, CD38, HLA-DR, CXCR4) for surface s taining as per ma nufacturer‚Äôs protocol. 
Additionally, after fixation and permeabilization, cells will be stained with anti-human Ki-67- 
151Eu (B56; BD Pharmingen Ab conjugated with lanthanide MaxPar Europi[INVESTIGATOR_390585] 151Eu 
using the MaxPar X8 Ab labeling kit) for 30 min at room temperature. Cells will be acquired on 
CyTOF 2 instrument (DVS; Fluidigm Sciences). All data will be analyzed and graphs generated using the DVS Cytobank software (Cytobank). 
STATISTICAL CONSIDERATIONS and ANALYTICAL PLAN 
SPECIFIC AIM 1: 
The quantitative change in MDSCs (% MDSCs by [CONTACT_4133], QIF score by [CONTACT_485200]) during 
treatment with the ENT/anti-PD1 combined therapy will be estimated using mixed effects models 
to take into account the within-patient correlation of measurements over time. Likelihood ratio 
tests will be pe rformed to confirm if random intercepts and slopes are n ecessary in the model. The 
fixed effect for change in MDSCs over time will be evaluated for significance. The variability in the rate of change in MDSCs across patients will also be examined. The association between the 
clinical outcome and a meaningful reduction in MDSCs, which will be defined after a review of 
the data, will be assessed with the chi-square test. The quantity of MDSCs at baseline and during 
treatment as continuous variables can also be compared between responding and non-responding 
patients using a t-test or Mann-Whitney U-Test, if more appropriate. We will apply the same statistical analyses for the expression of arginase I and ROS and arginase activity of MDSCs (SA 
1.3) and suppressive activity of MDSCs by [CONTACT_35755] T-cell proliferation & IFN- »ñ production (SA 
1.4). 
SPECIFIC AIM 2: MDACC study demonstrated 20% of leukemic blasts express PD-L1 when 
positive is considered when more than 5% CD34+ blasts express PD-L1 by [CONTACT_640326]34+ controls, PD-L1 is nearly 0%13. An association of clinical response with the expression of 
PD-L1 MDS CD34+ blasts will be assessed by a Pearson chi-square test on a 2x2 table of 
frequencies. The dependent variable will be defined as response (yes versus no), and flow 
cytometry/IHC categories (negative vs positive) will be the independent variables. We will also monitor the dynamic change of PD-L1 expression over the course of treatment and its correlation with clinical response. Longitudinal measurements of PD-L1 will be examined using mixed- 
effects modeling. 
SPECIFIC AIM 3: Statistical analyses of the frequency of CD8+, CD4+, Foxp3 Tregs, 
CD8+/Foxp3+ Tregs, T CM/TEMRA, TEM/TEMRA, the percentage of Ki67 and GzmB in PD-1+, 
Eomes+ CD8 T cells to compare changes over time from baseline to several time-points w ill be 
performed by [CONTACT_640327] a Benjamini-Hochberg correction to control for 
false discovery rates. 